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 RIASSUNTO 
La leucemia linfoblastica acuta di tipo B  (B-ALL) è un tumore caratterizzato 
dall’accumulo nel midollo osseo di linfociti immaturi, blasti, di tipo B che successivamente 
invadono il sangue, raggiungendo anche i linfonodi, la milza, il fegato e il sistema nervoso 
centrale. I pazienti B-ALL che alla diagnosi non rispondono al trattamento con 
glucocorticoidi, sono spesso soggetti a prognosi infausta e a ricaduta della malattia. 
Comprendere quindi quali siano i meccanismi molecolari sottostanti a questa resistenza ai 
glucocorticoidi permetterebbe di evitare fenomeni di ricaduta e potenzialmente di trovare 
nuove efficaci terapie antitumorali. FOXO3a e FOXM1 appartengono alla stessa famiglia 
di fattori di trascrizione denominati forkhead. Sebbene non sia ancora stato chiarificato 
quale sia il ruolo svolto da questi due fattori di trascrizione nelle B-ALL, i lavori riportati 
in letteratura dimostrano che FOXO3a e FOXM1 generalmente svolgono ruoli opposti 
all’interno della cellula. FOXM1 infatti è un importante oncogene che regola 
principalmente la proliferazione cellulare promuovendo la progressione tumorale. Per 
questo motivo, FOXM1 è spesso sovraespresso in diversi tipi di tumori, contribuendo 
quindi alla resistenza terapeutica e alla progressione tumorale. FOXO3a al contrario è un 
noto soppressore tumorale la cui attivazione è fondamentale per favorire la citotossicità di 
molti composti chemioterapici. Tuttavia la sua localizzazione intracellulare ed attività 
trascrizionale sono regolate da una complicata rete di modificazioni post-traslazionali, 
quali la fosforilazione, l’acetilazione, la metilazione e l’ ubiquitinazione.  
Nella prima parte di questo studio abbiamo quindi esaminato se questi due fattori di 
trascrizione, FOXO3a e FOXM1, svolgono un ruolo nelle B-ALL. In particolare abbiamo 
analizzato se FOXM1 è coinvolto nella proliferazione cellulare e nella risposta al 
trattamento chemioterapico. Inoltre abbiamo svolto una serie di esperimenti per 
comprendere se FOXO3a è coinvolto nella risposta al trattamento coi glucocorticoidi 
(desametasone) e se la sua attività trascrizionale viene modulata da modificazioni post 
transazionali quali la fosforilazione e l'acetilazione. I dati ottenuti hanno dimostrato che 
entrambi i fattori di trascrizione, FOXM1 e FOXO3a svolgono un ruolo chiave nelle 
leucemie B-ALL. FOXM1 è un importante regolatore della proliferazione tumorale, infatti 
la sua downregolazione provoca una significativa diminuzione della proliferazione 
cellulare associata all’arresto del ciclo cellulare in G2/M. FOXM1 inoltre risulta essere un 
importante target terapeutico per le B-ALL in quanto la sua inibizione può 
significativamente incrementare l’effetto citotossico dei chemioterapici che sono 
 normalmente utilizzati per trattare i pazienti affetti da B-ALL. Il fattore di trascrizione 
FOXO3a gioca un ruolo centrale nel mediare la risposta al trattamento con desametasone. 
Infatti, in seguito al trattamento, FOXO3a diventa trascrizionalmente attivo solo nelle 
cellule che sono sensibili (RS4;11 e SUP-B15). FOXO3a trasloca nel nucleo dove regola 
l’espressione di geni proapoptotici. Diversamente nelle cellule resistenti al desametasone, 
REH, FOXO3a rimane inattivo e localizzato nel citoplasma. Inoltre, FOXO3a diventa 
maggiormente fosforilato e acetilato, nei siti Ser7 e Lys242/245 rispettivamente, solo nelle 
cellule sensibili, suggerendo che probabilmente queste due modificazioni post-
translazionali contribuiscono nel promuovere la sua attivazione trascrizionale.  
Nella seconda parte dello studio ho analizzato il meccanismo molecolare di due classi di 
composti antitumorali, gli arilamino triazoli e le fenilcinammidi, entrambi sintetizzati per 
inibire, in maniera selettiva, la proliferazione ed indurre morte cellulare nelle cellule 
tumorali. In particolare, è stato studiato l'effetto di tali molecole sulla polimerizzazione 
della tubulina, sul ciclo cellulare e sull'attivazione dell'apoptosi per la delucidazione di un 
possibile meccanismo d'azione. I composti testati hanno mostrato attività antiproliferativa 
comparabile o superiore rispetto ai composti di riferimento. Per quanto riguarda il 
meccanismo d'azione, in generale, entrambi questi composti inducono un blocco del ciclo 
cellulare in fase G2/M il quale porta all'attivazione del processo apoptotico caspasi- 
dipendente. Tuttavia gli arilamino triazoli agiscono principalmente come inibitori della 
polimerizzazione della tubulina, mentre le fenilcinammidi agiscono riducendo 
significativamente i livelli di antiossidante intracellulare glutatione, provocando quindi un 
aumento dello stress ossidativo intracellulare che in ultima analisi porta ad apoptosi. 
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SUMMARY 
B-cell acute lymphoblastic leukaemia (B-ALL) is one of the most common paediatric 
disorders characterized by an accumulation of B-cell blasts reminiscent of normal stages of 
differentiation and by infiltration of various extramedullary sites.   
B-ALL patients that respond poorly to glucocorticoid therapy when diagnosed are usually 
predicted to undergo relapse. Therefore understanding the biological mechanisms 
underlying this poor responsiveness is crucial for the development of more effective 
therapies. FOXM1 belongs to the Forkhead Box (FOX) superfamily of transcriptional 
factors and is a major regulator of cell proliferation and cell cycle progression. Its 
expression increases at the entry of cell cycle S-phase, remains stable during G2/M phase, 
and finally, is degraded at the mitotic exit. FOXM1 is a bona fide proto-oncogene and its 
up-regulation is often associated with a high proliferation rate, resistance to drugs and poor 
prognosis of many tumours, as well as with the development and progression of many 
malignancies. Therefore, downregulation of FOXM1 expression and activity might be a 
key strategy to inhibit tumour progression. In the first study we investigated the potential 
role of FOXM1 in B-ALL cell proliferation, aiming to understand if FOXM1 can be 
targeted to either increase the efficiency of chemotherapeutic treatment, or to overcome 
drug resistance in this haematological malignancy. We observed that FOXM1 protein and 
mRNA levels are higher in B-ALL patients and cell lines when compared to lymphocytes 
of healthy donors (peripheral blood mononuclear cells, PBMCs). We then downregulated 
FOXM1 in REH and NALM-6 cell lines using a specific FOXM1 siRNA or thiostrepton 
treatment: there was a significant  reduction in cell proliferation, cell cycle arrest in G2/M 
and an increase in sub-G1 cells. Importantly, we observed that thiostrepton acts in synergy 
with conventional chemotherapeutic agents, increasing their efficiency and partially 
reversing the glucocorticoid resistance in REH cells. Altogether, our results suggest that 
FOXM1 inhibition could be a useful strategy to increase the efficacy of existing 
therapeutics for B-ALL and to overcome drug resistance.   
 
In the second study we focused our attention on another FOX family member: the 
transcription factor FOXO3a. Although FOXO3a is mainly described as a bona fide 
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tumour suppressor, literature reveals that it might also play a role as a proto-oncogene, by 
inducing cancer development and drug resistance according to the cellular context. 
FOXO3a transcriptional activity is regulated by a complex array of post-translational 
modifications. Amongst there, phosphorylation and acetylation are the major regulators of 
FOXO3a subcellular localization and transcriptional function. In this work, we investigated 
whether FOXO3a is involved in dexamethasone responsiveness of B-lymphoblastic 
leukaemia (B-ALL). Western blot and immunostaining data showed that FOXO3a 
becomes active only in sensitive cells following dexamethasone treatment. In 
dexamethasone sensitive cells (RS4;11 and SUP-B15), FOXO3a translocates from the 
cytoplasm to the nucleus, where it induces the expression of BIM, p27 and the activation 
of apoptosis signature through caspase-3 cleavage. Moreover knockdown experiments 
clearly reveal that FOXO3a expression and function is fundamental for dexamethasone 
mediated cytotoxicity. We then performed a series of experiments to clarify if its activity is 
regulated by phosphorylation and/or acetylation. More importantly, two post-translational 
modifications, phosphorylation on Ser7 and acetylation on Lys242 and Lys245, appeared 
to be crucial for dexamethasone-mediated FOXO3a activation in sensitive cells. Clarifying 
which are the biological processes that prevent these post-translational modifications from 
occurring in dexamethasone-resistant REH cells, might pave the way to overcoming 
glucocorticoid resistance in B-ALL. 
 
 
 
 
 
 
 
 
 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
4 
 
1 GENERAL INTRODUCTION 
 
Forkhead box (FOX) proteins are evolutionarily conserved transcriptional regulators which 
control a wide spectrum of biological processes such as cell cycle progression, pro-
liferation, differentiation, metabolism, senescence, survival and apoptosis
1
. Therefore, a 
loss or gain of FOX function might alter the cell’s fate and promote tumorigenesis as well 
as cancer progression. 
FOXO3a and FOXM1, two of the most important members of FOX's family of 
transcription factors, are key players in cancer initiation, progression, drug response and 
chemotherapy resistance
2
. Accordingly, FOXO3a and FOXM1 proteins are indirect targets 
of several widely used cancer drugs. Some chemotherapeutic drugs, such as doxorubicin, 
epirubicin and cisplatin, mediate their cytotoxic effects partly by targeting and perturbing 
the FOXO3a and FOXM1 function
3
. However, the role exerted by FOXM1 and FOXO3a 
in B-ALL cells proliferation and drug response has not been clarified yet. 
 
 
1.1  B-ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) 
 
B-lymphoblastic leukaemia (B-ALL) is the most common childhood tumor and dominates 
within the lymphoid leukaemia groups in children (where >80% ALLs are B-ALLs)
4
.  
B-ALL malignant disorder derives from clonal proliferation of B-lymphoid precursors with 
arrested maturation
5
. B-ALL symptoms are caused by the decrease in production of normal 
marrow elements and by the direct B-leukaemic cell infiltration in the marrow or other 
organs. Symptoms can include fever, increased risk of infection, increased tendency to 
bleed (due to thrombocytopenia) and signs indicative 
of anaemia including pallor, tachycardia, fatigue and headache
6
. 
Standard treatment options for newly diagnosed childhood B-ALL patients include 
chemotherapy treatment and, more commonly, a four-drug induction regimen, composed 
of vincristine, corticosteroid (dexamethasone or prednisone), L-asparaginase, Ara-c 
(Cytarabine) and either doxorubicin or daunorubicin. Over the years, the association of 
primary glucocorticoid resistance with poor prognosis in childhood B-ALL has been 
described frequently. Poor response to glucocorticoid has been correlated with increased 
risk of relapse and therapeutic failure
7–9
. Understanding the mechanisms that regulate 
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dexamethasone responsiveness is therefore an important goal to evade bad prognosis in 
paediatric B-ALL. 
1.2 FORKHEAD BOX TRANSCRIPTION FACTORS 
 
Forkhead box (FOX) superfamily of transcription factors play a major role in cell fate 
decisions. They regulate crucial biological processes such as cell proliferation, 
differentiation, metabolism, tissue homeostasis, senescence, survival, apoptosis, and DNA 
damage repair
3
. All members of this family are characterized by a highly conserved 
“winged-helix” DNA- binding domain (DBD) which is composed of about 110 amino 
acids. In the human genome, fifty forkhead proteins have been identified and categorized 
into 19 subgroups  on the basis of sequence homology and forkhead domain structure
10
. 
Several FOX factors activate target genes by binding to forkhead response elements 
(FHREs) in the gene’s promoter region. This is followed by the recruitment of the co-
activator histone acetyltransferase CBP/p300, which creates a relaxed open chromatin 
structure that permits binding of the transcriptional machinery
11,12
. Literature shows that 
FOX proteins might exert opposite roles in cell fate decisions by regulating a wide range of 
gene networks that are involved in cell cycle progression, proliferation, differentiation, as 
well as in cellular metabolism, senescence, survival and apoptosis
1
. 
It has been demonstrated that two of the mostly studied FOX's transcription factors, 
FOXM1 and FOXO3a, bind to the same DNA motif in target promoters. However,  they 
produce opposing transcriptional effects
2,13
: FOXO3a mainly plays as a tumor suppressor, 
whereas FOXM1 acts primarily as proto-oncogene. Inactivation of FOXO3a or 
overexpression of FOXM1 is therefore often associated with tumorigenesis and cancer 
progression. However, FOXO3a can also contribute to cancer’s drug resistance by driving 
the expression of genes important for drug efflux, DNA repair and cell survival pathways 
in drug resistant cancers
14,15
. Given their pivotal roles in drug sensitivity and resistance, 
both FOXO3a and FOXM1 could be important targets for the treatment of cancer and for 
overcoming drug resistance
16
. 
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1.2.1 FOXM1 
Forkhead Box M1 (FOXM1), also previously known as Trident (in mouse), HFH-11 (in 
human), WIN or INS-1 (in rat), MPP-2 (partial human cDNA) and FKHL-16 is a member 
of the Forkhead superfamily of transcription factors
3
. There are three FOXM1 isoforms, A, 
B and C. Isoform FOXM1A has been shown to be transcriptionally inactive, whereas 
FOXM1B e C are transcriptionally active.  
Structurally, FOXM1 full-length protein can be divided into three distinct functional 
regions: an N-terminal Repressor Domain (NRD), a Forkhead/Winged-helix domain 
(FKH) and a Transactivation Domain (TAD). It is believed that the NRD folds back to 
suppress the transactivational activity of the TAD
17
. 
 
 
Figure 1: FOXM1 protein domains: NRD, FKH and TAD. (Adapted from Ref 
3
). 
 
FOXM1 plays a major role in regulating cell proliferation and cell cycle progression
18–20
. 
As such, it is ubiquitously expressed in all embryonic tissues, and proliferating cells of 
both epithelial and mesenchymal origin
21
. However, FOXM1 can also be a potent 
oncogene of which deregulation leads to cancer initiation, progression and to development 
of cancer drug resistance: FOXM1 has been found to be upregulated in many human solid 
tumours such as liver, prostate, brain, breast, lung, colon, pancreas, skin, cervix, ovary, 
mouth, blood and nervous system
22
. 
 
 
1.2.1.1 FOXM1 IN TUMORIGENESIS 
 
FOXM1 exerts its oncogenic function regulating a wide spectrum of biological processes, 
including cell proliferation, cell cycle progression, cell differentiation, DNA damage 
repair, angiogenesis, metastasis, apoptosis and drug resistance
3
. 
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Figure 2: FOXM1 regulates several biological processes. (Adapted from Ref
20
). 
 
 Cell cycle progression and cell proliferation 
FOXM1 is a master regulator of genes fundamental for cell cycle progression: its 
overexpression is necessary for the hyper-proliferative pattern of tumor cells. FOXM1 
synthesis starts in the early G1-phase and is stimulated by growth factors. FOXM1 
activity increases at the entry of cell cycle S-phase, remaining stable during G2/M 
phase, and is finally degraded at the mitotic exit. To exert its activity, FOXM1 
associates itself with cyclin E-cdk2 complexes in the G1 and S phases of the cell cycle, 
whereas it preferentially binds the cyclin B-cdk1 complex in the G2 phase
23
. Through 
the G1-S phases,  FOXM1 regulates the transcriptional activity of a number of genes, 
including genes encoding Plk1, Aurora B, Cyclin B1, CDC25B, CENP-A, 
and Survivin. This will promote several events of early mitosis, such as chromosome 
condensation, nuclear envelope disruption and the attachment of the mitotic spindle to 
the centromere. FOXM1 also regulates a series of genes essential for mitotic spindle 
integrity, such as CENPA, CENPF, NEK2 and KIF20
20,24
.
 
Furthermore, FOXM1 
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activity induces p27
Kip1
 and p21
Cip1
 degradation through upregulation of S-phase 
kinase-associated protein 2 (skp2) and CDK subunit 1. Thus, FOXM1 depletion results 
in cell cycle arrest in G2/M phase, mitotic spindle defects, chromosome disaggregation 
and mitotic catastrophe
25
. 
 
 Senescence and Stem cells: FOXM1 protects cells from genotoxic agent-induced 
senescence by enhancing DNA repair
26,27
. Furthermore, FOXM1 promotes stem cell-
like properties, such as cell renewal, immortalisation, sustained proliferative ability and 
pluripotency, by enhancing the OCT4 gene expression and so suppressing cellular 
differentiation. In this way FOXM1 can also enhance the WNT signalling pathway,  
which is crucial for the stem cell renewal
28,29
. 
 
 Angiogenesis: FOXM1 directly regulates VEGF expression, thus promoting the 
formation of the new blood vessels around the growing tumour, essential for the 
tumour’s growth30,31. In pancreatic cells FOXM1 induces the expression of caveolin, a 
structural component of caveolar membrane thus promoting tumor invasion
31
. 
 Metastasis: FOXM1 induces the epithelial-mesenchymal transition (EMT) phenotype 
in pancreatic cancer cells by activating mesenchymal cell markers, rendering tumor 
cells more invasive and aggressive
32
. Moreover, it has been documented in different 
malignancies, such as glioblastoma, colorectal carcinoma, and breast carcinoma, that 
FOXM1 enhances metalloproteinases (MMPs) expression
33–35
.
 
 Drug resistance: Recent research findings also place FOXM1 at the centre of drug 
resistance
20
. FOXM1 confers resistance to genotoxic drugs and radiation therapy by 
regulating DNA damage repair genes, particularly those involved in homologous 
recombination, including  XRCC1, BRCA2, CHEK1 (also known as CHK1), RAD51 
and BRIP1
3
. Congruously, FOXM1 silencing re-sensitizes drug-resistant cells to 
chemotherapy
27
. 
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1.2.1.2 FOXM1 REGULATION 
 
Through-out cell cycle progression, FOXM1 transcriptional activity depends upon its 
phosphorylation by cyclin, cyclin-dependent kinases (cdk) and Plk1 kinase. FOXM1 is 
firstly phosphorylated in the C-terminal activation domain by cyclin/cdks. Only then Plk1-
dependent phosphorylation can occur. The phosphorylated and transcriptionally active 
FOXM1 accumulates as the cells progress through the cell-cycle. At the end of the M-
phase, FOXM1 becomes dephosphorylated, and, in the early G1-phase of the next cycle, it 
is polyubiquitinated by APC/C-Cdh1 for degradation by the proteasome. FOXM1 
degradation in the early G1-phase is important for regulated entry into S-phase. Thus, in 
proliferating cells, FOXM1 is synthesized and degraded in every cycle of cell division. 
FOXM1 can also regulate its own expression: Halasi et al. showed that FOXM1 is 
involved in a positive auto-regulatory loop since it binds and activates its own proximal 
promoter
36
. Therefore, FOXM1 inhibition mediated by the thiazole antibiotic thiostrepton, 
not only downregulates FOXM1 transcriptional activity, but it also reduces its mRNA and 
protein levels
37
. It is believed that FOXM1 NRD domain might fold back to suppress the 
transactivational activity of the TAD domain.  
 
1.2.1.3 FOXM1 AND LEUKAEMIA  
 
FOXM1 also plays a major role in the promotion of cell proliferation and tumor 
progression in haematological malignancies. Previous studies conducted by Nakamura et 
al. in myeloid leukaemia, showed that FOXM1 has a capacity to regulate the cell cycle 
progression
38
. Interestingly Tüfekçi et al. found that the FOXM1 gene is overexpressed in 
the T-ALL cell line, and that dexamethasone and siomycin A caused a reduction in the 
gene expression levels of FOXM1
39
. Other studies have also revealed that FOXM1 
downregulation induces the inhibition of cell growth in B-lymphoma. However, FOXM1's 
involvement in B-lymphoblastic leukaemia progression and therapy has not been 
investigated yet. Bhatla et al. have identified in a cohort of relapsed B-ALL paediatric 
patients, a series of genes which are up-regulated included FOXM1. Recently Zhao et al. 
highlighted the hypothesis that FOXM1 could be an important target in B cell malignancy. 
FOXM1 acts as a coactivator of the nuclear factor kB (NFkB) in lymphoblastoid B cell 
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lines (LCLs), promoting cell proliferation and cancer transformation
40
. Taken together, this 
data suggests that FOXM1 might be a key biological target to block cancer cell 
proliferation and tumor development in B-ALL. 
 
 
1.2.2 FOXO3a TRANSCRIPTION FACTORS 
 
The FOXO proteins represent a subfamily within the larger group of FOX transcription 
factors. In mammals it consists of three members: FOXO1 (also called FKHR), FOXO3a 
(also called FKHRL1), and FOXO4 (also called AFX)
41
.  
FOXO3a regulates a multitude of important cellular processes, including proliferation, 
apoptosis, differentiation, and metabolism
42,43
. This transcription factor is structurally 
characterized by the presence of four domains: the highly conserved DNA binding domain 
(DBD or FHD) that defines all forkhead proteins, a nuclear localisation signal (NLS) 
located just downstream of DBD, a nuclear export sequence (NES) and a C-terminal 
transactivation domain (TAD).  
 
 
 
Figure 3: FOXO3a protein domains: FHD, NLS, NES and TAD. (Adapted from Ref 
3
). 
 
 
FOXO3a exerts its transcriptional function only when it is localized in the nucleus. 
However, its intracellular localization and activity is often strongly influenced by an 
intricate network of signal transduction cascades that might induce its translocation from 
the nucleus to the cytoplasm and subsequent proteasomal degradation. 
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1.2.2.1 POST-TRANSLATIONAL MODIFICATIONS (PTMS) OF FOXO3a 
 
FOXO3a is regulated by a broad variety of external stimuli, including insulin, insulin-like 
growth factor (IGF-1), nutrients, cytokines and oxidative stress. These environmental 
stimuli control FOXO3a activity by altering the complicated combination of post-
translational modifications that regulate FOXO3a protein expression, subcellular 
localization or DNA binding. The post-translational modifications that primarily regulate 
FOXO3a subcellular localization and function are phosphorylation, acetylation, 
ubiquitination  and methylation. 
 
 Phosphorylation 
The most important control mechanism characterized for FOXO3a is its regulation by the 
PI3K/Akt pathway
42
. Upon PI3K activation by growth or survival factors, Akt 
phosphorylates FOXO3a at the conserved residues Thr32, Ser253 and Ser315. This leads 
to 14-3-3 proteins binding, nuclear exportation and subsequent FOXO3a degradation via 
the ubiquitination-mediated proteasome pathway
44,39
.  Another factor that can promote the 
nuclear export of FOXO3a is the Casein kinase (CK) 1 dependent FOXO3a 
phosphorylation at Ser318 
45,46
. 
 
                         
Figure 4: FOXO3a translocates from nucleus to the cytoplasm following PI3K/Akt dependent 
phosphorylation. 
 
Similarly, ERK-mediated phosphorylation of FOXO3a on S294, S344 and S425 residues 
provokes FOXO3a cytoplasm retention and its degradation through ubiquitin E3 ligases, 
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MDM2
47
. Conversely, under stress conditions, FOXO3a can be phosphorylated by two of 
the three canonical MAPKs (i.e. ERK, p38, and JNK), p38 and JNK/SAPK kinases, 
leading to its nuclear relocalization and transcriptional activation. JNK  
activates FOXO3a by phosphorylation, as it acts on the related FOXO4 at Thr447 and 
Thr451, whereas p38 phosphorylates FOXO3a on Ser7
48,42
. 
 
 Ubiquitination  
When FOXO3a is phosphorylated at specific residues, the ubiquitination process promotes 
its proteasomal recognition and degradation. The ubiquitin E3 ligases (MDM2) binds to 
FOXO3 as a consequence of ERK mediated FOXO3a phosphorylation whereas Skp2, 
another E3 ligase, can recognize the Ser253 phosphorylated FOXO3a and degrade it by 
polyubiquitination
49,50
. 
 
 Acetylation 
Similarly to phosphorylation, acetylation might both promote or decrease FOXO3a 
transcriptional activity. The effect of acetylation on FOXO3a is controlled by histone 
acetyltransferase and by histone deacetylases. Immuno-precipitation analysis revealed that 
the acetyltransferase CBP/p300 binds to the first 52 amino acids of the N-terminal region 
of FOXO3a
51
. p300 might also directly acetylate FOXO transcription factors at Lys-242, 
Lys-245 and Lys-262 residues
52
. However, p300-dependent acetylation was shown to have 
a dual function in FOXO-mediated transcription: it can either attenuate its transcriptional 
activity or it can promote the recruitment and assembly of the transcriptional machinery, 
thus increasing FOXOs DNA-binding ability and transcriptional activity
53,54
. FOXO3a 
acetylation status can be further modulated by class III histone deacetylases (sirtuins), such 
as SIRT1, SIRT2, SIRT3 and SIRT6. Motta et al. showed that the nicotinamide adenine 
dinucleotide (NAD)-dependent histone deacetylase, SIRT1 contracts the p300-mediated 
transactivation of FOXO3a
55
. Furthermore, SIRT6 overexpression correlates to FOXO3a 
inactivation and SIRT6 depletion sensitizes MCF7 cells to both paclitaxel and epirubicin 
treatment
56
. Altogether, these evidences suggest that FOXO3a acetylation might be 
fundamental for its activation.  
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 Methylation 
It has been found that FOXO3 methylation at lysine 270 inhibits FOXO3a-mediated 
oxidative stress and apoptosis
57
. Accordingly, Calnan et al. showed that methylation of 
FOXO3a at lysine 271 by methyltransferase Set9 decreases its protein stability, while 
moderately increasing FOXO3a transcriptional activity
58
. 
 
All these post-translational modifications might strongly influence FOXO3a activity. 
Although FOXO3a is mainly described as a bona fide tumour suppressor, literature reveals 
that this transcription factor might also act as a proto-oncogene contributing to cancer 
development and drug resistance. However, the mechanisms that allow FOXO3a to play a 
controversial role in cancer cells have not been well clarified. Studies suggest that 
FOXO3a transcriptional output might be related to its pattern of post-translational 
modifications resulting from different external stimuli
59,45
. 
 
 
1.2.2.2 FOXO3a IN LEUKAEMIA 
 
FOXO3a has crucial role in controlling cell cycle arrest, apoptosis and self-renewal in 
haematopoietic progenitor cells. However, FOXO3a might play an antagonistic role at the 
axis of cancer drug sensitivity and resistance: FOXO3a has been described both as a tumor 
suppressor and as proto-oncogene. Consistently with its putative role as tumor suppressor, 
a report by Kornblau, et al. showed that high levels of FOXO3a phosphorylation are 
correlated to an adverse prognosis in AML
60
. Recently, Ausserlechner et al. showed that 
activating the transcription factor FOXO3a induces apoptotic cell death in therapy-resistant 
T-ALL cells
61
. Furthermore, deletion of FOXO family members in mice leads to the 
development of T-cell lymphoma
62
. Beside its function as a tumor suppressor, FOXO3a 
might also facilitate cancer cell survival under certain circumstances. Naka et al. found that 
chronic myeloid leukaemic cells with nuclear localization of FOXO3a and decreased Akt 
phosphorylation are enriched in the LIC population (leukaemia initiating cells)
63
. 
Moreover, FOXO3a induces the expression of multidrug resistance (MDR) pumps 
following doxorubicin treatment
14
. 
 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
14 
 
The involvement of FOXO3a in B-ALL progression and therapy has not been investigated 
so far. A previous study of Bachmann et al. reported a correlation between dexamethasone 
resistance and BIM expression in childhood T and B- ALL
64
. More specifically, the 
glucocorticoid resistance seemed to correlate with defective induction of the pro-apoptotic 
protein BIM, a FOXO3a target gene. Furthermore, Dewar et al. depicted that  FOXO3a 
tumor suppressor activity is attenuated in BCR-ABL-mediated diseases and, more 
importantly, the therapeutic mediated reactivation of FOXO3a induces remission
65
. 
 
1.2.2.3 FOXO3a-FOXM1 INTERPLAY 
 
FOXO3a has been described as a functional antagonist of FOXM1. It has been found that 
FOXM1 is a direct transcriptional target repressed by FOXO3a proteins and a vital 
downstream effector of the PI3K-Akt-FOXO axis
66
. FOXO3a can act by either displacing 
FOXM1 from the response elements (FHRE) of promoters of its target genes, or by 
inducing the chromatin condensation, reducing then the FOXM1 accessibility to the gene 
promoter, or by directly repressing FOXM1 gene expression
20
.  
 
 
Figure 5: FOXO3a and FOXM1 antagonize each other's activity. (Adapted from Ref
20
). 
 
Although FOXO3a and FOXM1 compete for binding to the same response elements in 
target genes, they are capable of regulating distinct functional gene networks. 
For instance, FOXM1 activates while FOXO3a represses VEGF expression to control 
breast cancer cell angiogenesis and migration
66
. Importantly, FOXO3a downregulation 
drives the expression of genes essential for cell proliferation, survival and DNA damage 
repair, as well as cancer cell maintenance and progression
13
. Consistently, FOXM1 is often 
overexpressed and activated, whereas FOXO3a activity is frequently repressed, in drug-
resistant cancer cells
13,67
. Therefore, targeting the FOXO3a–FOXM1 axis is an attractive 
strategy for overcoming drug resistance. 
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1.3 AIM OF THE PROJECT 
 
FOXO3a and FOXM1 forkhead transcription factors are key players in cancer initiation, 
progression and drug resistance. However the role exerted by these transcription factors in 
B-ALL is still unknown. 
FOXM1 is a well-known oncogene that promotes tumor progression by improving cell 
cycle progression and cell proliferation. However, although its proto-oncogene function 
has been described in myeloid leukaemia and B-lymphoma, FOXM1 involvement in B-
lymphoblastic leukaemia has not been investigated yet. 
We performed a series of  experiments to investigate whether FOXM1 plays a role in B- 
lymphoblastic leukaemia progression. We further analysed whether FOXM1 inhibition by 
either knockdown or thiostrepton treatment might suffice to increase chemotherapy 
efficiency and overcome drug resistance.  
Furthermore, since the role exerted by FOXO3a in B-ALL is also still not clear, we 
performed a series of experiments to investigate if this transcription factor might regulate 
dexamethasone responsiveness in B-ALL. In addition, we analysed if phosphorylation and 
acetylation might modulate FOXO3a activity and thus sensitise cells to glucocorticoid 
therapy.  
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1.4. RESULTS 
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1.4.1 ABSTRACT  
Background: The Forkhead box protein M1 (FOXM1) is a transcriptional factor that play 
a central role in the regulation of cell cycle, proliferation, DNA repair, and apoptosis. Since 
FOXM1 is overexpressed in many tumor types and its up-regulation has been linked to 
high proliferation rates and poor prognosis, we studied the role of FOXM1 in B-
lymphoblastic leukaemia (B-ALL) in order to understand if FOXM1 could be a key target 
for leukaemia therapy. 
Methods: RT-PCR and western blot analysis was carried out in a small cohort of pediatric 
B-ALL patients to evaluate FOXM1 levels. To assess the biological relevance of FOXM1, 
in B-lymphoblastic leukemic (B-ALL), its expression was downmodulated by transient 
RNA interference in B-ALL cell lines (REH and NALM-6).  
Results:  Our results showed that FOXM1 expression is higher in both B-ALL patients and 
cell lines compared to PBMC or CD19
+
 cells from healthy donors. Furthermore, blocking 
FOXM1 activity in two B-ALL cell lines, by either knockdown or treatment with the 
FOXM1 inhibitor thiostrepton, causes significant decreases in the cell proliferation in both 
cell lines. The decrease in cell proliferation was accompanied by an induction of G2/M 
arrest of the cell cycle along with a reduction in the S phase. Moreover, thiostrepton 
synergises with chemotherapeutic agents commonly used in B-ALL therapy increasing 
their efficiency. Conclusion: Our results suggest that FOXM1 is highly express in both 
patients and B-ALL cells both  and that targeting FOXM1 could be an attractive strategy 
for leukaemia therapy and for overcoming drug resistance. 
 
 
Keywords. FOXM1; B-acute lymphoblastic leukemia; chemotherapy; drug resistance; 
thiostrepton 
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1.4.2 INTRODUCTION 
FOXM1 is a member of the Forkhead family of transcription factors, also known 
previously as Trident (in mouse), HFH-11 (in human), WIN or INS-1 (in rat), MPP-2 
(partial human cDNA) and FKHL-16.(Lam et al, 2013) FOXM1 is a potent oncogene 
whose expression is frequently up-regulated during cancer initiation. FOXM1 expression 
increases at the entry of the S-phase of the cell cycle, remains stable during G2/M phase, 
before it is degraded at mitotic exit.(Laoukili et al, 2005, 2008) FOXM1 also controls 
mitosis through regulating the transcription of the mitotic regulatory genes, including PLK, 
cyclin B1, Aurora A and B kinases (Wang et al, 2005) and in addition, it play a major role 
in maintaining chromosome stability.(Laoukili et al, 2005) FOXM1 has an important role 
in cell cycle progression and cell proliferation. As such, its expression levels correlate with 
the proliferative state of a cell. In fact, FOXM1 is highly expressed in all embryonic 
tissues, and in particular in proliferating cells of epithelial and mesenchymal 
origin.(Gemenetzidis et al, 2010) Its expression is also detected at increased levels in 
numerous human cancer cell lines and is associated with the development and progression 
of many malignancies(Huynh et al, 2011; Wang et al, 2011), high proliferation rates, 
drug(Khongkow et al, 2013; Li et al, 2013; Monteiro et al, 2013) and poor prognosis in 
many cancer types.(Liu et al, 2006; Bektas et al, 2008; Martin et al, 2008; Chu et al, 2012; 
Xia et al, 2012). 
B-lymphoblastic leukaemia (B-ALL) is a malignant disorder which derives from clonal 
proliferation of lymphoid precursors with arrested maturation. The involvement of 
FOXM1 in B-ALL progression and therapy has not been investigated so far. A previous 
study by Nakamura et al. has investigated the cell proliferation role of FOXM1 in myeloid 
leukaemia, showing its capability to promote cell cycle progression.(Nakamura et al, 2010) 
Another report by Uddin et al. has also described the involvement of FOXM1 in B-cell 
lymphoma migration and invasion.(Uddin et al, 2012) Other studies have also 
demonstrated that FOXM1 downregulation provokes the inhibition of cell proliferation in 
B-lymphoma(Wang et al, 2013) and very recently it has pointed out that FOXM1 pathway 
could be a potential therapeutic target in B cell malignancy.(Zhao et al, 2014) The fact that 
FOXM1 is an oncogene that promote tumor progression and that it is up-regulated in 
relapsed B-ALL patients(Bhatla et al, 2012) prompted us to investigate a potential role of 
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FOXM1 in B-ALL cell proliferation with the aim of understanding if it can be targeted to 
increase the efficiency of chemotherapeutic treatment, and to overcome drug resistance in 
this haematological malignancy. 
 
1.4.3 MATERIALS AND METHODS 
 
Primary leukaemia cell cultures 
The mRNA and protein samples of PBMC from healthy donors were obtained from cells 
separated by Ficoll-Paque centrifugation. Diagnostic RNA samples of bone marrow (BM) 
aspirates of B-leukaemic patient’s with a blast count of 80–95 % were kindly allowed from 
the cell bank of the Dipartimento di Salute della Donna e del Bambino, University of 
Padova, Italy. B-ALL patient samples were obtained after informed consent following the 
tenets of the Declaration of Helsinki. The study was approved by the Italian Association of 
Pediatric Onco-Hematology (AIEOP). All analyzed BCP-ALL samples were obtained at 
the time of diagnosis before treatment, after Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden) separation of mononuclear cells as described previously.(Accordi et al, 2013) The 
percentage of CD19
+
 cells ranged from 80% to 95%. Human B-leukaemia cell lines, REH, 
SEM, MHH-CALL2, RS4;11 and NALM-6, were grown in RPMI-1640 medium (Gibco, 
Milano, Italy) all supplemented with 115 units/mL penicillin G (Gibco, Milano, Italy), 115 
μg/mL streptomycin (Invitrogen, Milano, Italy), 10 % fetal bovine serum (Invitrogen, 
Milano, Italy), and maintained at 37 °C in a humidified atmosphere with 5 % CO2. 
Quantitative Real time PCR 
Total RNA was isolated from frozen cell pellets using the RNeasy Mini kit (Qiagen, UK) 
according to manufactures’ instructions and RNA purity and concentration were 
determined by measuring the spectrophotometric absorption at 260 nm and 280 nm on 
NanoDrop ND-1000. 1 μg of total RNA was reversed transcribed into first starnd cDNA 
using Superscript III first stand cDNA synthesis (Life technologies, UK) Briefly, 1 μl of 50 
μM oligo(dT)20 and 1 μl of 10 mM dNTPs mix were added to the RNA before the volume 
was adjusted to 11 μl using Rnase–free water. Samples were denaturated at 65 ºC for 5 min 
and then quickly chilled on ice for 1 min. Subsequently, 1 μl of the reverse transcriptase 
Superscript III (200U/ μl) was added, along with 1 μl 0.1 M DTT, 1 μl Rnase OUT 
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Recombinase Inhibitor and 1 x First Stand Buffer. The solution was incubated at 25 ºC for 
5 min then heated at 50 ºC for 50 min. The reaction was inactivated by heating at 70 ºC for 
15 min. For real-time quantitative PCR, 1 µl of cDNA was used as template in a 24 µl 
reaction carried out with Power SYBR Green kit (Applied Biosystems, UK) with ABI 
7800 system (Applied Biosystems, UK). The mRNA levels of target genes were calculated 
relative to the expression of L19 mRNA levels using the Ct method.  
Primers used: FOXM1-fwd 5’TGCAGCTAGGGATGTGAATCTTC3’; FOXM1-rv 5’ 
GGAGCCCAGTCCATCAGAACT3’; MKI67-F, 5’- CGACGGTCCCCACTTTCC-3’; 
MKI67-R,5’ GCTGGATACGGATGTCACATTC-3’; CCNB1-F, 5’- 
CAGTTATGCAGCACCTGGCTAAG-3’; CCNB1-R, 5’- 
TGTGGTAGAGTGCTGATCTTAGCAT-3’ ;AURKB-F, 5’- 
CAGTGGGACACCCGACATC-3’ ; AURKB-R, 5’- 
GCCCAATCTCAAAGTCATCAATT-3’ ; L19-F ; 5’- GCGGAAGGGTACAGCCAAT-
3’ ; L19-R, 5’- GCAGCCGGCGCAAA-3’. 
 
Western Blot Analysis 
 
REH, SEM, MHH-CALL2, RS4;11 and NALM-6, after experimental conditions, were 
collected, centrifuged, and washed two times with ice cold phosphate buffered saline 
(PBS). For western blot analysis cells were lysed as described previously.(Hui et al, 2008) 
Proteins were resolved  by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS−PAGE) (using 7 or 10 % acrylamide gels), transferred to PVDF Hybond-P 
membrane (GE Healthcare) and immunoblotted with primary antibodies against, FOXM1 
(Santa cruz, C-20), β-Tubulin (Santa cruz), Aurora B (Cell Signalling), Cyclin B1 (Santa 
cruz). The membranes were washed four times with Tris-Buffered Saline and Tween 20 
(TBS-T) for 15 min prior to incubation with the respective peroxidise (HRP)-conjugated 
secondary antibody (Dako, Ely, UK), at 1:2000 dilution for 30 min at room temperature 
and again washed four times with TBST-T for 20 min. Protein were visualised using 
enhanced chemiluminescence (ECL) detection system (PerkinElmer, Seer Green, UK) with 
Amsterdam Hyperfilm ECL (GE Helthcare, Little Chalfont, UK) and signal was detected 
using the SRX-101A X-ray developer (Konica Minolta, Tokio, Japan).  
 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
21 
 
RNA interference with small interfering RNAs (siRNAs) 
For FOXM1 silencing, REH or NALM-6 cells were transiently transfected with siRNA 
SMARTpool reagents purchased from Thermo Scientific Dharmacon (Lafayette, CO, 
USA) using the transfection reagent  Oligofectamine (Life Technologies, UK) according to 
the manufactures instructions. SMARTpool siRNAs used were: siRNA FOXM1 (l-
009762-00) and the non-specific (NS) control siRNA, ON-TARGETplus Non-Targeting 
pool (D-001810-10) confirmed to have minimal targeting of known genes. All siRNA 
pools were resuspended to 20 µM in 1x siRNA buffer. 
Annexin-V assay.  
Surface exposure of phosphatidylserine on apoptotic cells was measured by flow 
cytometry with a Coulter Cytomics FC500 (Beckman Coulter) by adding annexin-V 
conjugated to fluorescein isothiocyanate (FITC) to cells according to the manufacturer’s 
instructions (Annexin-V Fluos, Roche Diagnostic). Simultaneously, the cells were stained 
with PI. Excitation was set at 488 nm, and the emission filters were at 525 and 585 nm, 
respectively, for FITC and PI. 
Flow cytometric analysis of cell cycle distribution.  
For flow cytometric analysis of DNA content, 5 × 10
5
 of REH, and NALM-6 cells were 
either treated with 0.5 µM and 1µM of thiostrepton or knocked-down for FOXM1 and 
after 24, 48 and 72 h of treatment or knockdown, cell cycle analysis was performed as 
previously described.(Bortolozzi et al, 2014) 
Drugs Combination studies 
Cell proliferation was assessed by MTT (3-4,5-dimethylthiazol-2-yl-2,5-diphenyl 
tetrazolium bromide) assay after treatment. Equal concentrations of cells were plated in 
triplicate in a 96-well plate and incubated with 10 µl of MTT (Sigma-Aldrich, St Louis, 
MO, USA) for 4 h. Absorbance was measured at 562 nm using Victor
3TM
 1420 Multilabel 
Counter (PerkinElmer, Waltham, MA, USA). Cells were treated for 48 h using scalar 
dilutions of thiostrepton (Sigma-Aldrich), combined with cytarabine (Aractyn, Pfizer), 
daunorubicin (Pfizer), vincristine, dexamethasone (Sigma-Aldrich). Thiostrepton was also 
added to drug solutions at fixed combination ratios. The effectiveness of various drug 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
22 
 
combinations was analyzed by the Calcusyn Version 2.1 software (Biosoft). The 
combination index (CI) was calculated according to the Chou-Talalay method.(Chou, 
2010) A combination index of 1 indicates an additive effect of the 2 drugs. Combination 
index values less than 1 indicate synergy, and combination index values more than 1 
indicate antagonism.  
Statistical Analysis 
Results are presented as the mean ± SEM. The differences between different conditions 
were analyzed using the two-sided Student’s t test. P values lower than 0.05 were 
considered significant. *, p ≤ 0.05: **, p ≤ 0.01, ***p ≤ 0.001. 
 
 
1.4.4 RESULTS 
FOXM1 is overexpressed in B lymphoblastic leukaemic patients  
To investigate if FOXM1 transcription factor plays a role in B lymphoblastic leukaemia 
(B-ALL) proliferation, we analyzed FOXM1 mRNA levels in ten B-ALL pediatric patients 
and peripheral blood mononuclear cells (PBMC) from healthy donors. For these 
experiments, the mRNA was extracted from cell pellets of patients recruited at the time of 
diagnosis. In particular, the first two patients selected were characterized by chromosomal 
translocations at chromosome 12 and 21 [t(12;21)]; patients 3, 4 and 5 carried the 
translocation between the chromosome 9 and 22 [t(9;22)], whereas the other five patients 
were without translocations (Table S1, supplementary information). As shown in Figure 
1A, RT-qPCR data showed that FOXM1 mRNA levels were significantly higher in 
patients compared to the samples of healthy donors. Interestingly, associated with higher 
levels of FOXM1 mRNA, there was a significant increment of Cyclin B1 and Aurora B 
mRNA levels, two genes whose expression is directly regulated by FOXM1 (Figure S1, 
supplementary information). In addition to mRNA levels, protein expression was also 
examined by western blot analysis. As shown in Figure 1B, the expression of FOXM1 as 
well as its targets Aurora B and Cyclin B1 was generally higher compared to healthy cells, 
confirming higher FOXM1 activity.  
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Figure 1. FOXM1 is higher expressed both in B-ALL patients and in B-ALL cell lines compared to 
healthy donors. A) Basal FOXM1, mRNA levels were analyzed in ten samples of B-ALL patient’s and 
compared to peripheral blood mononuclear cells (PBMC) of healthy donors by RT-qPCR. B) FOXM1 is 
overexpressed in B-ALL cell lines. Total RNA from five B-ALL cell lines (REH, MHH-CALL2, SEM, 
RS4;11, NALM-6) was extracted and FOXM1, mRNA levels were analyzed and compared to PBMC of 
healthy donors by RT-qPCR. The results were normalised with L19 mRNA levels using the DDCt method 
The median of threshold cycles (Ct) values were normalized to the median of Ct values of the L19 mRNA 
levels. Results are the average ± SD of three independent experiments in triplicate. C) Cell lysates were 
obtained from ten B-ALL patients and analyzed for the expression of FOXM1 and its downstream target 
genes Cyclin B1 and Aurora B in comparison to PBMC. D) REH, MHH-CALL2, SEM, RS4;11, NALM-6 
cell lysates were collected at basal conditions for subsequent western blot analysis for the indicated 
antibodies.  
 
Similar results were obtained when the mRNA or protein expression levels of B-ALL 
patients were compared to those from CD19 positive cells isolated from healthy donors. In 
this case due to the scarcity of the protein extract we have performed western blot analysis 
utilizing the bone marrow of further ten patients, without translocation, obtaining similar 
results (figure S2, supplementary information). Taken together, these data showed that 
the expression levels and activity of FOXM1 are increased in B-ALL patient samples when 
compared to healthy lymphocytes, suggesting that FOXM1 plays a key function in 
supporting the cell proliferation and progression of B-ALL. 
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FOXM1 is overexpressed in B-ALL cell lines  
Next, we investigated the FOXM1 expression levels in five different B-ALL cell lines. 
More specifically, we analyzed the mRNA levels of FOXM1, at basal conditions, 
comparing five different B-ALL cell lines (REH, MHH-CALL2, SEM, NALM6, RS4;11) 
with mRNA samples of PBMC obtained from healthy donors. RT-qPCR analysis showed 
in Figure 1C reveals that FOXM1 mRNA levels were significantly higher in B-ALL cell 
lines when compared to normal lymphocytes and this pattern was again accompanied by 
increased transcriptional levels of Cyclin B1 and Aurora B (Figure S2, supplementary 
information). In agreement with the mRNA expression patterns, western blot analysis 
revealed that FOXM1 expression was generally higher in leukaemic cells compared to 
normal lymphocytes. This was again associated with Cyclin B1 and Aurora B up-
regulation in leukaemic cells (Figure 1D). Similar results were obtained when FOXM1 
mRNA and protein expression was examined in B-ALLs isolated from patients and healthy 
CD19
+ 
cells (figure S2, supplementary information). 
 
Knockdown of FOXM1 decreases cell proliferation in B-ALL cell lines and induces a 
G2/M cell cycle arrest 
To test if FOXM1 has a role in promoting B-ALL proliferation, we knocked-down its 
expression in two B-ALL cell lines REH and NALM-6 using a specific FOXM1 siRNA 
pool and assessed their cell viability after 24, 48, and 72 h post-transfection. FOXM1 
silencing was confirmed by western blot and RT-qPCR analysis (Figure 2A-D). Aurora B 
and Cyclin B1 protein levels were clearly downregulated in FOXM1-depleted NALM-6 
and REH cells compared to cells transfected with non-specific (NSC) control siRNA pool 
(Figure 2A and 2B). Furthermore, in both REH and NALM-6 cell lines, RT-qPCR 
analysis revealed a significant decrease in Aurora B mRNA levels, although Cyclin B1 
mRNA levels appeared significantly decreased only in REH cells and not in NALM-6 
(Figure 2C and 2D). 
 
 
 
 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.0
0.5
1.0
 
 
 
C
C
N
B
1
/ 
L
1
9
 m
R
N
A
FOXM1 
siRNA 
NSC
 siRNA 
0.0
0.5
1.0
FOXM1
 siRNA 
 
 
 
F
O
X
M
1
/ 
L
1
9
 m
R
N
A
NSC
 siRNA 
**
0.0
0.5
1.0
1.5
 
 
A
U
R
K
B
/ 
L
1
9
 m
R
N
A
 
FOXM1 
siRNA 
NSC
 siRNA 
**
0.0
0.5
1.0
F
O
X
M
1
/ 
L
1
9
 m
R
N
A
 
 
 
FOXM1 
siRNA 
NSC
 siRNA 
**
0.0
0.5
1.0
1.5
  
 
A
U
R
K
B
/ 
L
1
9
 m
R
N
A
 FOXM1 
siRNA 
NSC
 siRNA 
*
0.0
0.5
1.0
C
C
N
B
1
/ 
L
1
9
 m
R
N
A
 
 
 
 
 
FOXM1 
siRNA 
NSC
 siRNA 
*
A B 
C D 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
26 
 
 
 
 
 
 
 
 
Figure 2. FOXM1 knockdown in REH and NALM6 cells induces a significant decrease in cell 
proliferation. NALM-6 (A) and REH (B) were transfected with the siRNA FOXM1 and the non-specific 
(NSC) control siRNA. Western blot analysis and RT-qPCR confirmed the knockdown of endogenous 
FOXM1 and the reduced expression of Aurora B and Cyclin B1 in NALM-6 cells (C) and REH cells (D). 
Cell viability analysis, was performed by tripan blue assay, after 72 h of transfection in NALM-6 (E) and 
after 48 h of transfection in REH (F). Data are presented as mean ± SD of three independent experiments. 
Statistical analysis was performed using Student’s t-tests against the cells transfected with the non-specific 
(NS) control siRNA. *, p ≤ 0.05: ** p ≤ 0.01 
 
 
Cell proliferation analysis assessed by tripan blue exclusion assay, revealed that upon 
FOXM1 depletion, there was a significant decrease on cell proliferation after 72 h of 
transfection in NALM-6 (Figure 2E) and after 48 h in REH cells (Figure 2F), suggesting 
that FOXM1 plays an important role in B-ALL cell proliferation. Tripan blue negative 
population (live cells) was strongly decreased in cells that were knocked-down for 
FOXM1, and this pattern was associated with no significant changes on dead cell levels 
(tripan blue positive) in NALM-6, and only with a slight increase in the percentage of dead 
cells in REH. These results pointed out that FOXM1 play an important role in B-ALL cell 
proliferation. 
To further analyze the role of  FOXM1 on cell cycle progression in B-ALL, we analyzed 
the cell-cycle phase distribution in NALM-6 and REH cells following FOXM1 
knockdown. As shown in Figure 3A and 3B in both cell lines, there was a significant 
increase of the percentage of cells in G2/M and a corresponding decrease of cells in S 
phase compared with non-specific (NSC) control cells. 
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Figure 3. FOXM1 downregulation in REH and NALM6 cells by a specific FOXM1 siRNA pool induce 
a G2/M cell cycle arrest. In NALM-6 (A) and REH cell (B) lines the endogenous FOXM1 expression was 
blocked by knockdown performed by using Oligofectamine™ Transfection protocol. After 24, 48 and 72 h of 
knockdown, cell cycle analysis was performed to investigate the effect of FOXM1 inhibition in cell cycle-
phase progression.  Results are the average ± SD of three independent experiments in triplicate. Statistical 
analysis was performed using Student’s t-tests against the cells transfected with the non-specific (NSC) 
siRNA. *, p ≤ 0.05: **, p ≤ 0.01, ***p ≤ 0.001. Effect of FOXM1 knockdown on the expression of proteins 
involved in cell cycle regulation. In NALM-6 (C) and REH (D) cell lines the endogenous FOXM1 expression 
was blocked by knockdown and after 48 h, cell were collected, and protein extracts were subjected  to 
western blot analysis for the indicated antibodies. 
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FOXM1 knockdown reduce the expression of cell cycle regulators 
We next evaluated if FOXM1 knockdown induces a modulation of the expression of 
proteins involved in late phase cell cycle regulation. As depicted in figure 3, the silencing 
of FOXM1 both in NALM-6 (figure 3C) and in REH cells (figure 3D), caused the 
downregulation of several cell cycle regulatory proteins such Cyclin B1, Aurora B, 
Survivin, and Cdc25b that are involved in mitotic progression.   
 
 
 
 
 
 
 
 
Figure 3 bis. FOXM1 downregulation in REH and NALM6 cells by a specific FOXM1 siRNA pool 
induce a G2/M cell cycle arrest. Effect of FOXM1 knockdown on the expression of proteins involved in 
cell cycle regulation. In NALM-6 (C) and REH (D) cell lines the endogenous FOXM1 expression was 
blocked by knockdown and after 48 h, cell were collected, and protein extracts were subjected  to western 
blot analysis for the indicated antibodies. 
 
The expression of the S-phase promoting Cdc25a phosphatase which plays a major role in 
G1/ S progression, dephosphorylating Cdk2 and activating CDK2-cyclin E activity 
(Nilsson & Hoffmann, 2000; Bertoli et al, 2013) was strongly reduced. Interestingly, both 
p27
Kip1
 and p21
Cip/Waf1
, two cyclin-dependent kinase inhibitors (CKI) proteins, which also 
play a role in the assembly of cyclin-CDK complexes were also downregulated. Altogether 
these results indicate that FOXM1 is strongly involved in modulating the expression of cell 
cycle regulatory proteins at both G1/S and at G2/M transitions. 
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Thiostrepton treatment induces a decrease in cell viability and induce a G2/M arrest 
To further confirm the role of FOXM1 on B-ALL cell proliferation, we treated cells with a 
thiazole ring containing antibiotic, thiostrepton, a well-established specific FOXM1 
inhibitor.(Kwok et al, 2008; Hegde et al, 2011) This drug causes growth inhibition in a 
small panel of B-ALL cell lines with GI50 in the micromolar and submicromolar range 
(Figure S5, Supplementary information). In this context, we treated both NALM-6 and 
REH cell lines with two different concentrations of thiostrepton, 0.5 µM and 1 µM, 
respectively for 24, 48, and 72 h. The results showed a significant reduction in cell 
viability, revealed by the considerable low numbers of trypan bluee negative cells in both 
NALM-6 and REH cell lines (Figure4 and 5A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. FOXM1 inhibition in NALM-6 cells by thiostrepton treatment induce apoptosis. NALM-6 
cells were treated with thiostrepton at the concentration of 0.5 µM or 1 µM, for 24, 48 and 72 h. Cell viability 
analysis was performed by tripan blue assay (A) whereas induction of apoptosis was assessed by flow 
cytometry after staining of the cells with Annexin-V-FITC and propidium iodide (B). Dual staining permits 
discrimination between live cells (annexin-V
-
/PI
-
), early apoptotic cells (annexin-V
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-
), late apoptotic cells 
(annexin-V
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thiostrepton reduce FOXM1 expression. Data are presented as mean ± SD of three independent experiments. 
Statistical analysis was performed using Student’s t-tests against the control sample (untreated). ** p ≤ 0.01 
 
Moreover flow cytometric analysis carried out after different times of treatment indicate 
that thiostrepton induce apoptosis as demonstrated by the appearance of  a large percentage 
of annexin-V positive cells in both cell lines (Figures 4B and 5B). It important to note that 
apoptosis occur in a concentration- and time-dependent manner. FOXM1 downregulation 
was confirmed by western blot analysis (Figure 4C and 5C) and by RT-qPCR (Figure 4D 
and 5D). It is also notable that in both cell lines FOXM1 protein levels along with its 
downstream target genes, were decreased after treatment with thiostrepton in a similar 
manner to that observed for FOXM1 silencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. FOXM1 inhibition in REH cells by thiostrepton treatment induce apoptosis. REH cells were 
treated with thiostrepton at the concentration of 0.5 µM or 1 µM, for 24, 48 and 72 h. Cell viability analysis 
was performed by tripan blue assay (A) whereas induction of apoptosis was assessed by flow cytometry after 
staining of the cells with Annexin-V-FITC and propidium iodide (B). Dual staining permits discrimination 
between live cells (annexin-V
-
/PI
-
), early apoptotic cells (annexin-V
+
/PI
-
), late apoptotic cells (annexin-
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) and necrotic cells (annexin-V
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reduce FOXM1 expression. Data are presented as mean ± SD of three independent experiments. Statistical 
analysis was performed using Student’s t-tests against the control sample (untreated). ** p ≤ 0.01 
 
We also analyzed the cell-cycle phase distribution in REH and NALM-6 cells following 
the treatment with both 0.5 μM and 1 μM concentrations of thiostrepton at 24, 48, and 72 
h. The results (Figure 6A and 6B) showed that in a similar manner, thiostrepton treatment 
induced an arrest in G2/M cell-cycle phase along with a decrease of the S phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. FOXM1 downregulation in REH and NALM6 cells by thiostrepton treatment induces a 
G2/M cell cycle arrest. NALM-6 (A) and REH cell (B) lines were treated with the indicated concentration 
of thiostrepton. After 24, 48 and 72 h of treatment, cell cycle analysis was performed to investigate the effect 
of FOXM1 inhibition in cell cycle-phase progression. Results are the average ± SD of three independent 
experiments in triplicate. Statistical analysis was performed using Student’s t-tests against the untreated cells. 
*, p ≤ 0.05: **, p ≤ 0.01, ***p ≤ 0.001. 
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Thiostrepton synergises with conventional chemotherapeutic agents in inhibiting B-
ALL proliferation 
Since FOXM1 downregulation led to a decrease in B-ALL cell proliferation, we next 
tested if thiostrepton can be used in combination with the most commonly used 
chemotherapeutics in B-ALL treatment. To this end, four different B-ALL cell lines, two 
glucocorticoid-resistant (REH, SEM) and two glucocorticoid-sensitive (NALM-6, RS4;11) 
were then treated for 48 h with thiostrepton in combination with chemotherapeutic agents 
(i.e. dexamethasone, asparaginase, daunorubicin, vincristine and Ara-C) used normally to 
treat pediatric B-ALL patients. More specifically, thiostrepton was combined with different 
drugs at fixed molar combination ratio, and cell viability analyzed by MTT assay (Figure 
7A and figures S6-S8). 
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Figure 7. Effect of thiostrepton treatment alone and in combination with different chemotherapic 
drugs in NALM-6 cells (A). Cells were treated at the indicated concentration and at fixed combination  ratio 
and viability was assessed by MTT test after 48 hof incubation. Data are expressed as mean ± SEM of three 
independent experiments. NALM-6 (B) and REH (C) cells were knocked down for FOXM1 and after 48 h 
were further treated for 48 h with dexamethasone at the concentration of 1 µM. Cell viability was analyzed 
by  flow cytometry after double staining of the cells with Annexin-V-FITC and PI. Result are expressed as 
mean ± SD of three independent experiments.  Statistical analysis was performed using Student’s t-tests 
against the cells transfected with the non-specific (NSC) siRNA. *, p ≤ 0.05: **, p ≤ 0.01 
 
As described above, thiostrepton alone has a significant cytotoxicity when used as single 
agent. More importantly, when used in combination with chemotherapic drugs, we 
observed a synergistic increase of their cytotoxicity as demonstrated by the values of 
combination index (CI) according to Chou and Talalay.(Chou, 2006, 2010) As depicted in 
Table 1 which reports CI values calculated at GI50, GI75 and GI90, revealed that in almost 
all cell lines tested, thiostrepton and chemotherapeutic drugs acted in a synergistic fashion 
(CI<1). Our results therefore show that in general, the pharmacological downregulation of 
FOXM1 caused by thiostrepton, can significantly increase the cell death effects provoked 
by the treatment with the conventional chemotherapeutic agents used alone.  
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Table 1. Combination index values (CI) in B-ALL cell lines treated with thiostrepton in combination with 
chemotherapic drugs. 
 GI50
b 
GI75
 b
 GI90
 b
 
Dauno (1:10)
a 
 
RS4;11 
SEM 
NALM-6 
REH 
 
 
2.4 
0.27  
0.06 
0.84 
 
 
0.17  
0.28  
0.12 
1.1 
 
 
0.01  
0.35  
0.25 
1.1 
Ara-C (1:1)
 a 
 
RS4;11 
SEM 
NALM-6 
REH 
 
 
0.07  
0.33  
0.0017 
0.16 
 
 
0.02  
0.35  
0.001 
0.29 
 
 
0.006 
0.42  
0.09 
0.54 
Dex (1:10)
 a 
 
RS4;11 
SEM 
NALM-6 
REH 
 
 
0.10  
0.18 
0.8 
1.1 
 
 
0.9  
0.15  
0.044 
0.97 
 
 
8.0 
0.13  
0.24 
0.85 
Vcr (1:1000)
 a 
 
RS4;11 
SEM 
NALM-6 
REH 
 
 
0.04 
1.1 
0.64 
0.09 
 
 
0.02 
0.75 
0.44 
0.02 
 
 
9.5 
0.6 
0.74 
0.01 
Asp (1:1)
 a 
 
RS4;11 
SEM 
NALM-6 
REH 
 
 
0.5 
1.6  
0.10 
1.3 
 
 
0.2 
0.8  
0.13 
0.05 
 
 
 
0.1 
0.4 
0.5 
0.15 
 
a
 Molar ratio with thiostrepton. 
b
 Growth inhibition determined after 48 h of treatment by MTT test. 
Abbreviations: Ara-C, cytarabine; CI, combination index; Dex, dexamethasone; Dauno, daunorubicin;  Vcr, 
vincristine. Synergy, additivity and antagonism are defined by a CI<1, CI=1 or CI>1, respectively. 
 
To further prove this last assumption, we knocked down FOXM1 in REH and NALM-6 
cells using siRNA and treated them with dexamethasone. After 48 h of treatment we 
analyzed cell viability by flow cytometry staining with Annexin-V and propidium iodide 
(PI). The result showed (Figure 7A and 7B) a significant decrease in cell viability after 48 
h of treatment in FOXM1 silenced cells compared to the controls, in particular in 
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glucocorticoid resistant cells, indicating that FOXM1 can be an important therapeutic 
target for overcoming glucocorticoid resistance in B-ALL.  
 
 
1.4.5 DISCUSSION 
FOXM1 is an important regulator of the cell cycle and plays a crucial role in 
tumorigenesis. Its overexpression has been also found in many different human cancers. 
Very little is known about its function in haematological malignancies. Our aim was to 
investigate the role of FOXM1 in B-ALL, the most common pediatric leukaemia. RT-PCR 
analysis performed on ten B-ALL patient samples showed that FOXM1 mRNA, is highly 
overexpressed in comparison to lymphocytes derived from healthy donors. Accordingly, 
this pattern was closely related to an increase in transcript levels of Cyclin B1 and Aurora 
B, two G2/M phase regulators directly regulated by FOXM1. Immunoblot analysis also 
demonstrated similar overexpression of FOXM1 and its downstream targets in samples 
from blast’s patients, suggesting that FOXM1 is also aberrant overexpressed in B-ALL as 
in many other cancer types. In agreement, five B-ALL cell lines analyzed also 
overexpressed FOXM1 and its downstream targets, confirming the results obtained in 
patients. An important finding from our study is that depletion of FOXM1 by siRNA 
caused a significant reduction in cell proliferation in B-ALL cell lines, suggesting a role 
for FOXM1 in the oncogenesis of B-ALL. Moreover, knockdown of FOXM1 led to a cell 
cycle arrest in G2/M, suggesting that FOXM1 promotes cell proliferation through 
modulation of cell cycle progression, as also reported by Nakamura at al. in acute myeloid 
leukemia cells.(Nakamura et al, 2010) Knockdown of FOXM1 in B-ALL cell lines led to a 
downregulation of proteins involved regulation of mitotic progression, consistent with 
previous data.(Nakamura et al, 2010) We also showed that FOXM1 silencing is 
accompanied by a decreased expression of p27
Kip1
 and p21
Cip1/Waf1
 proteins, which are 
known to assemble different Cyclin/Cdk complexes. More precisely they are 
phosphorylated by the Cdk2-cyclin E complex are recognized by the specificity subunits 
Skp2 and Cks1 of the SCF ubiquitin ligase complex, which targets them for ubiquitin- 
mediated proteasome degradation. (Carrano et al, 1999; Hara et al, 2001; Lu & Hunter, 
2010). 
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Thus it is also possible to speculate that their decreases reflect an accelerate 
ubiquitinylation and subsequent degradation. Thiostrepton is a thiazole antibiotic that 
inhibits the transcriptional activity of  FOXM1. It also downregulates FOXM1 mRNA 
expression as FOXM1 also positively autoregulates it own transcription.(Kwok et al, 2008; 
Koo et al, 2012) Indeed, both the mRNA and protein expression of FOXM1 was 
downregulated by thiostrepton in B-ALLs. In this study, we also found that thiostrepton 
remarkably reduces the cell viability of different B-ALL cell lines causing apoptosis in a 
concentration and time dependent manner, and induces a G2/M arrest of the cell cycle, 
consistent with the result obtained with the siRNA-mediated knockdown of FOXM1.  
Standard treatment options for newly diagnosed childhood B-ALL are predominantly 
chemotherapy. Importantly, patients that respond poorly to the chemotherapy treatment are 
predicted to undergo relapse in the future, so an understanding of the biological 
mechanisms which underlie this poor responsiveness is therefore crucial for the 
development of more effective therapies. Consistent with this, Bhatla et al. have identified 
in a cohort of relapsed B-ALL pediatric patients a series of up-regulated genes which also 
includes FOXM1.(Bhatla et al, 2012) 
In light of these results we examined if combining thiostrepton with the chemotherapeutics 
used in B-ALL therapy could increase their efficacy. Our results clearly indicate a strong 
synergistic effect (CI<1) between thiostrepton and drugs with different mechanisms of 
action in the four B-ALL cell lines tested. In particular, it is important to note that 
thiostrepton is able to partially reverse the glucocorticoid resistance in REH cells. 
Furthermore, these results were confirmed, in a more specific way, in the same cell lines 
silenced for FOXM1 (Figure 7). Given that patients that respond poorly to glucocorticoid 
therapy when diagnosed are usually predicted to undergo relapse in the future, our findings 
suggest that FOXM1 inhibition could be a potential useful strategy in clinical therapy to 
optimize the efficacy of existing therapeutics for B-ALL, although further studies are 
needed to better understand the molecular mechanism(s) involved in these synergistic 
effects. In summary, we show that FOXM1 has a role in both the oncogenesis and the 
development of drug resistance in B-ALL, and the targeting of  FOXM1 can be a useful 
means for treating B-ALL and for overcoming drug resistance.  
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1.4.7 SUPPLEMENTARY INFORMATION 
Table S1. Characteristics of patients sample. 
 
B-ALL 
sample 
Gender Age at 
diagnosis 
% of blast in 
BM 
Cytogenetics 
#1 F 6 82 9q22 
#2 M 16 91 9q22 
#3 F 5 77 12q21 
#4 M 3 90 12q21 
#5 F 3 63 12q21) 
#6 F 8 97 Normal 
#7 M 1 89 Normal 
#8 F 8 90 Normal 
#9 M 4 90 Normal 
#10 M 2 89 Normal 
#11 F 3 92 9q22 
#12 F 5 89 Normal 
#13 F 1 87 Normal 
#14 F 2 93 Normal 
#15 M 6 83 Normal 
#16 M 10 86 Normal 
#17 F 2 90 Normal 
#18 M 3 89 Normal 
#19 F 7 82 Normal 
#20 M 2 85 Normal 
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Figure S1. Basal AURKB and CCNB1 mRNA levels were analyzed in ten samples of B-ALL patient’s and 
compared to peripheral blood mononuclear cells (PBMC) of healthy donors by RT-qPCR. The results were 
normalised with L19 mRNA levels using the DDCt method. The median of threshold cycles (Ct) values was 
normalized to the median of Ct values of the L19 mRNA levels. Results are the average ± SD of three 
independent experiments in triplicate.  
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Figure S2. FOXM1 is highly expressed in B-ALL patients compared to CD19 positive cells (CD19
+
) from 
healthy donors. A) Cell lysates were obtained from ten B-ALL patients and analyzed for the expression of 
FOXM1 and its downstream target genes Cyclin B1 and Aurora B in comparison to CD19
+
 B-D) Basal 
FOXM1, AURKB and CCNB1 mRNA levels were analyzed in ten samples of B-ALL patients and compared 
to CD19
+
 from healthy donors by RT-qPCR. Results are the average ± SD of three independent experiments 
in triplicate.  
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Figure S3. Basal AURKB  and CCNB1 mRNA levels were analyzed in five B-ALL cell lines (REH, MHH-
CALL2, SEM, RS4;11, NALM-6) and compared to peripheral blood mononuclear cells (PBMC) of healthy 
donors by RT-qPCR. The results were normalised with L19 mRNA levels using the DDCt method. Results 
are the average ± SD of three independent experiments in triplicate.  
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Figure S4. A-C) FOXM1 and its downstream target genes are overexpressed in B-ALL cell lines. Total RNA 
from five B-ALL cell lines (REH, MHH-CALL2, SEM, RS4;11, NALM-6) was extracted and FOXM1 
mRNA levels were analyzed and compared to CD19
+
 from healthy donors by RT-qPCR. The results were 
normalised with L19 mRNA levels using the DDCt method. D) REH, MHH-CALL2, SEM, RS4;11, NALM-
6 cell lysates were collected at basal conditions for subsequent western blot analysis for the indicated 
antibodies.  
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Figure S5. GI50 values after incubation of the indicated B-cell lines with thiostrepton. Cell viability was 
analyzed after 72 h of incubation by MTT test. Data are expressed as the mean ± SE from the dose-response 
curves of at least three independent experiments. 
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Figure S6. Dose-response curves obtained in RS4;11 cells treated with thiostrepton and the indicated 
concentration of drugs at fixed molar combination ratio. Cell viability was obtained after 48 h of incubation 
by MTT test. Data are expressed as mean± SE of two independent experiment performed in triplicate. 
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Figure S7. Dose-response curves obtained in SEM cells treated with thiostrepton and the indicated 
concentration of drugs at fixed molar combination ratio. Cell viability was obtained after 48 h of incubation 
by MTT test. Data are expressed as mean± SE of two independent experiment performed in triplicate. 
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Figure S8. Dose-response curves obtained in REH cells treated with thiostrepton and the indicated 
concentration of drugs at fixed molar combination ratio. Cell viability was obtained after 48 h of incubation 
by MTT test. Data are expressed as mean± SE of two independent experiment performed in triplicate. 
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1.5.1 ABSTRACT 
Background: Glucocorticoids are widely used to treat B acute lymphoblastic leukaemia 
(B-ALL); however, the molecular mechanisms underlying glucocorticoid response and 
resistance remain poorly understood. In this study, we investigated the role and regulation 
of FOXO3a in mediating the dexamethasone response in B-ALL.  
Methods: B-ALL cell lines and patient samples, MTT assay, propidium iodide and 
annexin V staining, flow cytometry, immunoblotting and precipitation, real-time PCR, 
siRNA depletion, SIRT inhibitors were used in this study to investigate the function, 
regulation and expression of FOXO3a in B-ALL. 
Results: Our results showed that FOXO3a mediates the cytotoxic function of 
dexamethasone. In response to dexamethasone, we found that FOXO3a translocates into 
the nucleus, where it induces the expression of downstream targets, including p27
Kip1
 and 
Bim, important for proliferative arrest and cell death in the sensitive RS4;11 and SUP-B15 
B-ALL cells. Our data showed that FOXO3a activation by dexamethasone is mediated 
through the suppression of the PI3K-Akt signalling cascade. Furthermore, we also 
uncovered two post-translational modifications, phosphorylation on Ser-7 and acetylation 
on Lys-242/5, associated with FOXO3a activation by dexamethasone. Western blot 
analysis showed that the FOXO3a phosphorylation on Ser-7 is associated with p38/JNK 
activation, whereas the acetylation on Lys-242/5 is correlated with the downregulation of 
SIRT1/2/6 and the induction of the acetyltransferase CBP/p300.  
Conclusion: Collectively, our results suggest that FOXO3a and its post-translational 
regulation are essential for dexamethasone response and that targeting FOXO3a and 
sirtuins can enhance the dexamethasone function in B-ALL cells. 
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1.5.2 INTRODUCTION 
B acute lymphoblastic leukaemia (B-ALL) is one of the most common clonal malignant 
diseases in children, and it stems from unchecked proliferation of lymphoid progenitor 
cells. Glucocorticoids are the most effective and commonly used agents for treatment of B-
ALL; however, their efficacy is often hampered by the development of resistance (Gaynon 
and Carrel, 1999). In fact, glucocorticoid sensitivity at diagnosis has a major bearing on the 
eventual clinical outcome for patients with childhood B acute lymphoblastic leukaemia (B-
ALL) (Gaynon and Carrel, 1999). In consequence, uncovering the mechanisms that 
underlie dexamethasone responsiveness will not only help to identify reliable biomarkers 
for early diagnosis and for predicting disease relapse but also aid the design of targeted 
therapies to overcome glucocorticoid resistance in B-ALL. Despite this, the molecular 
mechanisms underlying glucocorticoid response and resistance remain poorly understood 
(Gaynon and Carrel, 1999). 
FOXO3a (previously known as FKHR-L1) is a member of the Forkhead family of 
transcription factors, which share a distinct forkhead DNA-binding domain (Lam et al., 
2013). FOXO3a plays an important role in proliferation, apoptosis, autophagy, 
metabolism, inflammation, differentiation, and stress resistance (Nestal de Moraes et al., 
2014; Ho et al., 2008). The stability, subcellular localization, the DNA binding affinity, 
and the transcriptional activity of FOXO3a are primarily regulated by a complex array of 
posttranslational modifications (Wang et al., 2014). FOXO3a is primarily regulated by the 
PI3K-Akt(PKB) signalling pathway (Tzivion et al., 2011; X. Zhang et al., 2011; Kops et 
al., 2002). In the presence of growth factors, the PI3K-Akt axis is activated and Akt 
phosphorylates the FOXO3a at three sites, Thr-32, Ser-253 and Ser-315, triggering the 14-
3-3 protein binding, nuclear export and subsequent degradation via the ubiquitynation-
mediated proteasome pathway (Tzivion et al., 2011; X. Zhang et al., 2011; Kops et al., 
2002). The Ser-315 residue locates within the nuclear export domain and its 
phosphorylation has been shown to be important for FOXO3a nuclear export (Boccitto and 
Kalb, 2011). The MAPK kinase ERK has also been shown to phosphorylate FOXO3a on 
Ser-294, Ser-344 and Ser-425, driving its proteasomal degradation via ubiquitin E3 ligase, 
MDM2 (Yang et al., 2008). Conversely, the phosphorylation mediated by the other two 
MAPKs, p38 and JNK (c-jun-NH2-kinase), promotes FOXO3a nuclear localization and 
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transcriptional activity. The stress-activated protein kinase p38 phosphorylates FOXO3a on 
Ser-7 promoting its nuclear localization, whereas JNK phosphorylates the FOXO3a-related 
FOXO4 at Thr-447 and Thr-451 (Ho et al., 2012; Essers et al., 2004). Furthermore, JNK 
can also activate FOXO3a indirectly by repressing the PI3K-Akt activity (Sunters et al., 
2006). Resembling phosphorylation, acetylation can both promote and decrease the 
transcriptional activity of FOXO3a. FOXO acetylation is controlled coordinately by the 
histone/lysine acetyltransferase and deacetylases. Co-precipitation analysis revealed that 
the acetyltransferase CBP/p300 binds the first 52 amino acids of the N-terminal region of 
FOXO3a (Mahmud et al., 2002). Interestingly, p300 also directly acetylates FOXO 
transcription factors at several conserved lysine residues, Lys-242, Lys-245 and Lys-262 of 
FOXO3a (Daitoku et al., 2004; Dansen et al., 2009; Matsuzaki et al., 2005). However, 
p300-dependent acetylation has been shown to have a dual function in FOXO-mediated 
transcription; it can either attenuate FOXO-transcriptional activity or it can promote the 
recruitment and assembly of the transcriptional machinery, increasing their DNA-binding 
ability and transcriptional activity (Perrot and Rechler, 2005; Senf et al., 2011). FOXO3a 
acetylation status is further modulated by class III histone/lysine deacetylases (sirtuins), 
including SIRT1, SIRT2, SIRT3 and SIRT6 (Olmos et al., 2011). For example, it has been 
demonstrated that SIRT1 can antagonise the p300-mediated acetylation and activation of 
FOXO3a (Motta et al., 2004). In agreement, studies conducted in breast cancer have also 
showed that SIRT6 overexpression correlates with FOXO3a inactivation and that SIRT6 
depletion sensitizes breast cancer cells to both paclitaxel and epirubicin treatments 
(Khongkow et al., 2013).  
 
FOXO3a functions primarily as a tumour suppressor in a number of haematological 
malignancies, playing a crucial role in controlling cell cycle arrest, apoptosis and self-
renewal of haematopoietic progenitor cells (Nordigarden et al., 2009; Miyamoto et al., 
2008). For example, hyperphosphorylation of FOXO3a has been shown to be correlated 
with adverse prognosis in AML (Kornblau et al., 2010). FOXO3a activation can induce 
apoptotic cell death in therapy-resistant T-ALL cells (Ausserlechner et al., 2013). 
Furthermore, deletion of FOXO1/3a/4 in mice has been found to lead to the development 
of T-cell lymphoma (Paik et al., 2007). Hitherto, the involvement of FOXO3a in B-ALL 
and its role in treatment response has remained undefined. Nevertheless, it has been shown 
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that in glucocorticoid resistant B-ALL patients, Bim, a downstream FOXO3a target (Essafi 
et al., 2005), is downregulated compared to their sensitive counterparts (Bachmann et al., 
2005). Moreover, FOXO3a expression has also been demonstrated to predict bortezomib 
sensitivity and patient remission in B-ALL (Dewar et al., 2011). Together these findings 
led us to hypothesize that FOXO3a has a key role in glucocorticoid sensitivity in B-ALL. 
In this study, we investigated the role and regulation of FOXO3a in mediating the 
dexamethasone response in B-ALL. More specifically, we intended to determine how 
phosphorylation and acetylation, two major FOXO3a post-translational modifications, 
influence FOXO3a subcellular localization and function. 
 
1.5.3 MATERIALS AND METHODS 
Cells, patient samples and cell cultures  
B-ALL patient samples were obtained after informed consent according to the tenets of the 
Declaration of Helsinki. The study was approved by the Italian Association of Pediatric 
Onco-Hematology (AIEOP). All analyzed BCP-ALL samples were collected at the time of 
diagnosis before treatment, after Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) separation 
of mononuclear cells as described previously (Accordi et al., 2013). For details, see 
Supplementary Materials and Methods  
 
Drug treatment and MTT proliferative assay 
See Supplementary Materials and Methods 
 
Flow cytometric analysis of cell cycle distribution and Apoptosis assay 
See Supplementary Materials and Methods 
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Subcellular fractionation, Immunoprecipitation (IP), Immunoblotting (IB) and 
immunofluorescent staining 
These procedures were performed as previously described (Myatt et al., 2014). For details, 
see Supplementary Materials and Methods. 
 
Real time-quantitative PCR (RT-qPCR) 
Total RNA was isolated from frozen cell pellets using the RNeasy Mini kit (Qiagen, UK) 
according to manufactures’ instructions.  
Also see Supplementary Materials and Methods 
 
Statistical Analysis 
Results are presented as the mean ± SD. The differences between different conditions were 
analyzed using the two-sided Student’s t test. P values lower than 0.05 were considered 
significant. *, p ≤ 0.05: **, p ≤ 0.01, ***p ≤ 0.001. 
 
 
1.5.4 RESULTS 
 
 Dexamethasone treatment induces FOXO3a activation in B-ALL sensitive cells  
 
Deregulation of the PI3K-Akt-FOXO3a pathway has been shown to be involved in cancer 
development and contribute to therapy resistance in different haematological malignancies 
(Vecchio et al., 2013; Kawauchi et al., 2009; Y. Zhang et al., 2011; Myatt and Lam, 2007). 
To explore the potential role played by FOXO3a in dexamethasone response, we first 
examined the expression of both total and phosphorylated forms of FOXO3a in one 
dexamethasone-resistant B-ALL cell line (REH) and two dexamethasone-sensitive cell 
lines (RS4;11 and SUP-B15) following treatment with 1 μM dexamethasone for 24 h 
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(Figure 1A). Dose-response curves were previously obtained by treating cells for 72 h with 
a range of dexamethasone concentrations (0-100 μM) and the results confirmed the 
dexamethasone-sensitivity of the B-ALL cells  (Figure 1B; Figure S1, supplementary 
data). Western blot analysis showed that baseline FOXO3a is more hyperphosphorylated at 
Akt-targeted sites, inducing Thr-32 and Ser-315, in the dexamethasone-resistant REH cells 
compared to the sensitive counterparts, RS4;11 and SUP-B15 (Figure 1A). The resistant 
REH cells expressed comparable levels of FOXO3a, P-FOXO3a (S315), P-FOXO3a 
(T32), P-FOXO3a (S253) before and after dexamethasone treatment. In contrast, in the 
sensitive cells, RS4;11 and SUP-B15, dexamethasone caused the down-regulation of 
FOXO3a phosphorylation at Thr-32, Ser-253 and Ser-315, indicative of FOXO3a nuclear 
relocation and activation (Myatt and Lam, 2007; Ho et al., 2008). In response to 
dexamethasone, FOXO3a activation in the sensitive cells was further confirmed by the 
increased expression of the FOXO3a target Bim and the consequent activation of 
apoptosis, as evidenced by caspase-3 , -7 and -9 cleavage and activation. In concordance, 
the expression of another FOXO3a downstream target p27
Kip1
 was also increased in 
sensitive cells following dexamethasone treatment. Notably, the p27
Kip1
 and Bim mRNA 
levels were also induced by dexmethasone in the sensitive and not the resistant cells, 
further supporting their transcriptional induction by FOXO3a  (Fig. 1C). Interestingly, 
unlike FOXO3a the expression of the other FOXO family members, FOXO1 and FOXO4 
were expressed at low levels in the sensitive cells before and after dexamethasone, 
suggesting that FOXO1 and FOXO4 are unlikely to have a crucial part to play in 
dexamethasone response (Figure 1A). Together, these results suggest that after treatment 
FOXO3a becomes hypophosphorylated at Akt-dependent sites and consequently, activated 
in the sensitive B-ALL cells. Conversely, in the resistant cells FOXO3a remained 
phosphorylated and inactive. We next analyzed the expression of the components of PI3K-
Akt signalling pathway after dexamethasone treatment (Figure 1D). In sensitive cells the 
Akt activator mTOR became dephosphorylated (at S2448), thus less active, after 
dexamethasone treatment. Accordingly, these data show that dexamethasone treatment 
leads to PI3K-Akt inactivation in sensitive cells, and as a consequence, FOXO3a becomes 
hypophosphorylated and activated. In contrast, FOXO3a remains phosphorylated and 
inactive in the resistant REH cells.  
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Figure 1. Dexamethasone induces FOXO3a activation and proliferative arrest in sensitive but not 
resistant B-ALL cells. The REH, RS4;11 and SUP-B15 B-ALL cell lines were treated with 1 µM 
dexamethasone for 0 and 24 h. A) Cell lysates were collected for western blot analysis for the indicated 
proteins. B) MTT assay was performed on REH, RS4;11 and SUP-B15 cells.  Results are the average ± SD 
of 3 independent experiments in triplicate. Statistical analysis performed using Students t-tests showed 
dexamethasone **very significantly reduced RSA;11 and SUP-B15 at all concentrations studied, whereas 
dexamethasone only *significantly inhibited REH proliferation at >10 μM dexamethasone (t-test: 0.0001-100 
μM verses 0 μM dexamethasone of the same cell line; *significant p<0.05, ** very significant p<0.01, and ns 
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not significant). C) Bim and p27
Kip1
 mRNA levels were analyzed by RT-qPCR analysis and results were 
normalised to L19 mRNA levels. Error bars show the standard deviations. Results are the average ± SD of 3 
independent experiments in triplicate. Statistical analysis was performed using Students t-tests (t-test: 0 h 
verses 24 h treatment; *significant p<0.05, and ns: not significant). D) Protein expression of P-mTOR 
(S2448), mTOR, Akt (S473), Akt and β-Tubulin was analyzed in the dexamethasone treated B-ALL cells. E) 
Protein expression of FOXO3a, P-FOXO3a (S315), FOXM1, Aurora B and β-Tubulin was analyzed at 
baseline conditions in five poor responder patients (PPR) and five glucocorticoid good responder patients 
(PGR) by western blot analysis. 
 
FOXO3a is hyperphosphorylated at Ser-315 in poor responder patients (PPR) 
To confirm the physiological relevance of our findings from the B-ALL cell lines, bone 
marrow cells from 10 pediatric B-ALL patients of good (PGR) and poor response (PPR) to 
prednisone therapy were studied by western blotting. In agreement with the data obtained 
from the cell culture models (Figure 1E), western blot results showed that while there was 
little difference in FOXO3a levels between the two groups. FOXO3a was generally more 
phosphorylated on the Akt-targeted Ser-315 residue in PPR individuals (1-5) compared to 
PGR patients (6-10) (Figure 1E). Collectively, these data indicated that FOXO3a at 
baseline conditions is more phosphorylated and therefore, less active in PPR patients, 
providing further evidence that FOXO3a has a role in modulating dexamethasone 
sensitivity. 
 
Dexamethasone treatment leads to cell cycle arrest and cell death in drug sensitive B-
ALL cells. 
To explore further the potential role of FOXO3a in dexamethasone treatment and 
resistance, we next studied the effects of dexamethasone on the B-ALLs by propidium 
iodide staining and flow cytometry. Consistent with the proliferation assays, the cell cycle 
analysis showed that whereas there were no significant shifts in cell cycle distribution of 
REH cells in response to dexamethasone, considerable cell cycle phase changes indicative 
of cell proliferative arrest and cell death were observed for the sensitive RS4;11 and SUP-
B15 cells (Figure 2A, 2B and 2C). Accordingly, in response to dexamethasone, there were 
also increases in sub-G1 cell population for the sensitive and not the resistant cells (Figure 
2B). We also detected a significant increase in G2/M population in SUP-B15 cells 
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following treatment (Figure 2C). Upon dexamethasone, we also observed a significant 
decrease in RS4;11 cells in S phase with a corresponding increase in G2/M phase cells 
(Figure 2C). The G2/M arrest observed can be due to the fact that FOXO3a negatively 
regulates the expression of genes, including cyclin B and FOXM1 (Figure 1A) important 
for G2/M progression (Myatt and Lam, 2007; Lam et al., 2013). Collectively, these data 
suggest that dexamethasone arrests cell cycle progression, particularly in G2/M phase, and 
induces cell death in the sensitive but not resistant B-ALL cells. It is also notable that this 
cell cycle arrest and cell death induced by dexamethasone in the sensitive cells correlated 
with FOXO3a activation (Figure 1), providing further evidence of a role of FOXO3a in the 
cytostatic and cytotoxic function of dexamethasone in B-ALLs. 
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Figure 2. Dexamethasone treatment perturbs cell proliferation and induces FOXO3a nuclear 
translocation in sensitive B-ALL cells. A) REH, RS4;11 and SUP-B15 cells treated with dexamethasone 
(1μM) for 0 and 24 h were subjects to flow cytometric analysis after propidium iodide staining. 
Representative cell cycle profiles with and without dexamethasone treatment are shown. B) and C) Cell cycle 
analysis of sub-G1 and G1-S-G2/M populations was performed on these dexamethasone-treated REH, 
RS4;11 and SUP-B15 cells. Error bars show the standard deviations. Results are the average ± SD of 3 
independent experiments in triplicate. Statistical analysis was performed using Students t-tests (t-test: 0 h 
verses 24 h treatment; *significant p<0.05, ** very significant p<0.01, and ns: not significant). D) After 0 
and 24 h of dexamethasone treatment (1 µM), immunofluorescent staining was performed on the REH, 
RS4;11 and SUP-B15 cells using the mouse FOXO3a antibody and DAPI. All of the images shown are 
typical results obtained from at least 10 different fields. FOXO3a localization was detected using a secondary 
Alexa conjugated antibody. Nuclei were stained with DAPI. Images were obtained using a video-confocal 
microscope (Vico, Ecliple Ti80, Nikon), equipped with a digital camera. E) After treatment, cells were 
collected, and cytosolic (Cyto)/nuclear fractionation (Nuclear) procedures were performed. The resultant 
fractions were standardized according to protein content, followed by Western blot analyses using the 
indicated antibodies.  
 
FOXO3a translocates to the nucleus after dexamethasone treatment in sensitive B-ALL 
cells 
As Akt-phosphorylation of FOXO3a promotes its relocation to the cytoplasm, we next 
analyzed whether dexamethasone treatment also influences FOXO3a subcellular 
localization. To this end, B-ALL cells were either untreated or treated with dexamethasone 
for 24 h, fixed and stained with a specific FOXO3a fluorescent-conjugated antibody. The 
results showed that upon dexamethasone treatment, FOXO3a translocated from cytoplasm 
into nucleus in the sensitive cell lines RS4;11 and SUP-B15, but not in the resistant REH 
cells (Figure 2D). To confirm this further, we examined the expression of FOXO3a in the 
cytoplasmic and nuclear fractions of the sensitive RS4;11 and resistant REH B-ALL cells 
in response to dexamethasone treatment. In agreement, the western blotting results showed 
that dexamethasone treatment increased the nuclear FOXO3a and p27
Kip1
 expression, the 
cytoplasmic Bim expression, but reduced the nuclear P-FOXO3a, FOXM1 and Aurora B 
expression substantially in the sensitive and not the resistant cells (Figure 2E). Together 
these results reinforce the idea that FOXO3a is activated in the dexamethasone-sensitive 
and not in the resistant B-ALL cells.  
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FOXO3a is a critical mediator of dexamethasone-induced apoptosis in B-ALL 
To test if FOXO3a is essential for the cytotoxic function of dexamethasone in B-ALL, we 
depleted its expression using a smart pool of FOXO3a siRNA and assayed for the ability of 
dexamethasone to induce cell death in the sensitive RS4;11 cells. After 48 h of transfection 
with FOXO3a siRNA or non-silencing control (NSC) siRNA, cells were treated for 
another 24 h with dexamethasone before they were collected for subsequent cell death 
analysis. The knockdown of FOXO3a in RS4;11 was confirmed at mRNA and protein 
levels using real-time quantitative (RTq)-PCR (Figure 3A) and Western blot analysis 
(Figure 3B), respectively. Importantly, the expression of two FOXO3a-targets, Bim and 
p27
Kip1
, also decreased substantially in the FOXO3a-silenced cells, confirming a depletion 
of FOXO3a activity. As shown in Figure 3C and 3D, dexamethasone failed to induce 
apoptosis in RS4;11 cells with FOXO3a knockdown, indicating that FOXO3a depletion 
conferred dexamethasone resistance to the RS4;11 cells and therefore suggesting that 
FOXO3a plays a central role in mediating the cytotoxic function of dexamethasone in B-
ALL.  
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Figure 3. Depletion of FOXO3a promotes resistance to dexamethasone in B-ALL cells. RS4;11 cells 
were transfected with NS (non-silencing) siRNA or FOXO3a siRNA. A) FOXO3a mRNA levels were 
analyzed 72 h after transfection by RT-qPCR analysis and results were normalised to L19 mRNA levels. B) 
Forty-eight hours after transfection, cells were treated for 24 h with dexamethasone and then subjected for 
western blot analysis for FOXo3a, p27Kip1 and Bim expression.  C) The dexamethasone treated RS4;11 
cells were assayed for cell viability by Annexin V (AV) and propidium iodide staining. Representative flow 
cytometric analysis was shown. D) The results represent average of three independent cell death experiments 
± SD. Statistical significance was determined by Student’s t-test: **P ≤ 0.01; ns, not significant). 
 
Dexamethasone promotes FOXO3a phosphorylation on Ser-7  
In addition to Akt, MAPK kinases also phosphorylate and modulate FOXO3a activity (Ho 
et al., 2008). In particular, it has been reported that p38 and JNK regulates FOXO3a 
nuclear localization and that p38 and JNK also phosphorylates FOXO3a on Ser-7 (Ho et 
al., 2012). To explore the molecular mechanisms by which dexamethasone modulates 
FOXO3a function, we next analyzed the expression patterns of FOXO3a and MAPK 
kinases, including ERK, p38, and JNK, in REH, RS4;11 and SUP-B15 B-ALL cells in 
response to dexamethasone treatment. The results showed that the FOXO3a Ser-7 
phosphorylation level increased in sensitive but not resistant cells following 
dexamethasone treatment (Figure 4A). Furthermore, while there was an induction in 
activity of the two canonical MAPKs, p38 and JNK, as revealed by the phosphorylation 
specific antibodies, ERK expression and activity remained relatively constant in RS4;11 
and SUP-B15 cells after dexamethasone (Figure 4A). Conversely, in REH cells the JNK 
activity decreased whereas ERK activity increased marginally (Figure 4A). These results 
indicate that p38 and JNK may have a role in mediating dexamethasone function in B-
ALL. To test this conjecture, we next assessed if inhibition of JNK, p38 or ERK kinases 
using small molecule inhibitors can influence dexamethasone sensitivity. More 
specifically, REH and RS4;11 cells were treated for 48 h with 1 μM of dexamethasone 
combined with a range of concentrations (0-100 μM) of JNK, p38 and ERK inhibitors, 
SP600125, SB202190 and PD98059, respectively, and cell viability analyzed by MTT 
assay (Figure 4B and Supplementary Figure S1). Interestingly, we observed a significant 
decrease in the cytotoxicity of dexamethasone when administered with the JNK inhibitor, 
SP600125, in both RS4;11 and REH cells (Figure 4B). By comparison, the dexamethasone 
cytotoxicity did not alter significantly when combined with either the p38 or ERK 
inhibitors (Figure S1, Supplementary data).  
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Figure 4. Dexamethasone enhances FOXO3a Ser-7, JNK and p38 phosphorylation in sensitive and not 
resistant B-ALL cell lines. A) REH, RS4;11 and SUP-B15 cells were treated with dexamethasone (1μM) for 
0 and 24 h. Cells were collected after treatment and were subjects to western blot analysis with antibodies 
shown. B) REH and RS4;11 cells were treated with the a range of concentrations of (0-100μM) SP600125 
and/or dexamethasone. Cell viability analysis was performed after 48 h using MTT assay. (t-test:  SP600125 
with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** very significant p<0.01 and 
no marker: not significant . 
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FOXO3a nuclear localisation is associated with phosphorylation on Ser-7 and 
acetylation on Lys-242/245 in B-ALL cells 
Acetylation has been described to modulate the transcriptional activity of FOXO3a (Shiota 
et al., 2010; Khongkow et al., 2013). In addition, a recent study has also demonstrated that 
JNK-phosphorylation can promote FOXO1 acetylation and activation (Vahtola et al., 
2010). These findings have led us to propose that dexamethasone activates JNK to mediate 
FOXO3a phosphorylation and consequently, acetylation. To examine if dexamethasone 
induces FOXO3a acetylation, immunoprecipitation experiments were performed on REH, 
RS4;11 and SUP-B15 cells using anti-FOXO3a antibodies. Western blot results using pan-
acetylation antibodies showed that in response to dexamethasone there was a net increase 
in FOXO3a acetylation levels in the drug sensitive RS4;11 and SUP-B15 but not in the 
resistant REH cells (Figure 5A). By contrast, when the Western blots were reprobed with a 
monoclonal anti-FOXO3a, the results indicated that the FOXO3a acetylation observed was 
not a result of the expression patterns of FOXO3a following dexamethasone treatment 
(Figure 5A). Similar results were obtained, when the reverse immunoprecipitation and 
western blotting was performed using a pan-acetylation and a FOXO3a antibody, 
demonstrating that dexamethasone induces FOXO3a acetylation in sensitive and not 
resistant B-All cells (Figure 5B). We next used the FOXO3a (S7) antibody to 
immunoprecipate the FOXO3a complex and probed with a pan-FOXO3a antibody. The 
western blot results showed that FOXO3a Ser-7 phosphorylation demonstrated similar 
expression patterns as FOXO3a acetylation in both the sensitive and resistant B-ALL cells 
in response to dexamethasone (Figure 5C), implicating that dexamethasone mediates both 
FOXO3a Ser-7 phosphorylation and acetylation in B-ALL.  
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
63 
 
 
 
Figure 5. Dexamethasone enhances FOXO3a acetylation and Ser-7 phosphorylation in sensitive and 
not resistant B-ALL cell lines. A) REH and RS4;11 cells were treated with dexamethasone (1μM) for 0 and 
24 h. Co-immunoprecipitation (co-IP) was performed with a FOXO3a antibody (rabbit) and probed (IB) for 
Ac-Lysine and FOXO3a (mouse). B) Reverse co-immunoprecipitation (co-IP) was performed with the Ac-
Lysine antibody and probed with a FOXO3a antibody (rabbit). C) Co-IP was performed with the FOXO3a 
(S7) antibody and probed with a FOXO3a antibody (rabbit). Inputs (1/10 of IP), and IP products with IgG 
and specific antibodies were resolved on western blot and analyzed with IB antibodies as indicated.  
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FOXO3a Lys-242 and Lys-245 acetylation is associated with nuclear localisation, Ser-7 
phosphorylation and JNK activation 
The residues Lys-242 and Lys-245 (K242/5) located within the overlapping DNA-binding 
and nuclear localization signal (NLS) domains of FOXO3a have been demonstrated to be 
CBP-acetylation sites (Tsai et al., 2007; Lam et al., 2013)}. It is possible that these post-
translational modifications could alter FOXO3a DNA-binding and/or nuclear localization 
ability and thereby, impact its transcriptional activity. To investigate FOXO3a acetylation 
further, we generated an acetylation-specific antibody that recognizes the Lys-242 and 
Lys-245 acetylated FOXO3a. Using this Ac-FOXO3a (K242/5) specific antibody in 
western blot analysis, we found that FOXO3a increased in Lys-242/5 acetylation upon 
dexamethasone treatment in the sensitive but not resistant cells in a short time course 
(Figure 6A). The western blot results also revealed that the expression patterns of FOXO3a 
Lys-242/5 acetylation were similar to that of Ser-7 phosphorylation and JNK 
phosphorylation, providing further evidence that JNK phosphorylation is associated 
FOXO3a Ser-7 phosphorylation and acetylation on Lys-242/5 (Figure 6A). To test this 
idea further, we next examined the expression of total-acetylated, Lys-242/5 acetylated and 
Ser-7 phosphorylated FOXO3a in the cytoplasmic and nuclear fractions of the sensitive 
and resistant B-ALL cells in response to treatment with dexamethasone following 
immunoprecipitation with the anti-FOXO3a (Figure 6B). The results showed that the total 
acetylated, the Lys-242/5 acetylated, and the Ser-7 phosphorylated FOXO3a resided 
predominantly in the nuclei. In addition, Western blot results clearly showed that in the 
sensitive cells FOXO3a became more acetylated and phosphorylated after dexamethasone 
treatment. On the contrary, FOXO3a acetylation (total and Lys-242/245) and 
phosphorylation (Ser-7) decreased marginally following dexamethasone in the resistant 
REH cells. Collectively, these data suggest that Lys-242/245 acetylation and Ser-7 
phosphorylation is associated with dexamethasone-mediated nuclear relocalization and 
activation of FOXO3a (Figure 6B). In agreement, previous studies have shown that Ser-7 
phosphorylation and Lys-242/245 acetylation promote nuclear relocalization and activation 
of FOXO3a and FOXO1, respectively (Ho et al., 2012; Matsuzaki et al., 2005). 
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Figure 6. Dexamethasone enhances FOXO3a acetylation on Lys 242/245 in sensitive and not resistant 
B-ALL cell lines via Sirtuins A) REH, RS4;11 and SUP-B15 cells were treated with dexamethasone (1μM) 
for 0, 2 and 4 h. Cells were collected after treatment and were subjects to western blot analysis with 
antibodies shown. B) REH and RS4;11 cells were treated with dexamethasone (1μM) for 0 and 24 h. Co-
immunoprecipitation (co-IP) was performed on the respective nuclear and cytoplasmic lysates with a 
FOXO3a antibody (rabbit) and probed for P-FOXO3a (S7), Ac-Lysine, Ac-FOXO3a (K242/K245), and 
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FOXO3a (mouse). Inputs (1/10 of IP), and IP products with IgG and specific antibodies were resolved on 
western blot and probed for proteins as indicated. C) REH, RS4;11 and SUP-B15 cells were treated with 
dexamethasone (1μM) for 0 and 24 h. The treated cells were collected and subjected to western blot analysis 
for the proteins indicated. D) REH and RS4;11 cells were either untreated or treated with the SIRT inhibitors 
indicated in the presence of 1μM dexamethasone for 24 h and subjected to immunoblotting with antibodies 
indicated. E) REH and RS4;11 cells were treated with the a range of concentrations of (0-100μM) Sirtinol 
and/or dexamethasone. Cell viability analysis was performed after 24 h using MTT assay. (t-test:  Sirtinol 
with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** very significant p<0.01 and 
no marker: not significant . 
 
FOXO3a acetylation is associated with p300 activation and SIRT1/2/6 downregulation  
To investigate the mechanisms underlying FOXO3a acetylation, we studied the expression 
patterns of known mediators of FOXO3a acetylation, including the acetyl transferase 
CBP/p300 and the histone/lysine deacetylases SIRT1, SIRT2 and SIRT6, in response to 
dexamethasone in the B-ALL cell lines. Specifically, p300/CBP has been shown to 
mediate the FOXO3a acetylation on Lys-242, Lys-245 and Lys-262 residues, whereas 
SIRT1, -2 and-6 have been shown to target FOXO3a for deacetylation (van der Heide and 
Smidt, 2005; Wang et al., 2012; Peck et al., 2010; Di Fruscia et al., 2014; Khongkow et 
al., 2013). Western blot analysis showed that dexamethasone treatment upregulated 
CBP/p300 and downregulated SIRT1, -2 and -6 expression in the drug sensitive RS4;11 
and SUP-B15 cells (Figure 6C). By contrast, dexamethasone treatment did not affect 
CBP/p300 expression as well as SIRT1, -2 and -6 levels after dexamethasone treatment in 
the resistant REH cells. Taken together, these data suggest that the dexamethasone-induced 
FOXO3a acetylation in B-ALL is mediated by mechanisms involving the downregulation 
of SIRT1/2 and upregulation of CBP/p300 and that these control mechanisms are 
deregulated in resistant cells. As we had already shown that FOXO3a has a role in B-ALL 
dexamethasone sensitivity, we next tested if SIRT1, SIRT2 or general SIRT inhibition can 
re-sensitize the drug resistant B-ALL cells to dexamethasone. To this end, we treated both 
the drug sensitive RS4;11 and resistant REH cells with 1 μM of dexamethasone and a 
range of concentrations (0-100 μM) of EX-527 (a SIRT1 inhibitor) (Peck et al., 2010), 
PDF-170 (a SIRT2 inhibitor) (Di Fruscia et al., 2012) and Sirtinol (a pan SIRT1/2/6 
inhibitor) (Peck et al., 2010) (Figure 6D and 6E). MTT proliferation assay revealed that 
only Sirtinol, but not EX-527 or PDF-170, enhanced the antiproliferative effects of 
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dexamethasone in both the sensitive (RS4;11) and the resistant (REH) cell lines (Figure 
6E). These data suggest that sirtuins have a key role in modulating dexamethasone 
sensitivity and that the inhibition of at least SIRT1 and -2 simultaneously is required for 
overcoming dexamethasone resistance. We next tested if these SIRT inhibitors can 
combine with dexamethasone to restore FOXO3a acetylation (K242/5) in the resistant 
cells. Consistent with the proliferation assay results, western blot results showed that only 
Sirtinol and neither EX-527 nor PDF-170 could further enhance FOXO3a acetylation 
induced by dexamethasone in the resistant cells. Notably, FOXO3a acetylation (K242/5) 
was not enhanced by the SIRT inhibitors in the sensitive RS4;11 cells (Figure 6 D), and it 
is likely to be due to the fact that FOXO3a acetylation was already strongly induced by 
dexamethasone in these cells. 
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1.5.5 DISCUSSION 
It is well established that Akt (PKB)-mediated phosphorylation and inactivation of 
FOXO3a culminates in cytoplasmic localization and cell proliferation (Lam et al., 2013; 
Nestal de Moraes et al., 2014). Herein, we showed that in the sensitive B-ALL cell lines, 
RS4;11 and SUP-B15, FOXO3a became dephosphorylated on Akt-targeted sites, Ser253, 
Thr315 and Thr32 upon dexamethasone treatment, but its phosphorylation was unaffected 
by dexamethasone in the resistant REH cells. These findings suggest that FOXO3a has a 
central role in mediating dexamethasone response. In agreement with this, FOXO3a 
activation by dexamethasone is confirmed by the increased expression of two FOXO3a-
targets, p27
Kip1
 and Bim, important for cell cycle arrest and cell death. Dexamethasone-
treatment also caused cleavage of caspase-3, -7 and -9, indicative of apoptosis in the 
sensitive B-ALL. FOXO3a can also suppress the expression of targets important for the 
G2/M phase transition, including Cyclin B, Aurora B and FOXM1, (Lam et al., 2013), and 
this may explain the G2/M arrest observed after FOXO3a induction by dexamethasone. 
The dexamethasone-induced FOXO3a dephosphorylation at the Akt sites was 
accompanied by its translocation to the nucleus in the sensitive cells, whereas FOXO3a 
remained phosphorylated and retained in the cytoplasm in resistant cells, as revealed by 
immunofluorescence staining. The physiological relevance of this finding is confirmed in 
B-ALL patient samples where we found that FOXO3a is predominantly more 
phosphorylated on the Ser-315 residue in patients of good response (PGR) compared to 
poor responders (PPR) to prednisone therapy. Crucially, depletion of FOXO3a in the 
sensitive RS4;11 cells rendered these B-ALL cells significantly less responsive to 
dexamethasone treatment, confirming further the central role played by this transcription 
factor in dexamethasone response.  
Our findings also suggest that besides Akt-mediated phosphorylation, FOXO3a is 
differentially regulated by other post-translational mechanisms in dexamethasone sensitive 
and resistant B-ALL cells. More specifically, our data indicate that dexamethasone induces 
activation of JNK and p38 MAPKs and the phosphorylation of FOXO3a on Ser-7 in the 
sensitive but not the resistant B-ALL cells. Consistent with this, we have previously 
demonstrated that DNA damaging agents, such as doxorubicin, also activate the p38 
MAPK, which in turn will phosphorylate FOXO3a on Ser-7 to promote its nuclear 
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localization and activation to mediate cell cycle arrest (Ho et al., 2012). Surprisingly, our 
proliferative analysis shows that JNK, but not ERK or p38, inhibitor can combine 
effectively with dexamethasone to impair sensitive and resistant B-ALL proliferation. 
Consistently, our previous work has shown that JNK kinases can promote FOXO3a 
activity and expression by repressing Akt activity and also by direct phosphorylation in 
breast cancer cells (Sunters et al., 2003; Sunters et al., 2006). In this context, JNK induces 
FOXO3a nuclear relocalisation and the activation of its targets, including p27
Kip1
 and Bim, 
important for cell cycle arrest and cell death (Sunters et al., 2003; Sunters et al., 2006). 
Consistent with this, we also observed upon dexamethasone treatment, the activation of 
JNK and p38 MAPKs, which are associated with FOXO3a nuclear translocation, 
dephosphorylation at Akt-sites, induction of p27
Kip1
 and Bim expression and cell 
proliferative arrest in the sensitive and not the resistant B-ALL cells. Our observations, in 
conjunction with the results of previous studies, suggest that dexamethasone targets 
FOXO3a via JNK and Akt to mediate its cytotoxic and cytostatic function in B-ALL.  
 
We also found that FOXO3a is acetylated in the sensitive and not the resistant B-ALL cells 
and that FOXO3a acetylation can be further enhanced upon dexamethasone treatment. In 
these cases, our acetylation-specific FOXO3a antibody revealed that dexamethasone also 
causes FOXO3a to be acetylated at Lys242/5 in the sensitive and not the resistant cells. In 
attempting to explore the mechanism involved, we found that the expression of CREB-
binding protein (CBP) is increased, whereas SIRT-1 and -2 levels are suppressed by 
dexamethasone treatment. In agreement, previous research has shown that FOXO1/3a 
acetylation at Lys-242 and Lys-245 is mediated through the antagonistic action of cAMP-
response element-binding protein (CREB)-binding protein and the NAD-dependent 
histone/lysine deacetylase sirtuins (Matsuzaki et al., 2005; Tsai et al., 2007). However, the 
authors of these studies also predict that acetylation at Lys-242 and Lys-245 attenuates the 
DNA-binding activity and thereby impairs transcriptional activity of FOXO proteins 
(Matsuzaki et al., 2005; Tsai et al., 2007). On the contrary, our results indicate that 
FOXO3a acetylation, particularly at Lys-242/5, is associated with nuclear localization, 
induction of downstream anti-proliferative targets, cell proliferative arrest and sensitivity 
to dexamethasone. Hence, the analogy between this and our study is not perfect. However, 
in support of our findings, SIRT6 has recently been shown to regulate gluconeogenesis by 
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promoting FOXO1 nuclear exclusion (Zhang et al., 2014). Moreover, another recent study 
on pancreatic cancer also demonstrates that JNK-phosphorylation can promote FOXO1 
acetylation and activation as well as Bim expression (Pramanik et al., 2014). In this case, 
FOXO1 acetylation is also accompanied by increased expression of CREB-binding protein 
(CBP) and reduced SIRT1 expression (Pramanik et al., 2014). Furthermore, deacetylation 
of FOXO3a by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and 
degradation (Wang et al., 2012). Critically, we showed that the pan-SIRT inhibitor sirtinol, 
but not the specific SIRT1 (EX527) or SIRT2 (PDF-170) inhibitor, can combine with 
dexamethasone to restrict both sensitive and resistant B-ALL cell proliferation, suggesting 
at least both SIRT1 and -2 have to be suppressed simultaneously to exert the anti-
proliferative effects of dexamethasone. This observation is in concordance with our earlier 
results showing that both SIRT1 and SIRT2 were both downregulated in response to 
dexamethasone in the sensitive but not the resistant B-ALL cells. Together these data 
suggest a role for both SIRT1 and -2 in restricting the cytotoxic and cytostatic function of 
dexamethasone and that dexamethasone mediates its action through downregulating SIRT1 
and SIRT2 expression in B-All. Aptly, the pan-SIRT inhibitor sirtinol, but not the SIRT1 
or -2 inhibitor, can function in combination with dexamethasone to induce FOXO3a 
acetylation at Lys-242/5 in B-ALL cells. Collectively, ours and others’ results have led us 
to propose a signalling mechanism whereby dexamethasone can induce JNK to inhibit 
FOXO3a phosphorylation at Akt-sites and induce phosphorylation at Ser-7 and acetylation 
at Lys-242/5 to promote nuclear localization and thereby, transcription activity. As we 
have shown that FOXO3a has a essential role in dexamethasone responsiveness, it is 
therefore tempting to speculate that the sensitivity to dexamethasone is at least in part 
determined by acetylation and phosphorylation status of FOXO3a. However, to draw 
informed definitive conclusions on this model, additional in-depth experimental work is 
required to identify all the phosphorylation and acetylation sites involved and to define the 
regulation and function of these post-translational modifications. 
Nevertheless, our findings are of significance because they reveal a potential novel 
therapeutic strategy to treat B-ALL and to overcome dexamethasone resistance by 
concurrent upregulation of JNK and/or antagonism of sirtuins with dexamethasone. 
Evidently, our data suggest that pan-SIRT inhibitors, such as sirtinol, have substantial 
synergistic potential with dexamethasone and can be used to improve the efficacy of 
1 FOXM1 AND FOXO3a ROLE IN B-ALL 
 
71 
 
dexamethasone and to overcome dexamethasone resistance. Our data also provide 
evidence that FOXO3a phosphorylation at Ser-7, phosphorylation at Akt-targeted sites, and 
acetylation at Lys-242/5 can be reliable biomarkers for predicting and for monitoring 
dexamethasone response in B-ALL patients in the clinic. 
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1.5.7 SUPPLEMENTARY INFORMATION 
 
 
 
 
Supplementary Figure S1 
p38 and ERK inhibitors do not inhibit the cytotoxic and cytostatic function of dexamethasone in B-
ALL cell lines. REH and RS4;11 cells were treated with the a range of concentrations of (0-100μM) of p38 
and ERK inhibitors, SB202190 and PD98059 and/or dexamethasone. Cell viability analysis was performed 
after 48 h using MTT assay.  
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Supplementary Figure S2 
Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and cytostatic function of 
dexamethasone in B-ALL cell lines. REH and RS4;11 cells were treated with the a range of concentrations 
of SIRT inhibitors (0-100μM)  and/or dexamethasone. Cell viability analysis was performed after 24, 48 and 
72 h using MTT assay. A) Sintinol (SIRT1/2/6 inhibitor); B) EX527 (SIRT1 inhibitor); C) PDF-170 (SIRT2 
inhibitor). (t-test:  Sirtinol with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** 
very significant p<0.01 and no marker: not significant . 
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1.6 CONCLUSIONS 
 
B-ALL is one of the most common childhood cancer. Over the years, several evidences 
confirmed the importance on finding the molecular mechanisms underlying 
dexamethasone resistance at diagnosis. In fact, this condition is often associated with bad 
prognosis and future relapse conditions. 
In this study we aimed to clarify whether the transcription factors FOXM1 and FOXO3a, 
two members of Forkhead box (FOX) family, are involved in B-ALL. More specifically, 
we investigated if FOXM1 is involved in B-ALL tumor proliferation and drug resistance, 
and whether FOXO3a activation is fundamental for dexamethasone sensitiveness. We 
further analysed how FOXO3a activity might be regulated by post-translational 
modifications such as phosphorylation and acetylation. 
We firstly observed that protein and mRNA levels of FOXM1 were higher in ten B-ALL 
patient’s and five B-ALL cell lines (REH, MHH-CALL2, SEM, RS4;11, NALM-6) 
compared to peripheral blood mononuclear cells (PBMC) of healthy donors. To then 
investigate if FOXM1 is involved in cell proliferation and cell cycle progression we 
inhibited its expression through knockdown and thiostrepton treatment in one 
glucocorticoid-sensitive cell line, NALM-6, and one glucocorticoid-resistant cell line, 
REH. Results showed that FOXM1 downregulation causes a significant reduction on cell 
proliferation, cell cycle arrest in G2/M and increase on sub-G1 cells. More importantly, 
FOXM1 knockdown also leads to a downregulation of proteins involved in the regulation 
of mitotic progression and increases cell sensitiveness to dexamethasone treatment in both 
NALM-6 and REH. To then test if FOXM1 inhibition might improve chemotherapeutic 
agents efficiency we treated four different B-ALL cell lines with thiostrepton in 
combination with chemotherapeutic agents (i.e. dexamethasone, asparaginase, 
daunorubicin, vincristine and Ara-C). Combination index values (CI) calculated according 
to the Chou-Talalay method revealed that thiostrepton synergises with conventional 
chemotherapeutic agents in B-ALL reinforcing the hypothesis that FOXM1 might be a key 
target to optimize the efficacy of existing therapeutics for B-ALL and to overcome drug 
resistance. 
Studying the role of FOXO3a in B-ALL and in particular in glucocorticoid sensitiveness, 
we observed that in the sensitive B-ALL cell lines, RS4;11 and SUP-B15, the Akt 
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signaling pathway becomes downregulated following treatment leading then to the 
consequent FOXO3a activation. In fact we observed that in the sensitive B-ALL cell lines, 
RS4;11 and SUP-B15, FOXO3a becomes dephosphorylated on Akt-targeted sites, Ser253, 
Thr315 and Thr32 upon dexamethasone treatment, but its phosphorylation is unaffected by 
dexamethasone in the resistant REH cells. In agreement with this, FOXO3a activation by 
dexamethasone was confirmed by the increased expression of two FOXO3a-targets, 
p27
Kip1
 and Bim, and cell cycle arrest and apoptotis signatures. Furthermore 
immunostaining data confirmed that following dexamethasone treatment, FOXO3a 
translocates from cytoplasm to the nucleus only in sensitive cells whereas knockdown 
experiments showed that FOXO3a expression is essential for dexamethasone- induced 
cytotoxicity. These findings suggest that FOXO3a has a central role in mediating 
dexamethasone response. On trying to clarify why FOXO3a is differently regulated in 
resistant and sensitive cell lines, we analyzed if some other post-translational modifications 
might be involved in FOXO3a regulation. Interestingly western blot and 
Immunoprecipitation data showed that, upon dexamethasone treatment, FOXO3a becomes 
more phosphorylated at Ser7 and more acetylated at Lys 242 and Lys 245 residues only in 
sensitive cells. Moreover we also observed that the expression patterns of FOXO3a 
phosphorylation at Ser7 were similar to that of Lys 242/5 acetylation and JNK activation, 
providing evidence that dexamethasone induces JNK activation which is associated to 
FOXO3a Ser7 phosphorylation and Lys242/245 acetylation. In addiction our results clearly 
showed that the total acetylated, the Lys-242/5 acetylated and the Ser7 phosphorylated 
FOXO3a resided predominantly in the nuclei. In addition FOXO3a in sensitive cells 
becomes more acetylated and phosphorylated after dexamethasone treatment. On the 
contrary, FOXO3a acetylation (total and Lys-242/245) and phosphorylation (Ser-7) 
decreased marginally following dexamethasone in the resistant REH cells. Collectively, 
these data suggest that Lys-242/245 acetylation and Ser-7 phosphorylation are associated 
with dexamethasone-mediated nuclear relocalization and activation of FOXO3a. We also 
found that FOXO3a acetylation is associated with p300 activation and SIRT1/2/6 
downregulation. Furthermore, MTT and western blot analysis revealed that only the pan-
SIRT1/2/6 inhibitor (Sirtinol), but not the SIRT1 or -2 inhibitor (EX-527 and PDF-170), 
increases the antiproliferative effect of dexamethasone in both sensitive and resistant cell 
lines further enhancing the FOXO3a acetylation induced by dexamethasone. Therefore our 
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data suggest that sirtuins have a key role on modulating dexamethsone sensitivity and that 
the inhibition oft least SIRT1, and -2 simultaneously is required for overcoming 
dexamethasone resistance. Moreover our findings reveal a potential novel therapeutic 
strategy to treat B-ALL and to overcome dexamethasone resistance by concurrent 
upregulation of JNK and/or antagonism of sirtuins with dexamethasone. Our data also 
provide evidence that FOXO3a phosphorylation at Ser-7, phosphorylation at Akt-targeted 
sites, and acetylation at Lys-242/5 can be reliable biomarkers for predicting and for 
monitoring dexamethasone response in B-ALL patients in the clinic. Furthermore, it might 
be interesting to clarify the interplay between FOXO3a and FOXM1 in B-ALL. It is well 
known that FOXO3a can also exert its tumor suppressor function also by blocking FOXM1 
expression and activity: FOXO3a can represses the expression of genes implicated in 
tumour initiation, including FOXM1
20
. Recent research also showed that FOXO3a and 
FOXM1 antagonize each other's activity by competitively binding to the same target genes, 
which are involved in chemotherapeutic drug sensitivity and resistance. Therefore, we 
could assume that the FOXO3a-FOXM1 axis might be involved in dexamethasone 
responsiveness. Western blot data in fact showed that the FOXO3a activation, observed in 
glucocorticoid-sensitive cells, is also associated to the FOXM1 downregulation and 
consequent arrest in G2/M cell cycle phase. Therefore, understanding if there is an 
interplay between these two transcription factors, FOXO3 and FOXM1, will provide 
insight into chemotherapeutic drug action and will help to identify novel therapeutic 
approaches. 
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SUMMARY 
Over the years the biomedical research was focused on the development of new anticancer 
agents able to selectively target cancer cells at low concentration efficacy. Based on the 
idea that oncogenes and tumour suppressor genes are a critical force in the malignant 
transformation of cells, research efforts have focused on developing drugs that directly 
target these genes.  
Moreover, because cancer cells frequently have multiple genetic alterations, recent studies 
suggest that targeting the unique biochemical alterations which distinguish cancer cells 
from normal cells might be a feasible approach to achieve therapeutic activity and 
selectivity, and perhaps to prevent the development of drug resistance
12
. 
The most common features of human cancer is the cell cycle deregulation that leads to 
hyper proliferation pattern. In fact tumor cells  accumulate mutations that result in 
unscheduled proliferation as a consequence of unresponsiveness to growth inhibitory 
signals, self-sufficiency in growth factors or both
3
. Therefore several therapeutic strategies 
have been proposed for targeting the tubulin polymerization in cancer. Tubulin binding 
agents constitute an important class of compounds with broad activity in both solid and in 
hematologic neoplasia. They can act either promoting the microtubules polymerization and 
stabilization (i.e. taxanes, epothilones), or inducing microtubules depolymerization and 
instability (i.e. colchicine, vinca alkaloids, combretastatins)
4
. These agents are believed to 
block cell division by interfering with the function of the mitotic spindle, blocking cells at 
the metaphase/anaphase junction of mitosis. Moreover literature shows that tubulin-
binding agents may play their antitumoral effect also by disrupting the vascular structure
5
. 
In this work we evaluated the antiproliferative activity, interactions with tubulin and cell 
cycle effects of a new class of compounds that incorporated the structural motif of the 1-
(3’,4’,5’-trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton.  
Furthermore the effects of the most active agent, 3c were compared to the combretastatin 
molecule CA-4. Our data showed that this compound clearly induces apoptosis through 
caspase-9 and -3 activation. Furthermore the vascular disrupting activity was evaluated in 
HUVEC cells with compound 3c that showed an activity comparable to that of CA-4. In 
addition, compound 3c significantly reduced in vivo the growth of syngeneic hepatocellular 
carcinoma in Balb/c mice, suggesting that 3c could be a new antimitotic agent with clinical 
potential. 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
92 
 
Cancer cells are also characterized by altered metabolic activity which provokes increased 
levels of intracellular oxidative stress. Therefore cancer cells would be more vulnerable to 
further oxidative stress induced by Reactive Oxygen Species (ROS)-generating agents and 
more dependent on the enzymatic antioxidant systems. 
Importantly, this dependency might not be shared by many nontransformed cells, whose 
lower basal ROS levels and/or elevated antioxidant capacity could provide resistance to 
treatments that impair ROS metabolism. In keeping with this hypothesis, various small 
molecules, including ones with disulfide, α,β-unsaturated carbonyl, sulfonate, or other 
electrophilic functional groups, have been shown to elevate ROS levels by blocking the 
antioxidant enzymatic activity then inducing cancer cell death
6
.  
In this study we investigated whether a series of α-bromoacryloylamido arylcinnamide 
derivatives plays as antitumoral molecules by increasing ROS in cancer cells. We observed 
that the most potent hybrid compounds 4p caused a decrease in intracellular GSH content 
in cancer cells. However studies are underway to determine the precise molecular 
mechanism that leads to the decrease in intracellular GSH levels with the aim of develope 
new cancer therapeutic strategies 
. 
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2.1.1 GENERAL INTRODUCTION 
 
Resistance to chemotherapy is a major problem facing current cancer research. Over the 
years the biomedical research was focused on the development of new anticancer agents 
able to selectively target cancer cells at low concentration efficacy and to overcome drug 
resistance. Since malignant transformation is frequently driven by multiple genetic 
alterations in cancer cells, recent studies suggested that targeting the unique biochemical 
alterations, which distinguish cancer cells from normal cells might be a feasible approach 
to achieve therapeutic activity and selectivity, and perhaps prevent the development of 
drug resistance. 
Compared to the normal counterpart, cancer cells are characterized by the cell cycle 
deregulation that leads to their hyperproliferative pattern. Tumor cells  accumulate 
mutations that result in unscheduled proliferation, as a consequence of unresponsiveness to 
growth inhibitory signals, self-sufficiency in growth factors or both
7
. Therefore several 
antitumoral strategies have been proposed for targeting the cell division cycle in cancer by 
targeting tubulin polimerization
8
. 
 
2.1.1.1 TUBULIN STRUCTURE 
The microtubule system of eukaryotic cells is a critical element in a variety of fundamental 
cellular processes such as cell formation, maintenance of cell shape, regulation of motility, 
cell signaling, secretion, intracellular transport and mitotic spindle elongation for the 
correct chromosome segregation
9
. Microtubules are built from subunits, each of which is 
itself a dimer composed by two very similar globular proteins called α-tubulin and β-
tubulin
10
. The tubulin dimers stack together by non-covalent bonding to form the wall of 
the hollow cylindrical microtubules. This tube like structure is made of 13 parallel 
protofilaments, which are linear chains of tubulin dimers with α and β-tubulin alternating 
along its length. 
Each protofilament has a structural polarity, with α-tubulin exposed at one end and β-
tubulin at the other, and this polarity is the same for all protofilaments, giving a structural 
polarity to the microtubule as a whole. One end of the microtubule, thought to be the β-
tubulin end, is called plus end, and the other, the α tubulin end  is called minus end. The 
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microtubule system has a dynamic behavior, known as “dynamic instability”,  in which 
microtubules alternate between period of growing and shrinking through the addition or 
removal of tubulin monomers. This process is mediated by hydrolysis of GTP. 
 
 
 
Figure 1: The microtubule's structure is constituted by dimers of α-tubulin and β-tubulin. (Adapted from 
Ref
8
) 
 
 
2.1.1.2 TUBULIN AND CELL CYCLE PROGRESSION 
 
Microtubules dynamic plays a key role on mitosis progression and thus in cell division and  
proliferation. The mitosis (also called M phase) is divided into six stages: prophase, 
prometaphase, metaphase anaphase and telophase. At the onset of mitosis, the interphase 
microtubular network develop into the mitotic spindle. Microtubules extend in all 
directions from the two centromeres which are localized on pole of cell. During the 
prometaphase, an important stage in which there is disassemblation of the nuclear 
envelope, the spindle microtubules attach chromosomes through specialized protein 
complexes called kinetochores. With the methaphase the mitotic spindle moves to align at 
the equator of cell all chromosomes forming the metaphase plate, and finally during the 
anaphase chromosomes segregate into daughter cells
11
. 
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Figure 2: Microtubules involvement in mitotic spindles assemblation during mitosis. (Adapted from Ref
7
) 
 
 
2.1.1.3 TUBULIN TARGETING AGENTS 
 
Because of the central role of microtubules dynamic in mitosis progression and cell 
proliferation, drugs that affect microtubule assembly are important component in 
combination chemotherapy for the treatment of pediatric and adult cancer. The impressive 
success of antimitotic agents in patients is due to their potent antiproliferative effects and 
to their particular mechanism of action of altering microtubule dynamics. In dividing cells, 
such as cancer cells, microtubules are highly dynamic and exquisitely sensitive to 
therapeutic inhibitors. This explains why compounds that alter microtubule function have 
proved to be highly active in patients with cancer. The microtubule-targeted antimitotic 
drugs are often classified into two major groups, the microtubule-destabilizing agents and 
the microtubule-stabilizing agents, according to their effects at high concentrations on 
microtubule polymer mass
84
. The so-called “destabilizing” agents inhibit microtubule 
polymerization when present at high concentrations. Most of these agents bind in one of 
two domains on tubulin, the “vinca” domain and the “colchicine” domain. Vinca site 
binders include the vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine, and 
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vinflunine), the cryptophycins, the dolastatins, eribulin, spongistatin, rhizoxin, 
maytansinoids and tasidotin. Colchicine-site binders include colchicine and its analogs, 
podophyllotoxin, combretastatins, CI-980, 2-methoxyestradiol, phenylahistins 
(diketopiperazine), steganacins, and curacins. Furthermore some of the destabilizing 
agents, including the hemiasterlins, estramustine, noscapine, herbicides such as 
carbendazim, psychoactive drugs such as phenytoin, and food components such as 
sulforaphane found in cruciferous vegetables, bind to novel sites on tubulin
8
.  
The “microtubule-stabilizing” agents enhance microtubule polymerization at high drug 
concentrations and include taxol (paclitaxel, Taxol
™
), docetaxel (Taxotere
™
), the 
epothilones, ixabepilone (Ixempra
™
) and patupilone, discodermolide, eleutherobins, 
sarcodictyins, cyclostreptin, dictyostatin, laulimalide, rhazinilam, peloruside A, certain 
steroids and polyisoprenyl benzophenones. Most of the stabilizing agents bind to the same, 
or an overlapping, taxoid binding site on β-tubulin which is located on the inside surface of 
the microtubule. However, two of the agents, laulimalide and peloruside A, are not 
displaced by paclitaxel and for this reason are believed to bind to a novel site on tubulin. 
Overall several hundred compounds have been reported to arrest mitosis by their effects on 
microtubules. In all cases where it has been investigated, they do so most potently by 
suppressing microtubule dynamics.  
                                 
Figure 4: The “destabilizing” agents bind in one of two domains on tubulin, the “vinca” domain and the 
“colchicine” domain. The stabilizing agents bind to the same, or an overlapping, taxoid binding site on β-
tubulin which is located on the inside surface of the microtubule. (Adapted from Ref 
8
). 
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2.1.1.4 CYTOTOXIC EFFECT OF TUBULIN BINDING AGENTS  
 
Both classes of antimitotic drugs suppress microtubule dynamics causing alteration in the 
spindle organization, with a delay or a block at the metaphase-anaphase transition during 
mitosis with consequent G2-M cell cycle arrest. Furthermore activation of spindle assembly 
checkpoint in G2 phase and prolonged mitotic arrest provoke apoptosis induction
12
. The 
apoptosis is a programmed cell death characterized by chromatin condensation, DNA 
fragmentation and activation of caspases
13
. The apoptotic process could be triggered by 
two pathways called extrinsic and intrinsic pathway. Several works describe that tubulin 
binding agents induce apoptosis mainly through the intrinsic pathway activation, 
characterized by the alteration of mitochondrial parameters (such as alteration of 
membrane potential and ROS production). However, how cell death induction correlates 
with microtubule destabilization and mitotic arrest still remains unclear and 
controversial
14
. 
The intrinsic pathway of apoptosis is mainly initiated by the release of cytochrome c from 
the mitochondrion. Upon release into the cytoplasm, cytochrome c associates with dATP, 
procaspase-9, and the adaptor protein APAF-1, leading to the sequential activation of 
caspase-9 and effector caspases
15
. 
The release of apoptosis-inducing proteins from the mitochondria is regulated by pro- and 
antiapoptotic members of the Bcl-2 family. Antiapoptotic members (Bcl-2, Bcl-XL, and 
Mcl-1) associate with the mitochondrial outer membrane via their carboxy termini, 
exposing to the cytoplasm a hydrophobic binding pocket composed of Bcl-2 homology 
(BH) domains 1, 2, and 3, that is crucial for their activity. Perturbations of normal 
physiologic processes in specific cellular compartments lead to the activation of BH3-only 
proapoptotic family members (such as Bad, Bim, Bid, Puma, Noxa, and others). This leads 
to the altered conformation of the outer-membrane proteins Bax and Bak, which then 
oligomerize to form pores in the mitochondrial outer membrane resulting in cytochrome c 
release. Therefore the relative levels of expression of antiapoptotic Bcl-2 family members 
compared to the levels of proapoptotic BH3-only proteins at the mitochondrial membrane 
determines the activation state of the intrinsic pathway. It has been demonstrated that many 
microtubules binding agents can induce phosphorylation in serine residues of Bcl2 
antiapoptotic proteins, in cell that are blocked in G2-M phase, leading to loss of 
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prosurvival function and to destabilization of mitochondrial potential. Moreover Bcl2 
phosphorylation decreases its binding to the proapoptotic Bax protein, resulting in an 
increase of free Bax and apoptosis
16
. 
 
2.1.1.5 ANTIANGIOGENIC EFFECT OF TUBULIN BINDING AGENTS  
 
Recently it has been described that some microtubule-destabilizing agents might cause 
blood vessel disruption at no toxic doses thus acting also as antiangiogenic agents
17
. These 
drugs, binding to tubulin, not only provoke cytoskeleton alterations but are also able to 
impair endothelial cells functionality. This class of compounds is defined as vascular 
disrupting agents (VDA)
18
. Preclinical evaluation of tubulin-targeting VDAs showed that 
these compounds are able to disrupt tumor blood flow, causing tumor hypoxia and 
necrosis. One of the most important antimitotic agents and vascular disrupting agents 
(VDA) is Combretastatin A-4 (CA-4)
19,20
. Combretastatin-A4, isolated from the African 
tree Combretum caffrum, strongly inhibits tubulin polymerization by binding to the 
colchicine binding site on β-tubulin
21
. Furthermore in advanced clinical trials it was found 
that the water-soluble derivative of CA-4 (named CA-4P) has potent activity to reduce 
significantly the tumor blood flow inducing changes in endothelial-cell shape and plasma 
membrane blebbing, then increasing the permeability of cell monolayers
20
. These changes 
in endothelial cells result in significant reduction in tumour blood flow, increases in 
vascular permeability subsequently leading to vascular shutdown. 
 
Figure 5: Combretastatin A-4 (CA-4)
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2.1.2 AIM OF THE PROJECT  
Cancer cells frequently have multiple genetic alterations. However to target the unique 
biochemical alterations which differentiate cancer cells from normal cells might be a key 
strategy to selectively target cancer cells overcome drug resistance. 
The microtubule system plays an essential role on a variety of cellular processes, such as 
on maintaining of cell shape, intracellular transport and more importantly on cell cycle 
division. Therefore over the years several antitumoral compounds have been developed for 
targeting tubulin polymerization and thus cell cycle progression in cancer. Furthermore, 
many tubulin binding agents show antivascular effects against tumor endothelium, 
including the tubuling destabilizing agent CA-4.  
In this study we analysed a new series of compounds with general structure 3 synthetized 
starting from the CA-4 structure with the aim to improve their antimitotic and 
antiangiogenic activity. The new compounds incorporated the more electron rich structure 
of compound 2  and the trimethoxyphenyl skeleton that characterized the tubulin inhibitor 
CA-4 to afford a new series of 1-(3’,4’,5’-trimethoxybenzoyl)-3-arylamino-5-amino 1,2,4-
triazole compounds.  
We evaluated in vitro the effects of different substituents on benzene of arylamino moiety 
on antiproliferative activity and tubulin polymerization. The apoptotic and antitubulin 
activity of 3c was compared with Combretastatin-A4 (CA-4). Since a high antitumoral 
activity was observed, we also evaluated their efficacy to act as vascular disrupting agents 
(VDA) in endothelial cells as model, HUVEC. More importantly the 3c anticancer activity 
and then its potential clinical use was further evaluated with in vivo experiments by 
treating a syngenic model of mouse. 
 
 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
102 
 
2.1.3 RESULTS 
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2.1.3.1 ABSTRACT 
A new class of compounds that incorporated the structural motif of the 1-(3’,4’,5’-
trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton was 
synthesized and evaluated for their antiproliferative activity in vitro and in vivo, 
interactions with tubulin and cell cycle effects, and the most active agent, 3c, was 
evaluated for antitumor activity in vivo. Structure-activity relationships were elucidated 
with various substituents on the phenyl ring of the anilino moiety at the C-3 position of the 
1,2,4-triazole ring. The best results for inhibition of cancer cell growth were obtained with 
the p-Me, m, p-diMe and p-Et phenyl derivatives 3c, 3e and 3f, respectively, and, overall, 
these compounds were more or as active as CA-4. Their vascular disrupting activity was 
evaluated in HUVEC cells, with compound 3c showing activity comparable with that of 
CA-4. Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma 
in Balb/c mice, suggesting that 3c could be a new antimitotic agent with clinical potential.  
 
 
 
 
 
 
 
 
 
 
 
 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
104 
 
2.1.3.2 INTRODUCTION 
The cellular microtubule system, established by an equilibrium between the polymerization 
and depolymerization of αβ-tubulin heterodimers, is essential in a variety of cellular 
processes, including maintenance of cell shape, regulation of motility, intracellular 
transport of vesicles and organelles and cell division.
1
 Due to their role in eukaryotic cells, 
microtubules are a successful target for the development of numerous small natural and 
synthetic molecules that inhibit the formation of the mitotic spindle.
2-4
 Among the 
naturally occurring antimicrotubule agents, one of the most active is the cis-stilbene 
combretastatin A-4 (CA-4, 1a, Chart 1), isolated from the African cape bushwillow 
Combretum caffrum.
5
 CA-4 inhibits tubulin assembly by strongly binding to the colchicine 
site on β-tubulin.6 Its water soluble prodrug, CA-4 disodium phosphate (CA-4P, 1b),7 is in 
advanced clinical trials,
8
 and it was found to have potent activity in reducing tumor blood 
flow, thus acting as a vascular disrupting agent (VDA).
9
 Among the synthetic inhibitors of 
tubulin polymerization, we previously described a series of 2-arylamino-4-amino-5-
(3’,4’,5’-trimethoxybenzoyl)thiazoles with general structure 2 that showed strong 
antiproliferative activity against a panel of five cancer cell lines.
10
 These compounds also 
caused accumulation of HeLa cells in the G2/M phase of the cell cycle, as is typical for 
antimicrotubule agents. Derivatives 2a (R1=H) and 2b (R1=4’-Me) were the most active as 
inhibitors of tumor cell growth, with IC50 values of 6-23 and 15-86 nM, respectively, in the 
five cell lines.  
Ring bioisosterism is widely used as a rational approach for the discovery of new 
anticancer agents, especially for finding agents with optimal pharmacological properties.
11
 
Continuing our search strategy for novel and potent antimicrotubule agents, we have 
underway a pharmacophore exploration and optimization effort based on compounds with 
general formula 2. Here we describe replacing the thiazole nucleus with the more electron-
rich 1,2,4-triazole bioisosteric ring,
12,13
 to afford a new series of 1-(3’,4’,5’-
trimethoxybenzoyl)-3-arylamino-5-amino 1,2,4-triazole analogues with general structure 3. 
Our goal was to evaluate the steric and electronic effects of different substituents on the 
benzene portion of the arylamino moiety. Besides hydrogen (compound 3a), the examined 
substituents included fluorine (3b) and electron donating alkyl and alkoxy groups 
(compounds 3c-h and 3i-n, respectively). 
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Chart 1. Inhibitors of Tubulin Polymerization 
 
N
SN
H
O
R
R=H, F, Cl, CH3 and OCH3
2a, R=H
2b, R=p-CH3
2
3a, R=H
3b, R=p-F
3c, R=p-CH3
3d,R=m-CH3
3e, R=m,p-(CH3)2
3f, R=p-C2H5
3g, R=p-CH(CH3)2
3h, R=p-(CH2)3CH3
3i, R=p-OCH3
3j, R=m-OCH3
3k, R=m,p-(OCH3)2
3l, R=m,m',p-(OCH3)3
3m, R=p-OC2H5
3n, R=m,p-(OCH2O)
NH2
R
OCH3
H3CO
CH3O
H3CO
R=OH, Combretastatin A-4 (CA-4), 1a
R=OPO3Na2, CA-4P, 1b
1
OCH3
OCH3
OCH3
N
N
NN
H
R
3
NH2
1
2
3
4 5
O
H3CO OCH3
OCH3
 
Since it is well known that the trimethoxyphenyl skeleton is the characteristic structural 
requirement to maximize activity in a large series of inhibitors of tubulin polymerization, 
such as colchicine, CA-4 and podophyllotoxin,
14
 all newly prepared compounds 3a-n, 
retain the 3’,4’,5’-trimethoxybenzoyl group at the C-1 position of the 1,2,4-triazole ring. 
The newly synthesized derivatives were evaluated for their antiproliferative activity in a 
panel of human cancer cell lines, for their antitubulin activity (including cell cycle and 
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apoptotic effects) and their antivascular activity in HUVEC cells. Finally, the antitumor 
activity of 3c, the most potent member of the group in the in vitro studies, was evaluated in 
vivo in a syngeneic hepatocellular carcinoma in Balb/c mice in comparison with CA-4P.  
2.1.3.3 BIOLOGICAL RESULTS  
In vitro antiproliferative activities.  
Table 1 summarizes the antiproliferative effects of 1-(3’,4’,5’-trimethoxybenzoyl)-3-
anilino-5-amino 1,2,4-triazoles 3a-n against a panel of seven human cancer cell line, using 
CA-4 (1) as the reference compound.  
 
Table 1. In vitro cell growth inhibitory effects of compounds 3a-n and CA-4 (1) 
 
Compd  
IC50 
a
(nM) 
Jurkat CCRF-
CEM 
SEM HeLa HT-29 A549 MCF-7 
3a 1200±270 1000±90 1200±190 >10,000 6200±1200 >10,000 500±240 
3b 1900±400 2200±400 2400±210 410±70 2000±700 3800±160 370±30 
3c 0.81±0.03 0.21±0.04 0.51±0.10 3.2±1.3 0.82±0.10 0.51±0.22 1.0±0.61 
3d 42±16 330±60 30±10 440±50 460±80 870±30 15±3.2 
3e 2.0±0.11 0.81±0.10 0.40±0.11 2.0±0.82 3.0±0.91 1.0±0.82 4.0±0.21 
3f 1.0±0.09 3.0±0.09 0.81±0.21 6.0±1.0 0.21±0.08 0.92±0.51 5.0±1.0 
3g 520±40 1800±90 500±10 130±28 800±100 550±70 510±70 
3h >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 5200±110 
3i 51±10 1000±200 44±16 120±30 480±15 2400±100 260±80 
3j 7.2±2.0 120±30 1.0±0.4 30±1.2 700±32 54±4.3 11±4.2 
3k >10,000 9000±330 >10,000 >10,000 >10,000 >10,000 >10,000 
3l >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000 
3m 2500±220 2000±100 1900±170 2100±800 3700±400 6200±540 34±18 
3n 24±7.2 40±3.3 30±6 930±54 60±10 150±50 19±5.2 
CA-4 5±0.6 12±2.5 5±0.1 4±0.1 3100±100 180±50 370±100 
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a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
mean ± SE from the dose-response curves of at least three independent experiments carried out in triplicate. 
 
The 1-(3’,4’,5’-trimethoxybenzoyl)-3-amino-5-anilino 1,2,4-triazole isomers 7a-c, 7g-h 
and 7k-l were also evaluated for their activities, but, since they were all inactive (IC50>10 
μM), the data are not shown in Table 1. Three of the synthesized compounds, 
corresponding to the p-Me, m,p-di-Me and p-Et phenyl analogues 3c, 3e and 3f, 
respectively, were significantly more active than the rest of derivatives, with IC50 values of 
0.21-3.2, 0.4-4.0, and 0.21-6.0 nM, respectively, in the seven cell lines, as compared with 
4-3100 nM for CA-4. With average IC50 values of 1.0, 1.9 and 2.4 nM for 3c, 3e and 3f, 
respectively, 3c appears to be the most active compound in the series (for CA-4, the 
average value was 525 nM or, excluding the HT-29 cell line from the average, 96 nM). 
Thus, these three compounds are substantially more active than CA-4, and they are also 
more potent than their previously described isosteres 2a and 2b.
11
 In addition to these 
highly potent three derivatives, the m-OMe and m,p-methylenedioxy phenyl derivatives 3j 
and 3n, respectively, were more active than CA-4 against HT-29, A549 and MCF-7 cells. 
In short, the data shown in Table 1 indicate the importance of substituents and their relative 
position on the phenyl ring of the arylamino moiety at the C-3 position of the 1,2,4-triazole 
skeleton for activity and selectivity against different cancer cell lines. 
The unsubstituted anilino derivative 3a was weakly active (IC50>0.5 μM), and the 
introduction of a weak electron-releasing fluorine atom at the para-position of the phenyl 
(compound 3b) had the opposite effect, with slightly improved antiproliferative activity 
with respect to 3a against HeLa, HT-29, A549 and MCF-7 cells, while the activity was 
reduced against Jurkat, CCRF-CEM and SEM cells.  
We found that the small methyl group at the para-position of the phenyl ring, to furnish 
derivative 3c, improved significantly antiproliferative activity relative to 3a. Moving the 
methyl group from the para- to the meta-position, to furnish isomer derivative 3d, reduced 
antiproliferative activity from one to three orders of magnitude, with double digit 
nanomolar activity against Jurkat, SEM and MCF-7 cells. Since the para-toluidino moiety 
of 3c was favourable for potency, it is important to point out that the introduction of an 
additional methyl group at the meta-position, resulting in the meta, para-dimethyl 
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derivative 3e, produced a 2- to 4-fold reduction in antiproliferative activity against five of 
the six cancer cell lines, while 3c and 3e were equipotent against SEM and HeLa cells.  
The para-ethyl homologue 3f was 2-15-fold less active than methyl counterpart 3c against 
four of the seven cancer cell lines, with a minimal difference between the two compounds 
in the Jurkat and SEM cells, while 3f was 4-fold more potent than 3c against HT-29 cells. 
Replacing the para-ethyl group with branched (i-Pr) or larger (n-butyl) moieties 
(compounds 3g and 3h, respectively) was detrimental for activity in all cell lines, 
suggesting that an increase in steric bulk at this position caused a decrease in potency.  
The number and position of methoxy substituents on the phenyl ring (compounds 3i-l) had 
a major influence on antiproliferative activity. Replacement of the methyl moiety with a 
more electron-releasing methoxy group at the para-position of the phenyl ring (compound 
3i) decreased antiproliferative activity by 100-fold compared with 3c, indicating that the 
methyl and methoxy group are not bioequivalent at the para-position of the phenyl ring. 
The contribution of methyl or methoxy groups on the phenyl ring to activity (3c vs. 3d and 
3i vs. 3j, respectively) was position dependent, with opposite effects. While for the methyl 
group, as previously observed, the para-derivative 3c was considerably more potent than 
meta-isomer 3d, an opposite effect was observed for the two methoxy isomers 3i and 3j, 
with the meta-isomer 3j from 4- to 44-fold more potent than the para-isomer 3i in six of 
the seven cancer cell lines, the exception being the HT-29 cells. Either two or three 
methoxy substituents (derivatives 3k and 3l, respectively) caused substantial loss in 
antiproliferative activity relative to 3i and 3j, suggesting that steric factors account for the 
loss of activity observed with these two compounds. With the exception of the MCF-7 
cells, the para-ethoxy derivative 3m was 2- to 50-fold less potent than its methoxy 
counterpart 3m. The 3’,4’-methylenedioxy derivative 3n, with IC50 values in the double-
digit nanomolar range in five of the seven cancer cell lines, showed an antiproliferative 
activity intermediate between those of para- and meta-methoxy analogues 3i and 3j, 
respectively. 
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Evaluation of cytotoxicity in human non-cancer cells.  
To obtain a preliminary indication of the cytotoxic potential of these derivatives for normal 
human cells, two of the most active compounds (3c and 3f) were assayed in vitro against 
peripheral blood lymphocytes (PBL) from healthy donors (Table 2).  
 
 Table 2. Cytotoxicity of 3c and 3f in human non-cancer cells 
 
 
 
 
 
a
 Compound concentration required to reduce cell growth inhibition by 50%. 
b
 PBL not stimulated with PHA. 
c
 PBL stimulated with PHA. 
Values are the mean ± SEM for three separate experiments. n.d. not determined 
 
Both compounds were practically ineffective in quiescent lymphocytes, with an IC50 of 
about 30 µM. In the presence of  the mitogenic stimulus phytohematoagglutinin (PHA), the 
IC50 decreased to about 8 µM for both compounds, a value that is thousands of times 
higher than those observed against the lymphoblastic cell lines Jurkat and CCRF-CEM. 
Furthermore, compound 3c was also evaluated in human umbilical vein endothelial cells 
(HUVECs), and again the IC50 value was negligible compared with those found in the 
panel of cancer cell lines. Altogether these data suggest that these compounds may have 
cancer cell selective antiproliferative properties. 
 
Effect of compound 3c on drug-resistant cell lines 
Drug resistance has become a serious problem in cancer chemotherapy.
17,18
 One of the 
common mechanisms of resistance so far identified  both in preclinical and clinical studies 
 
Cell line  
IC50 (µM)
 a
 
3c 3f 
PBLresting
b
 31.2±8.7 34.0±11.7 
PBLPHA
c
 8.5±2.6 8.8±2.7 
HUVEC 11.9±3.8 n.d. 
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involves the overexpression of a cellular membrane protein called P-glycoprotein (P-gp) 
that mediates the efflux of various structurally unrelated drugs.
17,18 
We evaluated 
sensitivity of compound 3c in two multidrug-resistant cell lines, one derived from a colon 
carcinoma (Lovo
Doxo
),
19
 the other derived from a lymphoblastic leukaemia (CEM
Vbl-100
).
20
 
Both these lines express high levels of the P-gp.
19,20 
As shown in Table 3, compound 3c 
was almost equally potent toward cells resistant to doxorubicin or vinblastine showing a 
resistance index (RI), which is the ratio between GI50 values of resistant cells and sensitive 
cells, of 1.2 and 5.7 respectively, while doxorubicin in LoVo
Doxo
 and vinblastine in 
CEM
Vbl100
 showed a high RI of 118 and 193 respectively. 
 
Table 3. In vitro cell growth inhibitory effects of compounds 3c on drug resistant cell lines. 
 
 
 
 
 
 
 
a
IC50=compound concentration required to inhibit tumor cell proliferation by 
50%. Data are presented as the mean ± SE from the dose-response curves of two 
independent experiments performed in triplicate.  
b
The values express the ratio between IC50 determined in resistant and non-
resistant cell lines. 
 
 
Altogether these results suggest that this compounds might be useful in the treatment of 
drug refractory tumors. 
 
 
 
Compd 
IC50 
a
(nM)  
LoVo LoVo
Doxo
 Resistance ratio
b
 
3c 0.9±0.1 1.1± 0.5 1.2 
Doxorubicin 95.6 ± 43.2 11296 ± 356 118 
 CEM CEM 
Vbl100
 Resistance ratio
b
 
3c 0.21 ± 0.4 1.2± 0.5 5.7 
Vinblastine 1.0 ± 0.3 193 ± 39 193 
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Inhibition of tubulin polymerization and colchicine binding 
A subset of the compounds (3c-g, 3i-j and 3n) was evaluated for their in vitro inhibition of 
tubulin polymerization in comparison with CA-4. The same compounds were also 
examined for inhibitory effects on the binding of [
3
H]colchicine to tubulin (Table 4). 
 
Table 4. Inhibition of tubulin polymerization and colchicine binding by compounds 1a, 3c-g, 3i-j and 3n. 
Compound 
Tubulin assembly
a 
IC50±SD (µM) 
Colchicine binding 
b 
% ±SD 
3c 0.75±0.1 92±2 
3d 1.8±0.0 67±1 
3e 1.2±0.0 83±1 
3f 1.4±0.0 80±2 
3g 13±0.7 n.d 
3i 3.70.4 48±2 
3j 2.50.0 70±0.9 
3n 2.00.0 51±0.3 
1a 1.2±0.1 98±0.5 
 
a
 Inhibition of tubulin polymerization. Tubulin was at 10 μM. 
b
 Inhibition of [
3
H]colchicine binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 µM, 
respectively. 
n.d: not determined 
 
In the assembly assay, with 10 µM tubulin, compound 3c was highly potent, yielding an 
IC50 of 0.75 μM, almost twice as active as CA-4. Derivatives 3e and 3f had IC50 values of 
1.2 and 1.4 μM, comparable to value obtained with CA-4. Compounds 3d, 3i-j and 3n 
were less active as inhibitors of tubulin polymerization , with IC50 values of 1.8, 3.7, 2.5 
and 2.0 μM, respectively, while 3g was, relatively speaking, almost inactive. The order of 
inhibitory effects on tubulin assembly was 3c>3e=CA-4>3f>3d>3n>3j>3i>>3g. This order 
of activity as inhibitors of tubulin assembly correlates well with their order of activity as 
antiproliferative agents against Jurkat, CCRF-CEM, SEM and HeLa cells. 
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In the competition assay, compound 3c was again the most active derivative, inhibiting 
colchicine binding by 92%, versus 98% for CA-4. In the experiments summarized in Table 
4, the concentration of tubulin was 1.0 µM, while that of both the inhibitors and 
[
3
H]colchicine was 5.0 µM. Inhibition of colchicine binding by compounds 3e and 3f was 
lower, with 83% and 80% inhibition occurring with these agents. With the exception of 
compounds 3j and 3n, a good correlation was observed between antiproliferative activities, 
inhibition tubulin polymerization and inhibition of colchicine binding. 
To further investigate if the new derivatives interfered with the microtubule network, we 
examined the effects of 3c on HeLa cells by immunofluorescence microscopy. Following a 
24 h treatment with 3c at 50, 100 and 250 nM, the microtubule network was substantially 
modified in comparison with the untreated cells (Figure S1, Supporting Information). 
Altogether these results are consistent with the conclusion that the antiproliferative activity 
of these compounds derived from an interaction with the colchicine site of tubulin, and this 
ultimately results in interference with microtubule assembly.  
Molecular Modeling. To rationalize the experimental data observed for 3a-n, we 
performed a series of molecular docking simulations of these compounds in the colchicine 
site of tubulin. The proposed binding mode for 3c is very similar to the one presented by 
the co-crystallized DAMA-colchicine (Figure 1, panel A). In particular, it is possible to 
observe how the trimethoxyphenyl ring is in proximity of Cys241, while the phenyl ring 
occupies a hydrophobic region deep in the binding site, establishing a series of interactions 
with Met259, Thr314 and Lys352. Indeed, this sub-pocket is relatively small and, while the 
methyl substituent on the phenyl ring of 3c is able to fit in properly, larger groups, such as 
the isopropyl (3g) or the n-butyl (3h), cannot be accommodated into it. In these cases, the 
docking simulations are not able to generate a reasonable binding pose. The docking 
results are in accordance with the experimental data and they provide a possible structural 
justification of the SARs observed (Figure 1, panel B). Finally, it is interesting to note that 
the 3c binding conformation generated in the docking simulation is very similar to the 
conformation of the structure obtained experimentally by X-ray crystallography (Figure 1, 
panel C).  
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Analysis of 3-arylamino 1,2,4-triazole derivatives for effects on the cell cycle.  
The effects of a 24 h treatment with different concentrations of 3c on cell cycle progression 
in HeLa and Jurkat cells were determined by flow cytometry (Figure 2, panels A, B).  
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Figure 2. Percentage of cells in each phase of the cell cycle in HeLa (Panel A) and Jurkat cells (Panel B) 
treated with 3c at the indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed by 
flow cytometry as described in the experimental section. Data are represented as mean ± SEM of three 
independent experiments. 
A B 
A B 
C 
Figure 1. Panel A. Proposed binding for 3c (in grey) 
in the colchicine site. Co-Crystallized DAMA-
colchicine is shown in green. Panel B. Representation 
of the binding mode of 3c in the colchicine binding 
site, with a summary of the SARs observed for the 
reported series of compounds. Panel C. Superposition 
of the conformation obtained from the docking 
simulations (in grey) and the crystal structure (in 
yellow) of 3c. 
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The compound caused a significant G2/M arrest in a concentration-dependent manner in 
the cell lines tested, with a rise in G2/M cells occurring at a concentration as low as 60 nM, 
while, at higher concentrations, more than 70% of the cells were arrested in G2/M. The cell 
cycle arrest in the G2/M phase was accompanied by a corresponding reduction in cells in 
the other phases of the cell cycle. In particular, the G1 phase decreased in both cell lines 
whereas S phase reduction was mainly evident in Jurkat cells. We next studied the 
association between 3c-induced G2/M arrest and alterations in expression of proteins that 
regulate cell division. As shown in Figure 3 in HeLa cells, a 24 h treatment with 3c at 
concentrations lower than 100 nM caused no significant variation in cyclin B expression, 
which, in association with cdc2 controls both entry into and exit from mitosis,
21,22
 while at 
100 and 250 nM we observed a clear increase in the cyclin B1 band. 
 
                                      
                     
Figure 3. Effects of 3c on G2/M regulatory proteins (Panel A) and on p53, p21 and H2AX expression 
(panel B). HeLa cells were treated for 24 or 48 h with the indicated concentration of 3c. The cells were 
harvested and lysed for the detection of cyclin B1, p-cdc2
Tyr15
 and cdc25C (panel A) or p53, p21 and H2AX 
expression (panel B) by western blot analysis. 
To confirm equal protein loading, each membrane was stripped and reprobed with anti--
actin antibody. After a 48 h treatment, cyclin B1 expression decreased. More importantly, 
A 
B 
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p-cdc2
Tyr15
 expression decreased after either 24 or 48 h of treatment. However, no major 
changes in the expression of phosphatase cdc25c were observed. These results indicate that 
arrest at G2/M induced by 3c is caused by an immediate block of cyclin B1 activity, 
followed by its accumulation, leading to a persistent and marked decrease of p-cdc2
 Tyr15 
more detectable at the highest concentrations (100-250 nM) examined. 
In addition to the analysis of proteins that control cell cycle checkpoints, we also examined 
the expression of the tumor suppressor p53 after treatment of Hela cells with 3c. It is well 
known that prolonged mitotic arrest induces DNA damage and, consequently, p53 up-
regulation.
23,24
 As shown in Figure 3 (panel B), we detected in a concentration-dependent 
manner an increase in p53 expression that is particularly evident after 48 h of treatment. At 
the same time, we also observed a marked increase in the expression of phosphorylated 
histone γH2A.X, which is an early sensitive indicator of DNA damage.25 Interestingly, the 
expression of the cyclin-dependent kinase inhibitor p21, which was previously 
demonstrated to have an anti-apoptotic role,
26
 decreased both after 24 and 48 h of 
treatment. 
Compound 3c induces apoptosis  
To characterize the mode of cell death induced by 3c, a biparametric cytofluorimetric 
analysis was performed using propidium iodide (PI), which stains DNA and enters only 
dead cells, and fluorescent immunolabeling of the protein annexin-V, which binds to 
phosphatidylserine (PS) in a highly selective manner.
27
 
 
Dual staining for annexin-V and 
with PI permits discrimination between live cells (annexin-V
-
/PI
-
), early apoptotic cells 
(annexin-V
+
/PI
-
), late apoptotic cells (annexin-V
+
/PI
+
) and necrotic cells (annexin-V
-
/PI
+
). 
As shown in Figure 4, both HeLa (panel A) and Jurkat cells (panel B) treated with the two 
compounds for 24 h showed an accumulation of annexin-V positive cells that further 
increased after 48 h in comparison with the untreated cells. Analogous results were also 
obtained for compound 3e (see Figure S2, Supporting Information). 
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Figure 4. Flow cytometric analysis of apoptotic cells after treatment of HeLa cells (Panel A) or Jurkat cells 
(Panel B) with 3c at the indicated concentrations after incubation for 24 or 48 h. The cells were harvested and 
labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as mean ± SEM of 
three independent experiments 
Compound 3c induces caspase-dependent apoptosis 
We then analyzed by western blot which proteins are involved on the triggered apoptotic 
pathway upon treatment. HeLa cells were treated with different concentrations of 3c for 24 
and 48 h (Figure 5). 
 
Interestingly, 3c induced activation of the initiator caspase-9, in a time and concentration-
dependent manner. We observed also an activation of the effector caspase-3 and cleavage 
of its substrate PARP (Figure 5). Furthermore, the anti-apoptotic protein Bcl-2 was 
A B 
Figure 5. Western blot analysis of 
caspase-3, cleaved caspase-9, PARP Bcl-
2 and Bax after treatment of HeLa cells 
with 3c at the indicated concentrations 
and for the indicated times., To confirm 
equal protein loading, each membrane 
was stripped and reprobed with anti--
actin antibody. 
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decreased by treatment with 3c in a time dependent manner, while the expression of a pro-
apoptotic protein, Bax was slightly increased only at 250 nM and at 48 h. 
Derivative 3c has antivascular effects in vitro 
Tumor growth requires an oxygen supply, so the tumor microenvironment stimulates the 
development of additional blood vessels.
28
 Recent antitumor strategies are based on the use 
of chemotherapeutics with anti-angiogenic or antivascular drugs, in order to increase the 
efficacy of the treatment.
29
 Many tubulin binding agents show antivascular effects against 
tumor endothelium,
30 
including CA-4, and for that reason we evaluated 3c for effects on 
endothelial cells in vitro. We used human umbilical vein endothelial cells (HUVECs) as a 
model for angiogenesis/vasculogenesis processes in vitro. Endothelial cell migration to the 
tumor site is one of the described mechanisms of angiogenesis.
31
 Inhibiting this mechanism 
could be a strategy to arrest the development of tumor vasculature. We evaluated cell 
motility by scratching a HUVEC monolayer and monitoring the ability of cells to reclose 
the wound. As shown in Figure 6, (panel A), 3c is very efficient in arresting cell motility. 
The effect is statistically significant after a 24 h incubation, at all the tested concentrations 
(5, 10, 25 nM), while, after 6 h, 3c significantly inhibited cell motility at 10 and 25 nM, 
with a dose-response relationship observed (Figure 6, panel B). 
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Figure 6. Compound 3c has antivascular activity in vitro. Panel A. Confluent HUVECs in a monolayer were 
wounded, and cells treated with different concentrations of 3c and at different times were photographed, 7x 
magnification; bar=100 µm. The dotted lines define the areas lacking cells. Panel B. The graph shows the 
quantitative effect of 3c. Migration was quantified by measuring the gap closure at the indicated times as 
shown in panel A. Data are represented as mean ± S.E.M. of three independent experiments. *p<0.05, 
**p<0.01 vs control. Panel C. Inhibition of endothelial cell capillary-like tubule formation by 3c. Tubule 
formation on Matrigel was carried out as described in the Experimental section. Representative pictures (10X 
magnification; bar=100 µm) of preformed capillary-like tubules treated with increasing concentration of 3c 
for 1 or 3 h. Panel D. Quantitative analysis of the effects of 3c on the dimensional and topological parameters 
of the preformed capillary-like tubule networks, after a 3 h treatment. Data were represented as mean ± 
S.E.M. of three independent experiments. *p<0.05, **p<0.01 vs. control. 
 
To support the antivascular activity of 3c we evaluated the ability of the compound to 
disrupt the “tubule-like” structures, formed by HUVECs seeded on Matrigel. Matrigel is an 
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extracellular matrix, rich in pro-angiogenic factors that stimulate single endothelial cells to 
assume an extended shape. The overall effect results in a reticulum similar to a capillary 
network. 
As shown in Figure 6, panel C, after a 1 h incubation, 25 nM 3c visibly disrupted the 
network of HUVECs, as compared with the control. After 3 h, all the tested concentrations 
were effective in altering the tubule-like structures. An image analysis
32
 was performed to 
obtain a quantitative measurement of the total length of the tubules, the area and the 
number of meshes, the percent of area covered by HUVECs, and the number of branching 
points (Figure 6, panel D) after a 3 h treatment. 
The results indicate that the effects on endothelial cells induced by 3c are similar to those 
observed after CA-4 treatment, in the same experimental conditions, carried out by our 
group.
33 
 
Evaluation of antitumor activity of compound 3c in vivo
 
To evaluate the in vivo antitumor activity of 3c, a syngeneic hepatocellular carcinoma 
model in mice was used.
34
 Tumors were established by subcutaneous injection of BNL 
1ME A.7R.1 cells into the backs of Balb/c mice. In preliminary experiments in vitro, we 
determined that both compound 3c and CA-4, used as a reference compound, showed 
similar, potent cytotoxic activity (3c IC50 = 3.4±1.1 nM; CA-4 IC50 = 1.1±0.5 nM) against 
BNL 1ME A.7R.1 cells. Once the allografts reached a measurable size (about 100 mm
3
), 
twenty mice were randomly assigned to one of four groups. In two of the groups, 
compound 3c was injected intraperitoneally at doses of 5 and 10 mg/kg, respectively. In a 
third group, CA-4P was injected at 5 mg/kg, while the fourth group was used as a control. 
As depicted in Figure 7 (panel A), compound 3c caused a significant reduction in tumor 
growth, as compared with administration of vehicle, at 10 but not 5 mg/kg. The effect of 5 
mg/kg of CA-4P was not as great as that of 10 mg/kg of 3c, but the CA-4P effect was still 
significant relative to the control. During the treatment period, only a small decrease in 
body weight occurred in the 3c-treated animals (Figure 7, Panel B). 
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Figure 7. Inhibition of mouse allograft tumor growth in vivo by compound 3c. (A). Male mice were injected 
subcutaneously in their dorsal region with 10
7
 BNL 1MEA.7R.1 cells, a syngenic hepatocellular carcinoma 
cell line. Tumor-bearing mice were administered the vehicle, as control, or the indicated doses of 3c or CA-4P as 
reference compound at the concentration of 5 mg/kg. Daily injections were given intraperitoneally starting on day 1. The 
figure shows the average measured tumor volumes (A) and body weights of the mice (B) recorded at the beginning and 
at the end of the treatments. Data are presented as mean ± SEM of tumor volume and body weight at each time point for 
5 animals per group. *p<0.05, **p<0.01 vs. control.  
 
2.1.3.4 CONCLUSIONS 
The bioisosteric equivalence between thiazole and 1,2,4-triazole prompted us to synthesize 
a series of 1-(3’,4’,5’-trimethoxybenzoyl)-3-arylamino-5-amino 1,2,4-triazole derivatives 
with general formula 3, in which the 1,2,4-triazole ring replaced the thiazole system of 
previously published analogues with general structure 2. The substitution pattern on the 
phenyl of the arylamino moiety had variable effects.  
Compound 3c, bearing a p-toluidino moiety at the C-3 position of 1,2,4-triazole ring, its p-
ethyl homologue 3f and the m,p-dimethyl analogue 3e exhibited the greatest 
antiproliferative activity among the tested compounds, with IC50 values of 0.21-3.2, 0.21-
6.0 and 0.4-4.0 nM, respectively. These results were superior or comparable with those of 
the reference compound CA-4 against all cancer cell lines. The para-position tolerates 
small substituents, such as methyl (3c) or ethyl (3f) groups, while the inactivity of i-Pr or 
n-Bu derivatives 3g and 3h, respectively, indicates that bulky substituents were detrimental 
for activity. Placing the methyl group in the meta-position (3d) led to a dramatic drop in 
potency as compared with the para-isomer 3c, even though we observed excellent activity 
B A 
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with the meta, para-dimethyl derivative 3e. Compound 3c was the most potent inhibitor of 
tubulin polymerization and of colchicine binding (IC50=0.75 M for assembly, 92% 
inhibition of the binding of 5 M colchicine), and the antiproliferative activity of 3c, in 
terms of IC50’s, ranged from 0.21 to 3.2 nM in the seven cell tumor lines examined, values 
lower than that of previously published isosteric analogues.
11
 In addition, in preliminary 
experiment 3c had low toxicity in non tumoral cells and is active also in drug-resistant cell 
lines. Although 3c was almost twice as active as CA-4 as an inhibitor of tubulin 
polymerization, these two compounds showed similar activity as inhibitors of colchicine 
binding. Moreover, in a detailed series of biological assays, we clearly demonstrated that 
3c induced caspase-dependent apoptosis and late DNA damage and p53 induction. 
Compound 3c, in addition to its ability to inhibit tubulin polymerization, efficiently 
targeted endothelial cells, acting as a VDA. More importantly, in vivo experiments showed 
that this compound was able to significantly reduce the growth of a syngenic tumor model 
in mice, indicating that it is a very promising anticancer compound that warrants further 
evaluation for its potential clinical use. 
 
2.1.3.5 EXPERIMENTAL SECTION 
Cell growth conditions and antiproliferative assay. Human T-leukaemia (CCRF-CEM 
and Jurkat) and human B-leukaemia (SEM) cells were grown in RPMI-1640 medium 
(Gibco, Milano, Italy). Breast adenocarcinoma (MCF7), human cervix carcinoma (HeLa), 
and human colon adenocarcinoma (HT-29) cells were grown in DMEM medium (Gibco, 
Milano, Italy), all supplemented with 115 units/mL penicillin G (Gibco, Milano, Italy), 115 
μg/mL streptomycin (Invitrogen, Milano, Italy), and 10% fetal bovine serum (Invitrogen, 
Milano, Italy). CEM
Vbl-100
 cells are a multidrug-resistant line selected against vinblastine.
20
 
LoVo
Doxo
 cells are a doxorubicin resistant subclone of LoVo cells
21
 and were grown in 
complete Ham’s F12 medium supplemented with doxorubicin (0.1 µg/mL). LoVoDoxo and 
CEM
Vbl-100
 were a kind gift of Dr. G. Arancia (Istituto Superiore di Sanità, Rome, Italy). 
Stock solutions (10 mM) of the different compounds were obtained by dissolving them in 
DMSO. Individual wells of a 96-well tissue culture microtiter plate were inoculated with 
100 μL of complete medium containing 8 × 103 cells. The plates were incubated at 37 °C 
in a humidified 5% CO2 incubator for 18 h prior to the experiments. After medium 
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removal, 100 μL of fresh medium containing the test compound at different concentrations 
was added to each well in triplicate and incubated at 37 °C for 72 h. The percentage of 
DMSO in the medium never exceeded 0.25%. This was also the maximum DMSO 
concentration in all cell-based assays described below. Cell viability was assayed by the 
(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test as previously 
described.
37
 The IC50 was defined as the compound concentration required to inhibit cell 
proliferation by 50%, in comparison with cells treated with the maximum amount of 
DMSO (0.25%) and considered as 100% viability.  
Peripheral blood lymphocytes (PBL) from healthy donors were obtained by separation on 
Lymphoprep (Fresenius KABI Norge AS) gradient. After extensive washing, cells were 
resuspended (1.0 x 10
6
 cells/mL) in RPMI-1640 with 10% fetal bovine serum and 
incubated overnight. For cytotoxicity evaluations in proliferating PBL cultures, non-
adherent cells were resuspended at 5 x 10
5
 cells/mL in growth medium, containing 2.5 
µg/mL PHA (Irvine Scientific). Different concentrations of the test compounds were 
added, and viability was determined 72 h later by the MTT test. For cytotoxicity 
evaluations in resting PBL cultures, non-adherent cells were resuspended (5 x 10
5
 
cells/mL) and treated for 72 h with the test compounds, as described above.  
Effects on tubulin polymerization and on colchicine binding to tubulin.  
To evaluate the effect of the compounds on tubulin assembly in vitro,
38a
 varying 
concentrations of compounds were preincubated with 10 M bovine brain tubulin in 0.8 M 
monosodium glutamate (pH adjusted to 6.6 with HCl in a 2.0 M stock solution) at 30 ˚C 
and then cooled to 0 ˚C. After addition of 0.4 mM GTP, the mixtures were transferred to 0 
C cuvettes in a recording spectrophotometer and warmed to 30 °C. Tubulin assembly was 
followed turbidimetrically at 350 nm. The IC50 was defined as the compound concentration 
that inhibited the extent of assembly by 50% after a 20 min incubation. The capacity of the 
test compounds to inhibit colchicine binding to tubulin was measured as described,
38b
 
except that the reaction mixtures contained 1 M tubulin, 5 M [3H]colchicine and 5 M 
test compound. 
Molecular modeling. All molecular modeling studies were performed on a MacPro dual 
2.66GHz Xeon running Ubuntu 12.04. The tubulin structure was downloaded from the 
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PDB data bank (http://www.rcsb.org/ - PDB code: 1SA0).
39 
Hydrogen atoms were added to 
the protein, using the Protonate 3D routine of the Molecular Operating Environment 
(MOE).
40
 Ligand structures were built with MOE and minimized using the MMFF94x 
forcefield until a RMSD gradient of 0.05 kcal mol
-1
 Å
-1
 was reached. The docking 
simulations were performed using PLANTS.
41
 
Flow Cytometric Analysis of Cell Cycle Distribution. 
 5 × 10
5
 HeLa or Jurkat cells were treated with different concentrations of the test 
compounds for 24 h. After the incubation period, the cells were collected, centrifuged, and 
fixed with ice-cold ethanol (70%). The cells were then treated with lysis buffer containing 
RNase A and 0.1% Triton X-100 and then stained with PI. Samples were analyzed on a 
Cytomic FC500 flow cytometer (Beckman Coulter). DNA histograms were analyzed using 
MultiCycle for Windows (Phoenix Flow Systems). 
Apoptosis Assay.  
Cell death was determined by flow cytometry of cells double stained with annexin V/FITC 
and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure the surface 
exposure of PS on apoptotic cells according to the manufacturer’s instructions (Annexin-V 
Fluos, Roche Diagnostics). 
Western Blot Analysis. HeLa cells were incubated in the presence of 3c and after 
different times, were collected, centrifuged, and washed two times with ice cold phosphate 
buffered saline (PBS). The pellet was then resuspended in lysis buffer. After the cells were 
lysed on ice for 30 min, lysates were centrifuged at 15000 x g at 4 °C for 10 min. The 
protein concentration in the supernatant was determined using the BCA protein assay 
reagents (Pierce, Italy). Equal amounts of protein (10 μg) were resolved using sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (7.5−15% acrylamide 
gels) and transferred to PVDF Hybond-P membrane (GE Healthcare). Membranes were 
blocked with a bovine serum albumin (BSA) solution (BSA 5% in Tween PBS 1X), the 
membranes being gently rotated overnight at 4 °C. Membranes were then incubated with 
primary antibodies against Bcl-2, Bax, PARP, cleaved caspase-9, cdc25c (Cell Signaling), 
caspase-3 (Alexis), H2AX (Cell Signaling), p53 (Cell Signaling), cyclin B (Cell 
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Signaling), p-cdc2
Tyr15
 (Cell Signaling), p21 (Cell Signaling), or β-actin (Sigma-Aldrich) 
for 2 h at room temperature. Membranes were next incubated with peroxidase labeled 
secondary antibodies for 60 min. All membranes were visualized using ECL Select (GE 
Healthcare) and exposed to Hyperfilm MP (GE Healthcare). To ensure equal protein 
loading, each membrane was stripped and reprobed with anti-β-actin antibody. 
Antivascular activity. 
 HUVECs were prepared from human umbilical cord veins, as previously described.
33
 The 
adherent cells were maintained in M200 medium supplemented with LSGS (Low Serum 
Growth Supplement), containing FBS, hydrocortisone, hEGF, bFGF, heparin, 
gentamycin/amphotericin (Life Technologies, Monza, Italy). Once confluent, the cells 
were detached by trypsin–EDTA solution and used in experiments from the first to sixth 
passages. 
The motility assay for HUVECs was based on “scratch” wounding of a confluent 
monolayer.
42
 Briefly, HUVECs (1x10
5
) were seeded onto 0.1% collagen type I (BD 
Biosciences, Italy)-coated six well plates in complete medium until a confluent monolayer 
was formed. The cells were wounded using a pipette tip, and wells were washed with PBS 
to remove the undetached cells. Then, the cells were treated with the test compounds, and 
at different times from the scratch, the cells were photographed under a light microscope. 
At all indicated time points, the wound width was measured in four areas and compared 
with the initial width. 
Matrigel matrix (Basement Membrane Matrix, BD Biosciences, Italy) was kept at 4 °C for 
3 h, when 230 µL of Matrigel solution was added to each well of a 24-well plate. After 
gelling at 37°C for 30 min, gels were overlaid with 500 µL of medium containing 6 x 10
4
 
HUVECs. The cells were incubated over Matrigel for 6 h to allow capillary tubes to form. 
Different concentrations of test compound were added in the cultures and incubated for 
different times, and the disappearance of existing vasculature was monitored and 
photographed (five fields for each well: the four quadrants and the center) at a 10x 
magnification. Phase contrast images were recorded using a digital camera and saved as 
TIFF files. Image analysis was carried out using the ImageJ image analysis software, and 
the following dimensional parameters (percent area covered by HUVECs and total length 
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of HUVECs network per field) and topological parameters (number of meshes and 
branching points per fields) were estimated.
32
 Values were expressed as percent change 
from control cultures grown with complete medium. 
Antitumor activity in vivo.  
The in vivo cytotoxic activity of compound 3c was investigated using a syngeneic murine 
hepatocellular carcinoma cell line (BNL 1ME A.7R.1) in Balb/c mice.
34
 Male mice, 8 
weeks old, were purchased from Harlan (S. Pietro al Natisone Udine, Italy), and tumors 
were induced by a subcutaneous injection in their dorsal region of 10
7
 cells in 200 µL of 
sterile PBS. Animals were randomly divided into four groups, and, starting on the second 
day, the first group was daily dosed intraperitoneally (i.p.) with 7 µL/kg of free vehicle 
(0.9% NaCl containing 5% polyethylene glycol 400 and 0.5% Tween 80). Groups two and 
three were treated with compound 3c at the doses of 5 and 10 mg/kg body weight, 
respectively. The fourth group received the reference compound CA-4P at the dose of 5 
mg/kg body weight. Both compound 3c and CA-4P were dissolved in free vehicle. Tumor 
sizes were measured daily for 7 days using a pair of calipers. In particular, the tumor 
volume (V) was calculated by the rotational ellipsoid formula: V = A x B2/2, where A is the 
longer diameter (axial) and B is the shorter diameter (rotational). All experimental 
procedures followed guidelines recommended by the Institutional Animal Care and Use 
Committee of Padova University. 
Statistical Analysis. Unless indicated otherwise, the results are presented as the mean ± 
SEM. The differences between different treatments were analyzed using the two-sided 
Student’s t test. P values lower than 0.05 were considered significant. 
Supporting information available. Detailed characterization of synthesized compounds 
7a-c, 7g-h and 7k-l. Immunofluorescence analysis of tubulin network and apoptosis assay 
on HeLa cells. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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2.2.1 GENERAL INTRODUCTION 
 
In eukaryotic cells Reactive Oxygen Species (ROS) are constantly generated and 
eliminated in the biological system
22
. Growing evidences suggest that compared to normal 
cells, cancer cells exhibit increased intrinsic ROS stress, due in part to oncogenic 
stimulation, increased metabolic activity and mitochondrial malfunction. Therefore cancer 
cells survival depends on the alternative enzymatic detoxification reactions which are 
activated to overcome to the imbalanced redox status. As such, to develop drugs that target 
this cancer-specific biochemical alteration might be a feasible approach to achieve 
antitumor therapy
23
. 
 
2.2.1.1 REACTIVE OXIGEN SPECIES (ROS)  
Reactive oxygen species (ROS), such as superoxide anion (O2−), hydrogen peroxide 
(H2O2), and hydroxyl radical (HO•), hydroxyl ion, and nitric oxide, consist of radical and 
non-radical oxygen species formed by the partial reduction of oxygen
24
.  
 
ROS are constantly produced by both enzymatic and non-enzymatic reactions. Enzyme-
catalysed reactions that generate ROS include those involving NADPH oxidase, xanthine 
oxidase, uncoupled endothelial nitric oxide synthase (eNOS), arachidonic acid and 
metabolic enzymes such as the cytochrome P450 enzymes, lipoxygenase and 
cyclooxygenase. The mitochondrial respiratory chain is a non-enzymatic source of ROS. 
Since the maintenance of ROS intracellular homeostasis is fundamental for the 
Figure 1: Reactive oxygen 
species (ROS) 
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mitochondrial, metabolic and cellular function, the intracellular ROS normally exist in 
balance with biochemical antioxidants in all aerobic cells. Moreover oxidative stress
occurs when this critical balance is disrupted because of excess ROS or antioxidant 
depletion.  
 
2.2.1.2 ANTIOXIDANT ENZYMES 
In normal and cancer cells the ROS intracellular homeostasis is maintained through ROS-
scavenging systems such as superoxide dismutases (SOD1, SOD2 and SOD3), catalase, 
and the two non-enzymatic small molecule antioxidants, thioredoxin (TRX) and 
glutathione (GSH)
25,26
. 
 
 
Figure 2: ROS-scavenging systems SOD (1), GSH (2), Catalase (3), Thioredoxin (4).  (Adapted from Ref
27
) 
 
Superoxide dismutase (SOD) catalyzes the conversion of two superoxide anions into a 
molecule of hydrogen peroxide (H2O2) and oxygen (O2) (Eq. 1) whereas in the 
peroxisomes of eukaryotic cells, the enzyme catalase converts H2O2 to water and oxygen, 
and thus completes the detoxification initiated by SOD (Eq. 2)
28,26
. 
 
Eq. 1. 2 O2-+ 2H+  H2O2 + O2 
Eq. 2. 2 H2O2  2 H2O + O2 
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Thioredoxin system (Trx), which is composed of NADPH, thioredoxin reductase (TrxR), 
and thioredoxin provides the electrons to thiol-dependent peroxidases (peroxiredoxins) to 
remove reactive oxygen and nitrogen species with a fast reaction rate. 
Glutathione system is the most important intracellular defense against the deleterious 
effects of reactive oxygen species. This tripeptide (glutamyl-cysteinyl-glycine) plays as a 
sulfhydryl (-SH) antioxidant
29
. Reduced GSH is the biological active form that is oxidized 
to glutathione disulfide (GSSG) during oxidative stress. The glutathione GSH oxidation to 
GSSG is catalyzed by the antioxidant enzyme GSH peroxidase, whereas the recycling of 
GSSG to GSH is accomplished mainly by the enzyme glutathione reductase. Therefore the 
ratio of the oxidized form of glutathione (GSSG) and the reduced form (GSH) is a dynamic 
indicator of the oxidative stress of an organism
30
. 
 
         
 
Furthermore, Vitamin C or ascorbic acid is a water soluble molecule capable of reducing 
ROS, while vitamin E (α-tocopherol) is a lipid soluble molecule that has been suggested as 
playing a similar role in membranes. 
 
2.2.1.3 ROS HOMEOSTASIS IN CANCER CELLS 
Mounting evidences suggest that, compared with their normal counterparts, many types of 
cancer cell have increased levels of ROS
1
. The high ROS levels in cancer cells are a 
consequence of altered metabolism, increased aerobic glycolysis (the so called Warburg 
effect), activation of oncogenes and mitochondrial dysfunction
1,31,32
. As such, while 
normal cells can tolerate a certain level of exogenous ROS stress owing to their ‘reserve’ 
antioxidant capacity, cancer cells are more vulnerable to further oxidative stress. In fact, an 
Figure 3: The glutathione 
antioxidant system 
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additional increase of ROS stress in cancer cells could cause elevation of ROS above the 
threshold level of toxicity, leading to cancer cell death. 
 
 
 
Figure 4: Different ROS homeostasis in normal and cancer cells. (Adapted from Ref
1
) 
 
For this reason, compared to the normal counterpart, cancer cells would be more dependent 
on the enzymatic antioxidant systems and more vulnerable to further oxidative stress 
induced by exogenous ROS-generating agents or compounds that inhibit the antioxidant 
system. Therefore, to manipulate ROS levels treating cells with ROS-generating agents or 
compounds that inhibit the antioxidant systems might be a way to selectively kill cancer 
cells without causing significant toxicity to normal cells
1
. 
 
 
2.2.1.4 OXIDATIVE STRESS-INDUCING AGENTS  
 
The induction of oxidative stress can lead to the preferential killing of cancer cells. Several 
compounds have been described to exert their potent antitumoral activity by either 
activating a ROS-dependent apoptotic pathway (isoobtusilactone) or blocking the 
intracellular antioxidant systems such as Glutathione, SOD (elesclomol, piperlongumine, 
camalexin)
6,33
.  GSH metabolism appears to be actively involved in protecting cancer cells 
from apoptosis and in mechanisms of multidrug and radiation resistance. In particular, 
increased levels of GSH within tumour cells have been associated with resistance to 
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platinum-containing anticancer compounds, anthracyclines and alkylating agents
23
. Thus, a 
therapeutic approach that modulates GSH levels in cancer cells could affect the efficacy of 
other anticancer therapies. Several approaches for blocking GSH synthesis in cancer cells 
have been attempted. Piperlongumine perturbs GSH/GSSG antioxidant activity then 
increasing intracellular ROS in tumour cells. Moreover piperlongumine failed to raise ROS 
levels in non-cancerous cells probably resulted from their lower levels of these 
antioxidants, exerting then a selective antitumor activity
34
. Similarly the L-Buthionine 
sulphoximine (BSO) treatment provokes glutathione (GSH) intracellular depletion, 
followed by an increase in ROS
35
. 
 Because of the strong efficiency and selectivity of these ‘oxidative stress inducing’ 
compounds, to find molecules that associated with normal chemotherapeutic agents or by 
themselves exert a strong antitumoral citotoxity is the most important aim of several 
pharmaceutical enterprises
23
. 
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2.2.2 AIM OF THE PROJECT 
 
To increase the intracellular ROS levels could be an important strategy to selectively kill 
cancer cells. Cancer cells are characterized by higher levels of reactive oxidative species 
(ROS) compared to the normal counterpart. As such cancer cells are more vulnerable to 
damage by further ROS insults induced by exogenous agents. In this study we evaluated 
the antiproliferative effect of a series of new compounds which covalently combine two 
pharmacophores: the arylcinnamide skeleton and the α-bromoacryloyl moiety. The 
biological effects of various substituents on the N-phenyl ring of the benzamide portion 
were also described. 
We evaluated the effects of α-bromoacryloylamido arylcinnamides 4a-r on 
antiproliferative activity and tubulin polymerization in vitro. Furthermore we evaluated 
sensitivity of two of the most active compounds 4p and 4r in two multidrug-resistant cell 
lines, Lovo
Doxo
 and CEM
Vbl-100
) both expressing high levels of the P-gp. Since a high 
antitumoral activity was observed, we further monitored their effect on ROS intracellular 
homeostasis using two fluorescent probes 2’,7’-dichlorodihydrofluorescein diacetate 
(H2DCFDA) and hydroethidine (HE). Moreover we analysed if  the phenylcynnamides 
could affect the intracellular GSH content. 
 
 
 
  
 
 
 
 
 
 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
139 
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2.2.3.1 ABSTRACT 
 
The combination of two pharmacophores into a single molecule represents one of the 
methods that can be adopted for the synthesis of new anticancer molecules. A series of 
novel antiproliferative agents designed by pharmacophore hybridization approach, 
combining the arylcinnamide skeleton and a α-bromoacryloyl moiety, was synthesized and 
evaluated for its antiproliferative activity against a panel of seven human cancer cell lines. 
The biological effects of various substituents on the N-phenyl ring of the benzamide 
portion were also described. In order to study the possible mechanism of action, we 
observed that 4p slightly increased the Reactive Oxygen Species (ROS) production in 
HeLa cells, but more importantly a remarkable decrease of intracellular GSH content was 
detected in treated cells compared to controls. These results were confirmed by the 
observation that only thiol-containing antioxidants were able to significantly protect from 
induced cell death. 
 
Keywords. Apoptosis, phenylcinnamides, Michael acceptor, in vitro antiproliferative 
activity, GSH depletion, oxidative stress. 
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2.2.3.2 INTRODUCTION 
Molecular hybridization which covalently combines into a single molecule two different 
bioactive molecules with complementary pharmacophoric functions or with different 
mechanism of action is an effective tool to design highly active novel anticancer agents [1-
9]. Antitumor activity of cinnamic acid derivatives was explored by many research group 
[10-17]. Several laboratories reported that the low molecular weight compounds, 
phenylcinnamide showed anticancer activity against various human cancer cell lines and in 
cell lines which are resistant to conventional antimitotics, expressing P-gp efflux pumps. 
Phenylcinnamide derivatives with general structure 1 (Chart 1), are a class of compounds 
initially identified by Hergenrother et al. as potential anticancer agents [18, 19], with a 
moderate cytotoxic activity (IC50 ranging from 1 to 10 µM). These compounds interact 
with microtubules by interfering with the dynamic of tubulin polymerization. By the 
screening of 100-membered library of amides, compound 1a was identified as one of the 
most active derivatives, resulting moderately active against U-937 (lymphoma) and HeLa 
(cervical) cancer cells, with IC50 value of 3.0 and 11.3 M, respectively. This derivative 
arrested the cell cycle growth at the G2/M phase and induced apoptotic cell death in HeLa 
cancer cell line. Since the 3,4,5-trimehoxyphenyl substitution was demonstrated to be the 
essential structural requirement for optimal biological activity in numerous tubulin 
inhibitors, the antiproliferative activity of 1a was associated to the inhibition of tubulin 
polymerization, although it weakly binds to the colchicine site of tubulin. Increasing the 
bulk of the meta-substitution on the phenyl ring of the styryl portion, from methoxy to 
benzyloxy, to furnish derivative 1b, allow to increase the antiprolferative activity relative 
to 1a, with IC50 values of 1.8 and 2.1 M, against U-937 and HeLa cells, respectively. 
Raffa et al. described a series of cinnamoyl anthranilates with general structure 2, which 
inhibited the proliferation of human leukaemia K562 cells with IC50 values ranging from 
0.57 to 5 M [20]. COMPARE  analysis, effects on tubulin polymerization and on cell 
cycle distribution indicated that these compounds act as antitubulin agents.  
The compound α-bromoacrylic acid is an alkylating moiety with low chemical reactivity 
and devoid of cytotoxic effects (IC50>120 μM on the murine leukaemia L1210 cells) [21]. 
The α-bromoacryloyl moiety is present in a series of potent anticancer distamycin-like 
minor groove binders, including PNU-166196 (brostallicin, 3), which was evaluated as a 
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first-line single agent chemotherapy in patients with advanced or metastatic soft tissue 
sarcoma [22, 23]. It has been hypothesized that the reactivity of the α-bromoacryoyl 
moiety results from a first-step Michael-type nucleophilic attack, followed by a further 
reaction of the former vinylic bromo substituent alpha to the carbonyl, leading successively 
either to a second nucleophilic substitution or to a beta elimination [24]. 
Phenylcinnamids are characterized by the presence of a α,β-unsaturated carbonyl moiety, 
which can be considered as an Michael acceptor, an active pharmacophore often employed 
in the design of anticancer drugs [10,25]. Because of their ability to interact with cellular 
nucleophiles, Michael acceptors are often employed as a powerful tool in the design of 
anticancer agents [26, 27]. Combining two bioactive pharmacophores, corresponding to the 
phenylcinnamide skeleton and α -bromoacryoyl moiety, within a unique structure might 
exhibited synergic effects in anticancer activities. In a continuing study of hybrid 
compounds containing the α-bromoacryloyl moiety as potential anticancer drugs, we 
synthesized a novel series of hybrid compounds with general structure 4, in which this 
moiety was linked to the arylcinnamide scaffold. 
In particular, we have synthesized two different series of compounds, characterized by the 
α-bromoacryloyl moiety located at the meta- or para-position on the phenyl of the 
benzylidene fragment, corresponding to compounds 4a-p and 4q-r, respectively. The 
structure-activity relationship (SAR) was investigated by the insertion of different 
substitutions [both electron-releasing (CH3, alkoxy, OCF3, SCF3, morpholin-4-yl) and 
electron-withdrawing (F and Cl) groups] at different positions on the phenyl ring of the 
benzamide portion.  
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4d, Ar=3-F-C6H5
4e, Ar=3,4-F2-C6H4
4f, Ar=4-Cl-C6H5
4g, Ar=4-CH3-C6H5
4h, Ar=4-CH3-C6H4CH2
4i, Ar=4-OCH3-C6H5
4j, Ar=4-OC2H5-C6H5
4k, Ar=4-OCF3-C6H5
4l, Ar=4-SCF3-C6H5
4m, Ar=3,4-(OCH3)2-C6H4
4n, Ar=3,5-(OCH3)2-C6H4
4o, Ar=3,4,5-(OCH3)3-C6H3
4p, Ar=4-(morpholin-4'-yl)-C6H5  
 
Chart 1. Structure of phenylcinnamides 1a, 1b and 2, brostallicin (3) and -bromoacryloylamido 
arylcinnamides 4a-r. 
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2.2.3.3 BIOLOGICAL RESULTS AND DISCUSSION 
In vitro antiproliferative activities.  
In Table 1, we report the antiproliferative effects of α-bromoacryloylamido arylcinnamides 
4a-r against the growth of human cervix carcinoma (HeLa), colorectal carcinoma (HT-29 
and LoVo), lymphoblastic leukaemia (CEM, Jurkat and SEM) and breast carcinoma 
(MCF-7) cells, using the phenylcinnamides 1a and 1b as positive controls.  
 
Table 1. In vitro cell growth inhibitory effects of compounds 1a-b, 4a-r and 7o 
 
Compound  
IC50 
a
(M) 
HeLa HT-29 LoVo CEM Jurkat SEM MCF-7 
4a 7.3±2.1 16.6±5.9 3.9±0.18 0.19±0.09 5.0±0.7 1.1±0.26 27.3±3.9 
4b 1.4±0.1 6.5±0.6 1.16±0.11 1.8±0.44 0.68±0.22 0.83±0.25 2.8±0.5 
4c 16.8±4.8 36.6±2.6 4.8±0.8 16.6±4.5 6.2±1.8 8.4±3.7 13.6±3.8 
4d 1.2±0.4 4.6±0.4 1.0±0.2 26.0±4.1 1.0±0.3 0.62±0.31 3.3±0.5 
4e 1.9±0.1 8.7±3.9 0.54±0.07 0.013±0.006 0.55±0.19 0.09±0.03 2.69±0.2 
4f 2.8±0.3 7.9±1.0 5.9±1.0 0.46±0.02 2.6±0.16 1.19±0.45 11.0±1.3 
4g 1.5±0.12 1.2±0.3 1.5±0.3 0.27±0.05 0.24±0.04 0.19±0.04 2.5±0.5 
4h 1.7±0.4 2.7±0.3 1.9±0.3 0.55±0.13 0.74±0.17 1.3±0.2 2.2±0.8 
4i 0.79±0.25 2.3±0.2 0.55±0.08 0.026±0.01 0.47±0.15 0.07±0.03 2.5±0.3 
4j 2.0±0.13 3.4±0.3 0.85±0.03 0.098±0.033 0.93±0.12 0.18±0.04 5.5±1.0 
4k 29.0±3.4 61.2±11.1 30.3±0.9 13.0±4.0 30.3±4.5 19.3±2.3 43.3±1.8 
4l 19.0±3.2 39.8±2.8 29.3±2.2 15.3±2.5 30.1±2.1 12.7±2.6 30.1±1.4 
4m 0.56±0.18 1.9±0.4 0.15±0.02 0.021±0.005 0.19±0.05 0.003±0.0004 2.8±0.4 
4n 2.2±0.18 3.6±0.2 1.21±0.32 0.011±0.004 0.98±0.33 0.04±0.017 3.0±0.4 
4o 0.88±0.19 2.3±0.5 0.14±0.04 0.059±0.025 0.29±0.03 0.018±0.003 1.8±0.3 
4p 0.43±0.1 1.6±0.4 0.51±0.11 0.61±0.08 0.04±0.01 0.057±0.013 2.6±0.2 
4q 1.6±0.3 3.1±0.3 0.06±0.01 0.022±0.005 1.4±0.47 0.08±0.03 3.0±0.2 
4r 0.49±0.17 3.7±0.9 2.1±0.9 0.025±0.013 0.41±0.05 0.11±0.09 3.0±0.6 
7o 53.1±4.6 63.1±6.5 45.2±5.6 40.9±13.6 43.3±4.8 2.81±2.8 55.4±11.1 
1a 16.5±2.6 44.1±0.9 43.0±3.0 23.4±4.1 12.5±0.9 18.2±1.9 27.0±4.5 
1b 2.2±0.39 3.6±0.2 21.7±5.0 17.3±6.0 3.5±0.5 8.5±2.3 2.4±0.8 
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
mean ± SE from the dose-response curves of at least three independent experiments). 
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Compound 1b, with IC50’s ranging from 2.2 to 21.7 μM, was 1.5- to 12-fold more potent 
than its methoxy counterpart 1a. With only two exceptions (4k and 4l), all the molecules 
that were generated by the hybridization of the α-bromoacryloyl moiety with the 
arylcinnamide system were more active than 1a. For the benzyloxy derivative 1b, its 
activity was lower than that of derivatives 4b, 4e-j, 4m-r against the LoVo, CEM, Jurkat 
and SEM cells. Among the hybrid compounds, six of them (4e, 4i, 4m-o and 4q) exhibited 
potent activity, with double-digit nanomolar IC50 values against both the CEM and SEM 
cell lines. The validity of the hybridization approach was confirmed comparing the potency 
of compound 4o with that of the amino phenylcinnamide derivative 7o. This latter 
compound was 30-700 fold less active than the corresponding α-bromoacryloylamido 
derivative 4o, demonstrating that the presence of a α -bromoacryloyl moiety significantly 
enhanced antiproliferative activity. 
With the exception of the CEM cells, compound 4b bearing the more lipophilic 1-naphthyl 
moiety exerted a more pronounced antiproliferative activity toward cell lines tested in 
comparison with the unsustituted phenyl derivative 4a.  
The antiproliferative activities of the hybrid molecules were influenced by the substituents 
on the phenyl ring of the aniline/benzylamino moiety. A comparison of the para-position 
substitution on the phenyl ring demonstrated that ERGs such as methyl (4g and 4h), 
methoxy (4i) or ethoxy (4j) and morpholin-4-yl (4p) increased antiproliferative activity 
compared with the unsubstituted benzene derivative 4a, whereas trifluoromethoxy (OCF3, 
4k) or trifluoromethylsulfanyl (SCF3, 4l) substituents produced a dramatic loss of potency. 
Introduction of a weak electron-withdrawing group, a para-fluorine atom (4c), decreased 
the activity relative to 4a on six cancer cell lines, the exception being the MCF-7 cells. 
Moving the fluorine from the para- (4c) to the meta-position (4d) enhanced 
antiproliferative activity 4-15 fold in six of the seven cell lines, the exception being the 
CEM cells. Antiproliferative activity increased 2-30 fold by increasing halogen size from 
fluorine to chlorine (4f). Relative to the activity of derivative 4c, insertion of an additional 
fluorine atom at the meta-position to yield 4e increased antiproliferative activity (4-1300 
fold) against all cancer cell lines. By comparing the effect of substituents with opposite 
electronic properties at the para-position of phenyl ring, a 2-10 fold increase in potency 
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was observed by replacing the electron withdrawing chlorine atom (4f) with an electron-
donating methyl group (4g). The cell growth inhibitory activities of N-4’-tolyl and N-4’-
methylbenzyl derivatives 4g and 4h, respectively, were very similar against the HeLa, 
LoVo and MCF-7 cells, while 4h had significantly reduced activity (from 2-7 fold) as 
compared with 4g against the remaining cell lines. The antiproliferative activity of hybrid 
compounds can be further characterized in terms of the substitution pattern and the number 
of methoxy groups on the phenyl ring. The results show that mono-, di- or trimethoxy 
substitution on the 3’, 4’, and/or 5’-positions of the phenyl ring (compounds 4i, 4m-o and 
4q-r) were well tolerated and increased activity, usually substantially, as compared with 
the unsubstituted benzamide derivative 4a. A single methoxy substituent on the para-
position of the phenyl ring (compound 4i) led to a 7-15 fold increase in antiproliferative 
activity relative to 4a. Comparing 4i with 4m, an additional methoxy group at the meta-
position had little effect on activity against HeLa, HT-29, CEM and MCF-7, but there were 
2-, 3- and 20-fold increases in activity against the Jurkat, Lovo and SEM cells, 
respectively. The 3’,4’-dimethoxy derivative 4m was generally (6 out of 7 cell lines) more 
active than the isomeric 3’,5’-dimethoxy analogue 4n. Finally, adding a third methoxy 
group to produce the 3’, 4’, 5’-trimethoxyphenyl derivative 4o caused a reduction in 
activity against five of the seven cancer cell lines.  
Turning specifically to the para-substituted phenyl derivatives, replacing 4’-methoxy (4i) 
with the 4’-ethoxy homologue (compound 4j) produced a 2-4 fold reduction in activity. 
This loss of activity became much more pronounced if the methoxy group was replaced 
with a bulkier trifluromethoxy (4k) or trifluoromethoxysulfanyl (4l) moiety.  This activity 
loss cannot be explained simply as being caused by a steric effect of the substitution at the 
para-position of the phenyl ring because insertion of an electron poor heterocycle such as 
morpholin-4-yl (compound 4p) enhanced antiproliferative activity 8-100 fold relative to 4a 
with six of the seven cancer cell lines (the exception was the CEM cells). Changing the 
location of α -bromoacryloylamido moiety from the meta- in 4i to the para-position in 4q 
had little effect on activity, except in the LoVo cells. Similarly, there was little difference 
in activity between the two isomeric trimethoxyphenyl derivatives 4o and 4r, except in two 
cell lines (LoVo and SEM cells).  
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Evaluation of cytotoxicity in human peripheral mononuclear cells (PBMC). 
To obtain more insights into the cytotoxic potential of these new compounds for normal 
human cells, two of the most active compounds (4p and 4r) were assayed in vitro against 
human peripheral mononuclear cells (PBMC) obtained from healthy donors. As showed in 
Table 2, compounds 4r and 4p showed, in resting PBMC, a lesser degree of toxicity 
having an IC50 of about 3-5-4.0 µM that is roughly 10-100 fold lower respect to the 
lymphoblastic cell lines Jurkat and CEM. On the contrary they proved cytotoxic only for 
PHA-stimulated PBMC, suggesting that these compounds acts only in proliferating cells. 
 
Table 2. Cytotoxicity of 4p and 4r for human peripheral blood mononuclear cells (PBMC) 
 
 
 
 
 
 
 
  
Compound concentration required to reduce cell growth inhibition by 50%. 
b
 PBMC not stimulated with PHA. 
c
 PBMC stimulated with PHA. 
Values are the mean ± SEM for three separate experiments. 
 
Effects of phenylcynnamides on drug-resistant cell lines 
Drug resistance is an important therapeutic problem caused by the appearance of tumor 
cells endowed with differing mechanisms that confer resistance against a variety of 
anticancer drugs.[29, 30]
 
Among the most common mechanisms of resistance are those 
related to the over-expression of a cellular membrane protein called P-gp that mediates the 
efflux of various structurally unrelated drugs.[29, 30]
 
In this context, we evaluated 
sensitivity of two of the most active compounds 4p and 4r in two multidrug-resistant cell 
lines, one derived from a colon carcinoma (Lovo
Doxo
) [31],
 
the other derived from a T-cell 
leukaemia (CEM
Vbl-100
) [32],
 
both expressing high levels of P-gp. As shown in Table 3, 
compounds 4p and 4r were equally potent toward parental cells and cells resistant to 
 
Cell line  
IC50 (µM)
 a
 
4p 4r 
PBMCresting
b
 4.0±1.9 3.5±1.8 
PBMCPHA
c
 0.50±0.27 0.24±0.12 
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vinblastine or doxorubicin, suggesting that these compounds might be useful in the 
treatment of drug refractory tumors. 
Table 3. In vitro cell growth inhibitory effects of compounds 4p and 4r on drug resistant cell lines. 
 
 
 
 
 
 
 
a 
IC50=compound concentration required to inhibit tumor cell proliferation by 
50%. Data are presented as the mean ± SE from the dose-response curves of at 
least three independent experiments. 
b 
The values express the ratio between IC50 determined in resistant and non-
resistant cell lines. 
 
In vitro inhibition of tubulin polymerization. 
Previous studies have shown that compound 1a most likely derived its antiproliferative 
activity from an interaction at the colchicine site of tubulin, causing inhibition of tubulin 
polymerization [19]. To investigate whether the antiproliferative activities of the most 
active hybrid compounds (4e, 4i, 4m, 4o-p, 4r) were related to an interaction with the 
microtubule system, these molecules were evaluated for their in vitro inhibition of the 
polymerization of purified tubulin [33]. All tested compounds did not inhibit tubulin 
assembly at concentrations as high as 20 μM, indicating that they were inactive as 
inhibitors of tubulin polymerization. To further evaluate if the new derivatives interfered 
with the microtubule network, we examined the effects of 4r and 4p on HeLa cells by 
immunofluorescence microscopy. Shown in Figure 1 (Panel A) is the normal microtubule 
network of untreated cells. Following 24 h of treatment with 4p or 4r at 2.5 or 5.0 µM
(Figure 1, panels B-D), the microtubule network was not substantially modified in 
comparison with the untreated cells. Altogether these results were consistent with the 
 
Compd 
IC50 
a
(µM)  
LoVo LoVo
Doxo
 Resistance ratio
b
 
4p 0.51±0.11 1.05± 0.44 2.0 
4r 2.1 ± 0.9 1.37 ± 0.24 0.6 
Doxorubicin 0.096 ± 0.043 11.3 ± 0.35 118 
 CEM CEM 
Vbl100
 Resistance ratio
b
 
4p 0.61 ± 0.08 0.41 ± 0.09 0.7 
4r 0.025 ± 0.013 0.015 ± 0.005 0.6 
Vinblastine 0.002 ± 0.0005 0.021 ± 0.008 105 
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conclusion that the antiproliferative activity of these hybrid compounds was not derived 
from a direct interaction with tubulin and that it is unlikely that they act as microtubule 
binding agents.  
                                         
    
                   
Figure 1. Effects of compounds 4p (panels B and C) and 4r (panels D and E) on microtubule networks in 
Hela cells. Panel A, untreated cells. Cells were incubated with 2.5 µM (panels B and D) or 5.0 µM (panels C 
and E) of the compounds for 24 h and then stained with anti--tubulin primary antibody and secondary 
Alexa-conjugated antibody and then observed by confocal microscopy (magnification 20x). Cells were also 
counterstained with DAPI to visualize the nuclei. 
 
Analysis of cell cycle effects.  
 The effects of a 24 h treatment with different concentrations of 4r and 4p on cell cycle 
progression in HeLa cells were determined by flow cytometry (Figure 2, Panels A and B). 
The compounds caused a significant G2/M arrest in a concentration-dependent manner in 
the cell line tested, with a rise in G2/M cells occurring at a concentration as low as 2 µM. 
Importantly, the increase in G2/M phase cells was accompanied by a remarkable reduction 
in S phase cells for both compounds.  
 
A 
B 
C 
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Figure 2. Percentage of cells in each phase of the cell cycle in HeLa cells treated with the 4r (Panel A) and 
4p (Panel B) at the indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed by 
flow cytometry as described in the experimental section. 
 
Phenylcynnamides induce apoptosis in Hela cells 
To characterize the mode of cell death induced by 4r and 4p, a biparametric 
cytofluorimetric analysis was performed using PI, which stains DNA and enters only dead 
cells, and fluorescent immunolabeling of the protein annexin-V, which binds to 
phosphatidylserine in a highly selective manner [34]. 
 
Dual staining for annexin-V and 
with PI permits discrimination between live cells (annexin-V
-
/PI
-
), early apoptotic cells 
(annexin-V
+
/PI
-
), late apoptotic cells (annexin-V
+
/PI
+
) and necrotic cells (annexin-V
-
/PI
+
). 
As shown in Figure 3 (Panels A and B), Hela cells treated with the two compounds for 24 
h showed an accumulation of annexin-V positive cells that further increased after 48 h in 
comparison with the untreated cells. 
A B 
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Figure 3. Flow cytometric analysis of apoptotic cells after treatment of HeLa cells with 4r (Panel A) or 4p 
(Panel B) at the indicated concentrations after incubation for 24 or 48 h. The cells were harvested and labeled 
with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as means of three independent 
experiments. For the sake of clarity, error bars were omitted. 
 
Phenylcynnamides induce caspase-dependent cell death 
To evaluate if the apoptotic cell death induced by 4p and 4r is caspase-dependent, Hela 
cells were treated with the two compounds in the absence or presence of the pan-caspase 
inhibitor z-VAD.fmk. As shown in Figure 4 (panel A), the inhibition of caspases 
significantly increased cell viability suggesting a caspase-dependent process of cell death. 
To determine which caspases were involved in phenylcinnammide-induced cell death, the 
expression of caspases was evaluated by immunoblot analysis. We observed an activation, 
in a time- and concentration-dependent manner, of the effector caspase-3 and cleavage of 
its substrate PARP (Figure 4, panel B). Interestingly, the two compounds did not induce 
activation of caspase-9, the major initiator caspase of the mitochondrial apoptotic pathway 
(Figure 4, panel B). Indeed a clear activation of caspase-8 was observed for both 
compounds, suggesting that the induced apoptosis followed the extrinsic pathway. 
A B 
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Figure 4. (A). Percentage of cell viability after a 48 h incubation of HeLa cells with 4r or 4p (2.5 µM) in the presence 
or in the absence of z-VAD.fmk (100 µM). Means  SEM of three independent experiments. **P<0.01 vs. 4p or 
4r treated cells. (B). Western blot analysis of caspase-3, cleaved caspase-9, caspase-8 and PARP after 
treatment of HeLa cells with 4r or 4p at the indicated concentrations and for the indicated times. To confirm 
equal protein loading, each membrane was stripped and reprobed with anti--actin antibody 
 
Phenylcynnamides induce downregulation of Bcl-2 family proteins and DNA damage 
To further study the mechanism of apoptosis induction by phenylcinnamides, we evaluated 
the expression of proteins of the Bcl-2 family. As shown in Figure 5, the anti-apoptotic 
protein Bcl-2 was decreased by treatment with 4r in a time dependent manner. Also 4p 
produced similar effects, but they were more evident after 48 h of treatment. The 
expression of another anti-apoptotic protein, Mcl-1, was decreased by both compounds at 
2.5 µM, especially at 48 h. In contrast, two pro-apoptotic proteins of the Bcl-2 family, Bak 
and Bax, remained practically unchanged after treatment. Of particular interest was the 
nearly complete disappearance of Bid expression after treatment with either compounds an 
effect that is clearly evident after only a 24 h treatment at the lowest concentration used. 
Bid is a pro-apoptotic member of the Bcl-2 family, and many studies have demonstrated 
that, following apoptotic stimuli, activation of caspase-8 induces cleavage of Bid [35, 36].  
We also investigated whether 4r and 4p induced DNA damage by examining the 
expression of phosphorylated histone H2AX at Ser139 (γH2A.X). γH2A.X 
phosphorylation occurs shortly after DNA double strand break (DSB) induction, thus 
A B 
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identifying γH2A.X as an early sensitive indicator of DSBs, whether induced by ionizing 
radiation, oxidative stress or chemical agents [37]. As shown in Figure 5 (panel B), after a 
24 h treatment 4r induced γH2A.X expression, while 4p induced this effect only after 48 h. 
These findings show that both compounds induce DNA damage. Bid is also involved in 
promoting apoptosis following DNA damage and contributes to induction of a cell cycle 
arrest [38]. Thus, our findings that phenylcinnamides induce DNA damage along with 
strong activation of Bid could explain the arrest of the cell cycle observed after treatment 
of cells with these compounds. 
 
                                                                                                                                                                                                                                                                  
 
Phenyl cynnamides induce ROS production 
 
To better understand the mechanism of action of 4r, we analyzed ROS production. HeLa 
cells were treated for different times and with different concentrations of 4r, and the level
of intracellular ROS were monitored using two fluorescent probes, 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA) and hydroethidine (HE) [39]. As shown 
in Figure 6 (panel A), flow cytometric analysis showed an early but modest increase (1-6 
h) in the H2DCFDA-positive cells, and this occurred in a concentration-dependent manner. 
A 
B 
Figure 5. Western blot analysis of Bcl-2, 
Bax, Bak, Mcl-1and Bid (Panel A), and 
H2A.X (panel B) after treatment of Hela 
cells with 4p and 4r at the indicated 
concentrations and for the indicated times. 
To confirm equal protein loading, each 
membrane was stripped and reprobed with 
anti--actin antibody. 
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Using HE, which mainly detects superoxide anion [40], we did not detect any increase in 
fluorescence emission (data not shown), suggesting that superoxide anion does not play a 
major role.
 
In addition, a time-course study was performed, in which the mitochondrial 
potential was monitored by flow cytometry with the fluorescent probe 5,5’,6,6’-tetrachlo-
1,1’,3,3’-tetraethylbenzimidazol-carbocyanine (JC-1) (Figure 6, panel B). We found 
significant mitochondrial depolarization beginning after a 12 h treatment with 4r. Since the 
mitochondrial membrane depolarization has been associated with mitochondrial production 
of ROS [41,42],
 
these findings suggest that ROS, detected by H2DCFDA prior to the onset 
of apoptosis, were not produced as a consequence of mitochondrial damage.  
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Figure 6. Production of ROS (Panel A) and assessment of mitochondrial membrane potential (mt) (Panel 
B) following treatment of HeLa cells with compound 4r at the indicated concentrations. A. Cells were 
stained with H2DCFDA at the indicated times and analyzed by flow cytometry to measure production of 
ROS. B. The change in mt was measured by flow cytometry using JC-1 at the indicated times.  
 
More importantly, to prove that ROS are involved in the mechanism of cell death of 
compounds 4p and 4r we analyzed cell viability in the presence of different antioxidants, 
including tocopherol acetate (TOC), 2,6-di-tert-butylhydroxyanisole (BHA), N-
acetylcysteine (NAC), reduced glutathione (GSH) and dithiothreitol (DTT). Surprisingly, 
as shown in Figure 7 (panels A and B), only the thiol-containing scavengers (NAC, GSH 
and DTT) significantly increased cell viability. This suggests that ROS do not play a major 
role in the antiproliferative effects observed with 4p and 4r. 
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Figure 7. Effect of ROS scavengers on cell death induced by compounds 4r and 4p. HeLa cells were treated 
with the two compounds at 2.5 µM for 48 h in the presence of BHA (10 µM) TOC (100 µM) NAC (100 µM), 
GSH (1 mM) or DTT (1 mM). Cell viability was measured by the MTT assay. Data are represented as means 
± S.E.M. for four independent experiments. *p<0.01 vs compound alone.  
 
Phenyl cynnamides induce GSH depletion  
Since only thiol containing scavengers protect from cellular death induced by 
phenylcinnamides, we determined whether these compounds caused a decrease in 
intracellular GSH content. Therefore, we analyzed HeLa cells for changes in their GSH 
levels using the fluorescent probe 5-chloromethylfluorescein diacetate (CMFDA) and flow 
cytometry. CMFDA is a membrane permeable dye used for determining intracellular levels 
of GSH [43]. As shown in Figure 8 (Panels A and B), 24 h incubations with either 4p or 
4r, concentration-dependent manners, substantially reduced CMFDA fluorescence, 
indicating GSH depletion. Moreover, the effect was significantly counteracted by addition 
of NAC to the culture medium GSH is the most abundant thiol in mammalian cells and is 
involved in many cellular processes, including antioxidant defense, drug detoxification, 
cell signaling, and cell proliferation [43, 45].
 
Intracellular GSH loss is an early feature in 
the progression of cell death in response to different apoptotic stimuli and, because of its 
action as a primary intracellular antioxidant in the cells, a reduction in intracellular GSH 
content is generally believed to reflect generation of ROS [46]. Nevertheless, our findings 
suggest that phenylcinnamides induce apoptosis in HeLa cells by directly interacting with 
GSH or other intracellular thiols independently of ROS generation. In this context, we 
speculate that a possible mechanism of action of phenylcinnamides results from the 
A B 
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reactivity of the α-bromoacryoyl moiety and its forming an irreversible adduct with GSH 
through a Michael-type nucleophilic attack. This would readily lead to depletion of 
intracellular thiols [47]. 
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Figure 8. Compounds 4p (panel A) and 4r (panel B) induced GSH depletion in HeLa cells. Cells were 
treated with the indicated concentration of 4p or 4r and 100 µM NAC, as indicated. After 24 h incubations, 
the cells were stained with the fluorescent probe CMFDA and analyzed by flow cytometry. Data represent 
means  S.E.M. of three independent experiments. *p<0.01 vs compound alone. 
 
2.2.3.4 CONCLUSIONS 
The observation that the α,β-unsaturated carbonyl system of phenylcinnamide and the α-
bromoacryloyl group are capable of undergoing Michael addition and thus can act as 
trapping agents of cellular nucleophiles led us to prepare and evaluate a series of α-
bromoacryloylamido arylcinnamide derivatives with general structure 4. These compounds 
incorporate the two moieties within their structures. We found that most of the new hybrid 
compounds displayed high antiproliferative activity towards a panel of seven cancer cell 
lines, with one-digit micromolar to double-digit nanomolar IC50 values. The new 
derivatives had antiproliferative activity that was significantly greater than that of the two 
parent compounds 1a and 1b against six of the seven cancer cell lines. The least active 
compounds were derivatives with fluorine (4c), trifluoromethoxy (4k) and 
trifluoromethylsulfanyl (4l) at the para-position of the phenyl ring. A positive effect was 
observed by the replacement of phenyl with 1-naphthyl (compounds 4a and 4b, 
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respectively), with 4b having IC50 values of 0.68-6.5 μM as compared with 0.19-27.3 μM 
for 4a. Comparing the activity of hybrid compound 4o with that of the corresponding 
amino phenylcinnamide 7o, the latter showed weak or no antiproliferative activity 
(IC50=2.81-63.1 μM ) against the panel of cancer cell lines, and the insertion of the μ-
bromoacryloyl moiety was an important molecular change, leading to a significant increase 
in potency (IC50=0.018-2.3 µM for 4o).  
Preliminary mechanism of action studies demonstrated that the most potent hybrid 
compounds did not inhibit tubulin polymerization, but their activity seems to be related to 
depletion of intracellular GSH. Studies are underway to determine the precise molecular 
mechanism that leads to the decrease in intracellular GSH levels. Whether this occur 
through a direct chemical reaction or through interfering with the enzymatic synthesis of 
GSH remains to be determined. Understanding the precise mechanism may result in 
development of new cancer therapeutic strategies and possibly new drugs using 
phenylcinnamides as a lead chemotype.  
 
2.2.3.5 MATERIAL AND METHODS 
Human T-cell leukaemia (Jurkat and CEM) and acute B-cell lymphoblastic leukaemia 
(SEM) cells were grown in RPMI-1640 medium, (Gibco Milano Italy). Human cervix 
carcinoma (HeLa), breast adenocarcinoma (MCF-7) and colon adenocarcinoma (HT-29 
and LoVo) cells were grown in DMEM medium (Gibco, Milano, Italy). Both media were 
supplemented with 115 units/mL of penicillin G (Gibco, Milano, Italy), 115 g/mL 
streptomycin (Invitrogen, Milano, Italy) and 10% fetal bovine serum (Invitrogen, Milano, 
Italy). CEM
Vbl-100
 cells are a multidrug-resistant line selected against vinblastine [32] and 
were grown in complete RPMI 1640 medium supplemented with vinblastine 100 ng/ml. 
LoVo
Doxo
 cells are a doxorubicin resistant subclone of LoVo cells [33] and were grown in 
complete Ham’s F12 medium supplemented with doxorubicin (0.1 µg/mL). Individual 
wells of a 96-well tissue culture microtiter plate were inoculated with 100 L of complete 
medium containing 8 x 10
3 
cells. The plates were incubated at 37 °C in a humidified 5% 
CO2 incubator for 18 h prior to the experiments. Stock solutions (10 mM) of the different 
compounds were obtained by dissolving them in DMSO. After medium removal, 100 L 
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of the drug solution, dissolved in complete medium at different concentrations, was added 
to each well and incubated at 37 °C for 72 h. The percentage of DMSO in the medium 
never exceeded 0.25%. This was also the maximum DMSO concentration in all cell-based 
assays described below. Cell viability was measured by the (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay as previously described [48]. The IC50 was 
defined as the compound concentration required to inhibit cell proliferation by 50%. Some 
experiments were performed in the presence of different scavengers, such as BHA, GSH, 
TOC, DTT or NAC, all purchased from Sigma-Aldrich (Milano, Italy).  
 
Cell growth inhibitory activity in peripheral blodd mononuclear cells (PBMC) 
PBMC from healthy donors were obtained by separation on Lymphoprep (Fresenius KABI 
Norge AS) gradient. After extensive washing, cells were resuspended (1.0 x 10
6
 cells/mL) 
in RPMI-1640 with 10% fetal bovine serum and incubated overnight. For cytotoxicity 
evaluations in proliferating PBL cultures, non-adherent cells were resuspended at 5 x 10
5
 
cells/mL in growth medium, containing 2.5 µg/mL PHA (Irvine Scientific). Different 
concentrations of the test compounds were added, and viability was determined 72 h later 
by the MTT test. For cytotoxicity evaluations in resting PBMC cultures, non-adherent cells 
were resuspended (5 x 10
5
 cells/mL) and treated for 72 h with the test compounds, as 
described above.  
 
Effects on tubulin polymerization and on colchicine binding to tubulin.  
Bovine brain tubulin was purified as described previously [33].
 
To evaluate the effect of 
the compounds on tubulin assembly in vitro [49], varying concentrations were 
preincubated with 10 M tubulin in glutamate buffer at 30 ˚C and then cooled to 0 ˚C. 
After addition of GTP, the mixtures were transferred to 0 C cuvettes in a recording 
spectrophotometer and warmed to 30 °C, and the assembly of tubulin was observed 
turbidimetrically.  
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Immunofluorescence analysis. 
Cells were fixed in cold 4% formaldehyde for 15 min, rinsed and stored prior to analysis. 
Primary antibody staining was performed for β-tubulin (mouse, monoclonal 1:1000, 
Sigma-Aldrich, Milano, Italy). After incubation, cells were washed and incubated with an 
Alexa conjugated secondary antibody (1:2000, Life Technologies, Monza, Italy). Cells 
were counterstained with 4',6-diamidin-2-phenylindole (DAPI) (1:10000, Sigma-Aldrich, 
Milano, Italy). Images were obtained on a video-confocal microscope (Vico, Eclipse Ti80, 
Nikon), equipped with a digital camera.  
 
Annexin-V assay. 
Surface exposure of phosphatidylserine on apoptotic cells was measured by flow 
cytometry with a Coulter Cytomics FC500 (Beckman Coulter) by adding Annexin-V-FITC 
to cells according to the manufacturer’s instructions (Annexin-V Fluos, Roche Diagnostic). 
Simultaneously the cells were stained with PI. Excitation was set at 488 nm, and the 
emission filters were set at 525 nm and 585 nm for FITC and DAPI, respectively.  
Flow cytometric analysis of cell cycle distribution.  
For flow cytometric analysis of DNA content, 2.5 x 10
5
 Hela cells in exponential growth 
were treated with different concentrations of the test compounds for 24 and 48 h. After an 
incubation period, the cells were collected, centrifuged and fixed with ice-cold ethanol 
(70%). The cells were then treated with lysis buffer containing RNAse A and 0.1% Triton 
X-100, and then stained with PI. Samples were analyzed on a Cytomic FC500 flow 
cytometer (Beckman Coulter). DNA histograms were analyzed using MultiCycle for 
Windows (Phoenix Flow Systems). 
Assessment of mitochondrial changes and ROS production. 
The mitochondrial membrane potential was measured with the lipophilic cation JC-1 
(Molecular Probes, Eugene, OR, USA), while the production of ROS was followed by 
flow cytometry using the fluorescent dyes HE (Molecular Probes) and H2DCFDA 
(Molecular Probes), as previously described[50].  
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Detection of the intracellular GSH content.  
Cellular GSH levels were analyzed using CMFDA (Molecular Probes) [42]. Cells were 
treated with the test compound for different times. Cells were harvested, centrifuged and 
incubated in the presence of a solution of 5 µM CMFDA at 37 °C for 30 min. Cytoplasmic 
esterases convert non-fluorescent CMFDA to fluorescent 6-chloromethylfluorescein, 
which can then react with GSH. Fluorescence intensity was determined by flow cytometry.  
Western blot analysis.  
Aliquots of HeLa cell cultures, both control and containing the desired compounds at the 
indicated concentrations, were removed at time points as indicated. The cells were 
collected by centrifugation and washed twice with phosphate-buffered saline chilled to 0 
°C. The cells were then suspended in a lysis buffer at 0 °C for 30 min. The resulting 
suspensions were clarified by centrifugation (15000 x g, 4 °C, 10 min) and the protein 
concentrations of the supernatants determined with the BCA protein kit (Pierce, Italy). 
Protein aliquots of 20 µg were subjected to sodium-dodecyl sulphate-polyacrylamide gel 
electrophoresis using 7.5-15% gradient polyacrylamide gels. Proteins were then 
electroblotted to PVDF Hybond-p memberanes from GE Healthcare, Milano, Italy. The 
membranes were then treated with ECL Blocking Agent from GE Healthcare, using a 
rotary shaker at 4 °C, as instructed by the manufacturer. Membranes were next incubated 
for 2 h at room temperature with a variety of primary antibodies from Cell Signaling, 
Alexis, Upstate, and Sigma-Aldrich, as indicated in the individual experiments. Finally, 
membranes were incubated with peroxidase-labeled secondary antibodies for 60 min. All 
membranes were visualized using ECL Select (GE Healthcare) and exposed to Hyperfilm 
MP (GE Healthcare). To ensure equal protein loading, each membrane was stripped and 
reprobed with an anti--actin antibody. 
Statistical analysis.  
Statistical significance of differences between means of control and treated samples were 
calculated using Student’s t-test. P values < of 0.05 were considered significant. 
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2.3 CONCLUSIONS 
Two classes of antitumoral agents were synthesized with the aim to selectively target 
cancer cells at low concentration efficacy. More specifically each series of compounds 
targeted the unique biochemical alterations which distinguish cancer cells from normal 
cells: unscheduled proliferation and higher levels of intracellular ROS.  
Compounds with general formula 3 included the 1-(3’,4’,5’-trimethoxtbenzoyl)-3-
arylamino-5-amino-1,2,4-triazole molecular skeleton and acted as tubulin polimerization 
inhibitors, colchicine site binders. Compound 3c, bearing a p-toluidino moiety at the C-3 
position of 1,2,4-triazole ring, its p-ethyl homologue 3f and the m,p-dimethyl analogue 3e 
exhibited the greatest antiproliferative activity among the tested compounds. These results 
were superior or comparable with those of the reference compound CA-4 against all cancer 
cell lines. Compound 3c was the most potent inhibitor of tubulin polymerization and of 
colchicine binding (IC50=0.75 M for assembly, 92% inhibition of the binding of 5 M 
colchicine), and the antiproliferative activity of 3c, in terms of IC50’s, ranged from 0.21 to 
3.2 nM in the seven cell tumor lines examined. In addition, 3c showed low toxicity in non 
tumoral cells (peripheral blood lymphocytes from healthy donors ) and was active also in 
drug-resistant cell lines (LoVoDoxo, CEM Vbl100). Although 3c was almost twice as active as 
CA-4 as an inhibitor of tubulin polymerization, these two compounds showed similar 
activity as inhibitors of colchicine binding. Furthermore immunostaining analysis 
performed in Hela cells showed that the antiproliferative activity of 3c compound resulted 
from its capability to interfere with microtubule assembly. In addition the compound 3c 
caused a significant G2/M arrest in a concentration-dependent and it induced caspase-
dependent apoptosis and late DNA damage and p53 induction. Interestingly compound 3c, 
efficiently targeted endothelial cells, acting as a VDA. In fact after a 1 h incubation, 3c 
visibly disrupted the network of HUVECs, as compared with the control. Furthermore 
results also indicated that the effects on endothelial cells induced by 3c were similar to 
those observed after CA-4 treatment carried out by our group. More importantly, in vivo 
experiments showed that this compound was able to significantly reduce the growth of a 
syngenic tumor model in mice, indicating that it is a very promising anticancer compound 
that warrants further evaluation for its potential clinical use. 
Cancer cells are also characterized by altered metabolic activity which provokes increased 
levels of intracellular oxidative stress. A series of α-bromoacryloylamido arylcinnamide 
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derivatives with general structure 4 were evaluated. More specifically they incorporated 
α,β-unsaturated carbonyl system and the α-bromoacryloyl groups which are capable of 
undergoing Michael addition and thus can act as trapping agents of cellular nucleophiles. 
The new derivatives had antiproliferative activity that was significantly greater than that of 
the two parent compounds 1a and 1b against six of the seven cancer cell lines. A positive 
effect was observed by the replacement of phenyl with 1-naphthyl (compounds 4a and 4b, 
respectively), with 4b having IC50 values of 0.68-6.5 μM as compared with 0.19-27.3 μM 
for 4a.  
The compounds 4r and 4p caused a significant G2/M arrest in a concentration-dependent 
manner in Hela cells. Furthermore flow cytometric analysis showed an early but modest 
increase (1-6 h) in the H2DCFDA-positive cells following treatment suggesting an 
immediated increase on intracellular ROS. However mitochondrial depolarization 
measured by flow cytometry with the fluorescent dye JC-1, appeared only after a 12 h 
treatment with 4r suggesting that ROS detected by H2DCFDA prior to the onset of 
apoptosis, were not produced as a consequence of mitochondrial damage. Studying the 
mechanism of action we demonstrated that their activity seems to be related to depletion of 
intracellular GSH. In fact following treatment with either 4p or 4r the CMFDA 
fluorescence levels were substantially reduced. Moreover, the effect was significantly 
counteracted by addition of NAC (one of the most important thiol containing scavenger) to 
the culture medium. However studies are underway to determine whether this occur 
through a direct chemical reaction or through interfering with the enzymatic synthesis of 
GSH. Understanding the precise mechanism may result in development of new cancer 
therapeutic strategies and possibly new drugs using phenylcinnamides as a lead 
chemotype.  
 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
166 
 
2.4 REFERENCES 
1.  Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated 
mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 2009;8:579-
591.  
2.  Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: 
Successes, challenges and opportunities. Mol. Oncol. 2012;6:155-176.  
3.  Pérez de Castro I, de Cárcer G, Malumbres M. A census of mitotic cancer genes: 
New insights into tumor cell biology and cancer therapy. Carcinogenesis 
2007;28:899-912. 
4.  Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic 
microtubules: A new molecular perspective. Med. Res. Rev. 2011;31:443-481.  
5.  Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as 
tumour vascular targeting agents. Int. J. Exp. Pathol. 2002;83:21-38.  
6.  Adams DJ, Dai M, Pellegrino G, et al. Synthesis, cellular evaluation, and 
mechanism of action of piperlongumine analogs. Proc. Natl. Acad. Sci. 
2012;109:15115-15120.  
7.  Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can 
we improve on tubulin agents? Nat. Rev. Cancer 2007;7:107-117.  
8.  Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer 
therapeutics. Nat. Rev. Drug Discov. 2010;9:790-803.  
9.  Parker AL, Kavallaris M, McCarroll J a. Microtubules and their role in cellular 
stress in cancer. Front. Oncol. 2014;4:153.  
10.  Conde C, Cáceres A. Microtubule assembly, organization and dynamics in axons 
and dendrites. Nat. Rev. Neurosci. 2009;10:319-332.  
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
167 
 
11.  Walczak CE, Cai S, Khodjakov A. Mechanisms of chromosome behaviour during 
mitosis. Nat. Rev. Mol. Cell Biol. 2010;11:91-102.  
12.  Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the 
mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and 
mitotic slippage. Cancer Cell 2005;8:49-59.  
13.  Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 
2007;35:495-516.  
14.  Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. 
Cancer 2010;10:194-204. 
15.  Hassan M, Watari H, Abualmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular 
targeting therapy in cancer. Biomed Res. Int. 2014;2014.  
16.  Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer 
Res. 1997;57:229-233. 
17.  Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular 
disrupting agents that interact with tubulin: preclinical tumor imaging and biological 
assessment. Integr. Biol. (Camb). 2011;3:375-387.  
18.  A. Spear M, LoRusso P, Mita A, Mita M. Vascular Disrupting Agents (VDA) in 
Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic. Curr. 
Drug Targets 2011;12:2009-2015.  
19.  Marrelli M, Conforti F, Statti GA, et al. Biological potential and structure-activity 
relationships of most recently developed vascular disrupting agents: an overview of 
new derivatives of natural combretastatin a-4. Curr. Med. Chem. 2011;18:3035-
3081.  
20.  Patterson DM, Rustin GJS, Serradell N, Rosa E, Bolós J. Combretastatin A-4 
phosphate: Vascular disrupting agent oncolytic treatment of age-related macular 
degeneration. Drugs Future 2007;32:1025-1032.  
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
168 
 
21.  Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor 
activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest. 
New Drugs 1996;14:131-137.  
22.  Fulda S, Gorman AM, Hori O, Samali A. Cellular stress responses: Cell survival 
and cell death. Int. J. Cell Biol. 2010.  
23.  Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer 
strategy. Nat. Rev. Drug Discov. 2013;12:931-47.  
24.  Gill SS, Tuteja N. Reactive oxygen species and antioxidant machinery in abiotic 
stress tolerance in crop plants. Plant Physiol. Biochem. 2010;48:909-30.  
25.  Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. 
Free Radic. Biol. Med. 2010;48:749-762.  
26.  Scientist P, Instruments B. An Introduction to Reactive Oxygen Species. Obstet. 
Gynecol. Clin. North Am. 1998;25:1-13. 
27.  Li H, Horke S, Förstermann U. Oxidative stress in vascular disease and its 
pharmacological prevention. Trends Pharmacol. Sci. 2013;34:313-319.  
28.  Held P. An Introduction to Reactive Oxygen Species Measurement of ROS in Cells. 
BioTek Instruments 2012:1-14. 
29.  Forman HJ, Zhang H, Rinna A. Glutathione: Overview of its protective roles, 
measurement, and biosynthesis. Mol. Aspects Med. 2009;30:1-12.  
30.  Zhang H, Forman HJ. Glutathione synthesis and its role in redox signaling. Semin. 
Cell Dev. Biol. 2012;23:722-728.  
31.  Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. 
Cancer 2011;11:85-95. 
32.  Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 
2000;408:239-247. 
2 ANTITUBULINIC AND OXIDATIVE STRESS-INDUCING AGENTS 
 
169 
 
33.  Kuo P-L, Chen C-Y, Hsu Y-L. Isoobtusilactone A induces cell cycle arrest and 
apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 
signaling pathway in human breast cancer cells. Cancer Res. 2007;67:7406-7420.  
34.  Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule 
targeting the stress response to ROS. Nature 2011;475:231-234.  
35.  Armstrong JS, Steinauer KK, Hornung B, et al. Role of glutathione depletion and 
reactive oxygen species generation in apoptotic signaling in a human B lymphoma 
cell line. Cell Death Differ 2002;9:252-263.  
 
 
